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Abstract 
 
The modified Rankin Scale (mRS) is the preferred outcome measure in stroke trials. Typically, 
mRS assessment is based on a clinician’s rating of a patient interview and interobserver 
variability is common. Meta-analysis suggests an overall reliability of =0.46 but this may be 
less (=0.25) in multi-centre studies. Mandatory training in mRS assessment is employed in 
most trials to mitigate this but the problem persists. Variability in assigning outcomes may 
lead to endpoint misclassification increasing the challenge of accurately demonstrating a 
treatment effect.  We aimed to assess the impact of endpoint misclassification on trial power 
and explore methods to improve the use of the mRS in acute stroke trials.  
First we used the mRS outcome distributions of previous phase III randomised controlled 
trials (RCT) in stroke (NXY059 study and tPA NINDS study) to perform statistical simulations. 
We generated power estimates and sample sizes from simulated mRS studies under various 
combinations of sample size, mRS reliability and adjudication panel size. Simulations suggest 
that the potential benefit of improving mRS reliability from k 0.25 to k 0.5, k 0.7 or k 0.9 may 
allow a reduction in sample size of n= 386, n= 490 or n= 488 in a typical n=2000 RCT. 
We then developed a method for providing group adjudication of mRS endpoints and 
examined the feasibility, reliability and validity of its use in a multicentre clinical trial. We 
conducted a “virtual” acute stroke trial across 14 UK sites.  Local mRS interviews were scored 
as normal but also recorded to digital video camera.  Video clips were uploaded via secure 
web portal for scoring by adjudication committee reviewers. We demonstrated excellent 
technical success rates with acceptability to both participants and investigators. 370 
participants were included in our “virtual” acute stroke trial and 563 mRS video assessments 
were uploaded for central review.  96% (538/563) of study visits resulted in an adjudicated 
mRS score. At 30 and 90 days respectively, 57.5% (161/280) and 50.8% (131/258) of clips 
were misclassified. Agreement was measured using kappa statistics (/w) and intraclass 
correlation coefficient.  Agreement between the adjudication committee was very good (30 
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days w 0.85 [95%CI 0.81-0.86], 90 days w 0.86 [95% CI 0.82-0.88]) with no significant or 
systematic bias in mRS scoring in comparison to the local mRS.  We demonstrated criterion 
and construct validity of centrally adjudicated mRS scores through comparison with the 
locally assigned mRS score and other measures known to affect stroke outcome including 
baseline NIHSS (bNIHSS), Systolic Blood Pressure (SBP), blood glucose and home time.  
We studied our cohort of mRS video clips to identify any features predictive of variability in 
mRS scoring. Patient specific variables included participant age, pre stroke mRS, baseline 
stroke severity as graded by baseline NIHSS (bNIHSS) and presence of language disorder. 
Interview specific variables included length of interview, poor sound quality, location of the 
interview, use of a proxy or discussion of prior disability. At both 30 and 90 days only 
“interview length” was a significant predictor of agreement in mRS scoring. 
Using a sample of mRS video clips in English and Mandarin, we conducted a pilot study to 
assess the effect of translation of mRS interviews on interobserver reliability. The 
interobserver reliability of the translated mRS assessments was similar to native language 
clips (Native (n=69) w 0.91 [95%CI 0.86-0.99], Translated (n=89) w 0.90 [95% CI 0.83-0.96]). 
We then incorporated a translation step into the central adjudication model using our 
existing web portal. Inter observer reliability seen in the modified clips (w 0.85 [95% CI 0.74-
0.95]) was similar to that seen in the original video files (w 0.88 [95% CI 0.78-0.99]). 
Finally we aimed to investigate the ability of raters to detect more subtle degrees of disability 
within mRS ranks through blinded assessment of pairs of clips with matching mRS grades. 
These pairs contained either two clips with full agreement in mRS grade at initial group 
review or one clip with full agreement and one clip where scores were skewed in the 
direction of “more” or “less” disability.  Pairs were randomly assigned to multiple raters. We 
could not identify any reliable pattern in identification of the “less disabled” mRS clip. More 
sensitive grading of the mRS with “good” or “bad” forms of each grade is not reliable on the 
basis of this exploratory study.  Perhaps alternative methods of converting the ordinal ranks 
of the mRS scale into a more continuous distribution should be investigated; such as the use 
of a mean mRS score following multiple mRS ratings. 
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Prior estimates of mRS reliability in multicentre studies are poor [=0.25]. The risks of 
endpoint misclassification affecting trial power are substantial.  Simulations suggest that the 
effect of improving interobserver reliability and multiple mRS assessments may reduce study 
sample size by 25%, resulting in substantial ethical and financial benefits. Agreement 
between our adjudication committee was good [=0.59(95% CI:0.53-0.63), w=0.86(95% 
CI:0.82-0.88)]. Central review may bring many additional potential benefits: “expert” review, 
quality control and improved blinding in complex trial design. 
Central adjudication of mRS assessments is feasible, reliable and valid, including the use of 
translated mRS assessments.  This model of outcome assessment has been incorporated into 
four ongoing large clinical trials: CLEAR-3, MISTIE-3, EUROHYP-1 and SITS-OPEN. 
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“When you can measure what you are speaking about, and express it in numbers, you know 
something about it, when you cannot express it in numbers, your knowledge is of a meagre 
and unsatisfactory kind; it may be the beginning of knowledge, but you have scarcely, in your 
thoughts advanced to the stage of science, whatever the matter may be.”  
Lord Kelvin, 1883  
The University of Glasgow 
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Chapter 1  
Background and Introduction 
1.1. Introduction 
Modern medicine must rely upon robust evidence to verify the safety, quality and efficacy of 
new therapeutic strategies. The burden of delivering evidence lies with the scientists and 
physicians who believe that their hypotheses may translate into new treatments with 
potential to transform patient outcomes. This journey, from theory to change in clinical 
practice is challenging; academically, logistically and financially.  
Whether the aim is to investigate an entirely novel intervention or to use an existing drug in 
a new clinical context the process of gathering evidence must be meticulously planned, 
closely regulated and peer reviewed. From early laboratory work involving animal or tissue 
samples to large phase III randomised controlled trials in the target patient population this 
process is necessary to deliver a change in clinical practice that provides safer, more effective 
and more accessible therapies. 
The time and money invested by academic and commercial institutions in clinical research is 
substantial. Only a tiny percentage of novel compounds make it to market, many being 
abandoned in the early stages of development. It is estimated that discovery and 
development of each new pharmaceutical agent costs an average of $800 million US dollars 
and takes between nine and twelve years to gain the necessary regulatory approvals1. These 
compounds must generate enough income to cover their own development costs and 
recover the expenditure lost in early investigation of abandoned compounds. The financial 
burden continues to rise, attributable to a multitude of factors including increasing 
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regulatory requirements, complex trial design requiring large sample sizes, training and 
initiation of multiple international sites and increasing difficulty recruiting participants to 
clinical trials.  
To maintain the important advances in evidence based medicine we have achieved in recent 
decades we must find a way to make clinical research more efficient. This is a particular 
challenge in the field of acute stroke due to the heterogeneous nature of its aetiology, 
clinical presentation and possible outcomes. 
1.2. Evidence Based Medicine in Acute Stroke 
Acute stroke is a major cause of death and disability in the developed world2, 3 and its 
consequences place a substantial burden on healthcare resources and economic 
productivity4. The number and quality of clinical trials in the field of acute stroke has 
increased considerably in recent decades despite an acknowledgement that the funding 
available to stroke research is significantly less than other disease states such as cancer and 
coronary heart disease5. Improved understanding of the basic pathophysiological processes 
in stroke has led to marked changes in contemporary trial design, methodology and 
statistical analysis techniques. 
1.2.1. Trial Design 
Where the investigational product or procedure allows, a model phase III clinical trial should 
include several components in its design to ensure that results are valid, robust and reliable.   
These generic requirements are applicable to any field of medicine. The primary objective of 
the trial and its hypothesis must be clearly and prospectively stated, together with any 
proposed subgroup analyses. Acknowledging that there are likely to be systematic, cultural 
and demographic variables, where practical, studies should be multicentre to ensure that 
results are reproducible and generalisable internationally. Participants must be carefully 
selected according to predefined criteria (inclusion / exclusion) and followed up 
prospectively at specific, standardised time points. Treatment allocation should be randomly 
allocated and blinded to both participant and investigator (double blind) until the point of 
trial closure and data analysis. The number of participants necessary to demonstrate a 
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realistic and clinically relevant treatment effect must be determined in advance through the 
use of an appropriate power calculation. The outcome measure must be relevant, 
appropriate, valid and reliable. The statistical analysis plan must be developed and 
documented prior to data collection to avoid retrospective data manipulation. 
1.2.2. Early improvements in acute stroke trial design 
A 20 fold increase in the number of stroke trials was seen between 1950 and 1999. The total 
number of participants enrolled has increased markedly; mean (median) sample size in 1950s 
research was 38 (26) in comparison to 661 (113) in the 1990s. The integration of each of the 
“ideal” trial components in published stroke research in the second half of the twentieth 
century has gradually improved6. Prior to 1970 no published studies were multicentre, by the 
1990’s 68% met this standard. The proportion of published studies which were randomised 
(75% to 99%) and double blind (38% to 83%) also improved in the same time period. In the 
first decade of the 21st century more than 125 acute stroke trials successfully provided 
evidence to change practice (thrombolytic therapy in an extended time window, 
hemicraniectomy in select patients with malignant infarction and coiling in subarachnoid 
haemorrhage secondary to aneurysmal bleeds)7.  
Additional changes in trial design specific to stroke medicine are also notable. Our 
understanding of the underlying pathophysiology of stroke disease has improved participant 
selection. The clinical syndromes of stroke disease are well recognised and understood; 
however, the pathophysiological basis for each event may be quite different. Stroke subtype 
and severity are important prognostic factors relevant to trial design and selection of 
participants8. Recruitment criteria may often predefine a severity restriction to prevent the 
inclusion of participants who might attenuate the detection of a treatment effect in other 
subgroups. For example inclusion of either a very severely affected participant who is 
unlikely to survive or a very mildly affected participant who is almost certain to recover well 
is not informative.   
The timing of participant recruitment in acute stroke trials is crucial and time windows have 
progressively decreased6. The majority of interventional or pharmacological treatments aim 
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either to recanalise occluded vessels thus reperfusing damaged tissue or to protect 
vulnerable brain tissue at risk of permanent damage. Following brain ischaemia there is a 
complex cascade of events culminating in complete tissue death.  The time window for 
salvage of vulnerable tissue, known as penumbra, is short and subsequently very early rescue 
treatment is likely to yield greater clinical benefit. For this reason the time window from 
stroke onset to enrolment in stroke trials should be limited and tailored to the hypothesis of 
each individual agent. 
1.2.3. Lessons from previous Acute Stroke Trials 
Several large acute stroke trial programmes have been conducted with negative results, the 
lessons from which we can use in the planning and design of future studies.  The early ECASS 
studies (I9 and II10) were underpowered and perhaps chose an unfortunate combination of 
drug dose, timing and endpoints without the benefit of current knowledge.  Following 
publication of the NINDS tPA stroke study, thrombolysis was considered safe and effective, a 
study with more complex design11.  The Lubeluzole trials were conceived to demonstrate an 
effect on mortality seen in early studies12 that was not reproduced in later trials13, 14. A 
negative trial result with a trend towards significance in certain groups has previously 
prompted trialists to chase post hoc analysis, such as in the CLASS study programme15, 16. 
Consistent efforts were made to improve trial design in the last decades of the twentieth 
century. Landmark neuroprotectant studies (GAIN17 and SAINT18 trials) pioneered best 
practice in terms of trial design, sample size and statistical approaches but unfortunately the 
choice of drug and pre-clinical studies were flawed. Novel compounds showed promise in 
initial pre-clinical studies but the translation of these results into large scale phase three 
clinical trials was not possible, leading to negative results. The responsible factors are likely 
to be multifactorial, however lessons can be learned from imperfect methodologies to 
optimise future trial design.   
1.2.3.1. Translation of animal models to clinical studies 
It is very likely that the initial promise shown in pre-clinical studies using animal models 
provided ambitious and inaccurate estimates of the expected treatment effect of 
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neuroprotectant agents. Often the number of animals used in each study is small, 
encouraging meta-analysis of published studies to generate an estimate of treatment effect. 
There is substantial publication bias in preclinical studies. Any publication bias may lead to 
fundamental flaws in the generation of this estimated treatment effect, rendering it 
unrealistically high. The impact of this error is critical to the planning and design of the next 
phase of clinical research; the potential to introduce considerable error in power and sample 
size calculations for clinical studies is large.   
The relevance of animal model findings to clinical stroke in human subjects is questionable19.  
Investigating a new compound in animal models allows standardisation of many factors 
which clinical trialists can never hope to equal. The heterogeneity and complexity of stroke in 
human subjects is incomparable to animal infarct models where stroke location, severity and 
infarct size can be closely controlled. Time to treatment in human subjects is limited by 
patient presentation and clinical services, where in animal studies drug delivery is precisely 
timed and progressively delayed until a beneficial effect is no longer seen. Control of 
confounding factors that may affect outcome is possible in pre-clinical studies, both 
environmental (temperature / blood pressure) and physiological (sex / age / co-morbid 
illness). 
One opinion of how to optimise the translation of laboratory experiments to the bedside is to 
try and better emulate the animal experiment in our patient population20. However, to 
match a clinical trial to the animal model would necessitate tighter standardisation of 
participants enrolled and shorten the time to treatment, potentially resulting in unfeasibly 
slow participant enrolment and limiting the generalisability of results. It has also been 
advocated that initial trials in animal models should instead be designed to emulate clinical 
trials: multicentre, with randomisation, blinding and central review of results where 
appropriate. In either case it is important to acknowledge the limitations in matching animal 
experiments to human subjects when designing clinical studies. 
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1.2.3.2. Trial design errors 
With the value of hindsight, the design of several large neuroprotectant trials led to almost 
inevitable failure.  In the early 21st century stroke academics collectively reassessed the 
design issues that may have resulted in this disappointment21. 
Several common defects were identified, many of which arose from inaccurate translation of 
the animal studies to trial design as discussed above. The patient population was often 
unhelpful, for example enrolment of participants with lacunar infarcts (affecting purely white 
matter) in the study of drugs that are known to be active only at grey matter synaptic 
terminals. Small sample sizes were known to be insensitive to detection of the modest 
treatment effect expected. The timing of drug administration and dosages were considered 
too late and too small, leading to inadequate drug delivery to the penumbral tissue. Finally 
the choice of trial endpoint and statistical analytical techniques were criticised. 
1.3. Outcome measures in stroke trials 
The choice of outcome measure is fundamental to the design of any clinical trial. The 
objective in a randomised controlled clinical trial is to assess the effect of an intervention or 
treatment, either positive or negative. In order to do this a method of measuring and 
documenting the outcome of participants must be chosen that is relevant to the physician, 
the patient and the disease process. 
In many areas of clinical medicine the appropriate outcome measure is clear.  For example, in 
a trial of a new antihypertensive agent the trialists might choose to use blood pressure 
measurements or vascular events; in a study examining the effect of a new chemotherapy 
agent mortality rate or periods of remission may be the obvious choice. These “hard” 
endpoints are easy to conceptualise and relatively straightforward to measure and record. 
Unfortunately, stroke disease is a more difficult and complex area to study. Outcomes are 
variable, ranging from complete recovery to various degrees of disability and death. Death is 
typically considered the worst possible outcome in clinical trials; this is not necessarily the 
case in stroke medicine. To keep patients alive at the expense of severe disability and loss of 
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quality of life would be considered by many to be a worse outcome22. Stroke trials now 
favour a measure of functional recovery as the primary endpoint. While a functional 
assessment is theoretically attractive, in practice it adds a layer of complexity to the trial.  
Functional outcomes are varied and subjective and it can be difficult to reduce the complex 
qualitative experience of stroke survival to a numerical value. Measurement and 
documentation of these more subjective outcomes is much more problematic and can 
severely compromise clinical trials where assessment is not reliable, robust and reproducible. 
1.3.1. Early Stroke Outcome Research 
Accurate and meaningful assessment of patients’ progress after a stroke event is important 
in the context of an interventional stroke trial but also in observational research and registry 
data collection. Measurement of outcome is necessary to monitor the effect of stroke 
disease on the wider population, to allow an educated estimate of likely prognosis and to 
enable rational health care planning at a population level. This was recognised in the 1980s 
and began a movement to study stroke outcome measures as an entity23.  
The complex nature of stroke and heterogeneity of patient outcomes was noted as a 
challenge to creation of the “ideal” stroke outcome measure24, 25. Recognition of the 
components of a useful stroke outcome measure were detailed in a 1990 task force 
statement26. Broad recommendations to be considered in the study of stroke outcome 
measures were detailed: 1) Outcome must be measured in conjunction with the time from 
ictus, 2) The site and side of the stroke lesion should be specified, 3) Imaging should be used 
to classify stroke events and 4) outcome studies should be limited to patients with a first 
stroke in recognition of the introduction of confounding by prior disability. It was 
recommended that instruments must be simple to apply in a short space of time, encompass 
a description of activities of daily living (ADLs) together with an assessment of cognitive 
function, speech and communication, emotional wellbeing and social functioning27.  
These general principles have become the basis of a large body of literature pertaining to the 
use of various stroke outcome measures. In the past 20 years terminology has been 
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standardised and clinimetric properties examined to help guide the use of outcome scales in 
trial design.  
1.3.2. Functional Outcome 
Within the realms of “functional outcome” there is varied terminology to describe the degree 
to which residual symptoms affect a patient. The terminology has been regularly updated; 
the most recent WHO framework for describing function and limitation is found in the WHO 
International Classification of Functioning, Disability and Health (ICF). This is a 
multidimensional framework in which three levels of human functioning are described. – the 
body (or body part), the whole person and the whole person in the context of his/her 
position and role in society (Figure 1).  
An outcome measure may assess function at any of these three levels: problems in body 
structure/function (formerly impairment) - signs of an underlying pathological process, 
functional activity (formerly disability) - a limitation in execution of a particular task as a 
result of this problem or societal participation (formerly handicap) - the social effect of that 
impairment in overall quality of life and social role28.  
There are multiple stroke outcome scales designed to measure function at each of these 
levels. A sample of the extensive list of outcome measures relevant to stroke medicine and 
their relevance to the WHO ICF are summarised in Table 1. Opinion regarding the best level 
at which to measure function after stroke is divided – should we be interested only in the 
physical deficit or symptom, or is it of more relevance to the patient to determine how that 
symptom affects their ability to return to their previous activity level and fulfil their roles and 
responsibilities within society? Certainly the former is easier to measure with less subjectivity 
but it could be argued that this is not as useful or meaningful a measure as the latter.   
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Health Condition 
Body structure / 
function 
Activity Participation 
Environmental 
Factors 
Personal Factors 
Body structure / function: anatomical parts and physiological function of body 
systems.  
 
Impairments are problems with body structure/function  
 
Activity: execution of a task or action by an individual 
 
Participation: involvement of an individual in life situations 
 
Environmental and Personal Factors: physical, social and cultural environment 
which affects how individuals live and conduct their lives 
 
Activity Limitation: difficulties an individual may experience in performing activities 
Participation Restriction: problems an individual may experience in involvement in 
life situations 
Figure 1 Interactions among components of the WHO ICF 
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Table 1 Common scales used in measurement of stroke outcome by ICF 
stratification 
Scales that measure disorder of: 
 
Body Structure / Function 
(Impairments) 
 
Limitation to Activity 
(Disability) 
 
Limitation to Participation 
(Handicap) 
Glasgow Coma Scale (GCS) Barthel Index London Handicap scale 
Mini-Mental State Examination 
(MMSE) 
Nottingham ADL Scale Medical Outcomes Study Short 
Form – 36 
Geriatric Depression Scale Glasgow Outcome Scale Nottingham Health Profile 
Hospital Anxiety and 
Depression Scale 
Katz ADL Scale  
Modified Ashworth Test 10 metre walk test 
 Timed get-up-and-go test 
National Institute of Health 
Stroke Scale 
International Stroke Trial (IST) 
Simple Questions 
Stroke Adapted Sickness 
Impact Profile 
Fugl Meyer Assessment Modified Rankin Scale Stroke Impact Scale 
Orgogozo Stroke Scale Oxford Handicap Scale Stroke Specific Quality of Life 
Canadian Neurological Scale Hamrin Activities Index Frenchay Activities Index 
Scandinavian Stroke Scale Adams Disability Method 
General Neurological Scale 
Stroke Specific Scale 
Toronto Stroke Scale 
(Modified) Mathew Scale 
European Stroke Scale 
Frenchay Aphasia Screening 
Test 
The choice of outcome scale is entirely dependent upon the clinical application. The scale 
chosen for use in a busy outpatient clinical setting will differ from that chosen in a detailed 
research protocol. The relative strengths and limitations of various stroke outcome scales in 
the context of clinical trials are debated. The “ideal” outcome measure is unlikely ever to 
exist.  However, various instruments are preferred in contemporary stroke research and 
these merit further discussion29. (See section 1.3.4) The appropriateness and effectiveness of 
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a scale can be measured by describing its clinimetric properties. Before discussing the 
common stroke outcome measures in detail, an explanation of these clinimetric properties is 
necessary. 
1.3.3. Clinimetric Properties 
Scientifically valid research requires quantified comparisons between subjects. This requires 
translation of what often begins as a qualitative assessment, originating in a conversation, 
interview or physical examination, into quantitative data. After collection of these clinical 
and personal details they must be documented in a format that is easily comparable to other 
subjects. For many years clinical data were considered too “soft” to meet the standard of 
data quality demanded by scientists and clinical trials30-32. A description of the clinimetric 
properties of an outcome measure allows trialists to demonstrate that their assessment 
method and study design is robust and reliable. Practical and logistical issues must be 
considered together with the statistical clinimetric measurements to ensure optimum 
participation and follow up.   
Clinimetrics is the methodological discipline that focuses on quality of clinical measurements.  
Outcome scales are traditionally assessed in terms of validity, reliability and responsiveness.  
Other important metrics include feasibility; acceptability and cost benefit.   
1.3.3.1. Validity 
Some attributes, such as height or weight are easily definable. Less tangible concepts such as 
functional ability require a description of the validity of the measurement33. A scale is 
considered valid if it bears a strong relationship to the attribute that it aims to measure34.  
The concept of validity includes several key components. 
Content Validity and Face validity are relatively subjective terms which are used where an 
intuitive or consensus opinion would suggest that the content of the test appears to measure 
the attribute being studied. These may be considered where a committee of experts aim to 
develop a novel measure; however, a more objective test of its validity would be desirable 
before use in formal research. 
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Criterion Validity refers to a tests ability to match a criterion that is known to represent the 
attribute being studied (a “gold standard”). Where no such “gold standard” is available, 
measures of validity based upon other surrogate outcome measures or predictors are 
necessary. Convergent Validity refers to a tests relationship with other outcome measures.   
This is often used in studies examining new scales, allowing comparison with a variety of 
other established scales. Construct Validity refers to a tests relationship to other accepted 
indicators of measuring the desired attribute. This can be used in developing a novel 
outcome assessment tool by correlating the test result with other known prognostic 
indicators (for example with stroke subtype or blood pressure measurement in stroke 
outcome). 
1.3.3.2. Reliability 
Reliability is an important measure of a scales ability to be used clinically or for research 
purposes. The purpose of translating clinical data into scale format is to allow comparisons to 
be made with other subjects, however, without assurance of adequate reliability the content 
of the test is jeopardised by variability. Consistency of scoring is particularly important in 
scales with multiple items where the opportunity for disagreement is significant. In the 
development of scoring systems attempts should be made to ensure there are a minimal 
number of potential grades per modality tested with simple and unambiguous definitions35.   
Reliability can be measured in two ways – intra-observer reliability: reproducibility of results 
when tested repeatedly by the same assessor (also known as test-retest reliability) and inter-
observer reliability: reproducibility of results when tested by two or more separate 
observers. 
A measure of reliability estimates the degree of random error that is introduced in scoring.  
This error can be quantified using correlation statistics such as the kappa statistic () or 
intraclass correlation coefficient (ICC). 
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1.3.3.3. Measures of Inter-observer reliability 
The reliability of two or more observers rating an outcome can be measured using , w, or 
ICC, depending on whether the outcome is categorical, ordinal or continuous, respectively. 
All three measures are expected to range from 0 to 1 and have the same interpretation: a 
value of 0 represents observers guessing randomly while 1 indicates perfect agreement. 
When comparing two different methods of measurement a Bland Altman plot can be 
employed, this is a graphical representation of the difference between two methods. 
Kappa ()   measures reliability as agreement adjusted for chance. A kappa statistic is a 
measure of agreement between raters, beyond that which is expected by chance alone. It 
can be calculated to quantify agreement between raters for nominal and categorical data36.  
A kappa statistic of zero indicates agreement equal to that which would be expected by 
chance, a kappa statistic of one indicates perfect agreement. A negative kappa statistic 
would indicate active disagreement of a similar magnitude. Commonly accepted thresholds 
for kappa reliability statistics are present in the literature. A score of 0-0.2 is considered poor; 
0.21-0.4 fair; 0.41-0.6 moderate; 0.61-0.8 excellent and 0.81-1.00 excellent. A kappa statistic 
of 0.6 or above is considered necessary for clinical use.  is less useful for ordinal outcomes 
such as mRS because near agreement and strong disagreement have the same impact on .  
Weighted Kappa (w) Weighted , w, penalises near agreement less severely than strong 
disgreement, and is therefore more appropriate for ordinal outcomes. In this situation, a 
disagreement of more than one level on the scale (in either direction) would be considered 
more significant than disagreement across adjacent levels. Here a quadratic weight can be 
applied to the degree of disagreement to generate a weighted kappa statistic (w)
37 The most 
common method of calculating w is Fleiss-Cohen (quadratic) weighting. In this thesis, w 
always implies Fleiss-Cohen w.  
Intraclass Correlation Coefficient (ICC) Inter-observer reliability for continuous outcomes can 
be measured by the intraclass correlation coefficient, which measures the proportion of 
variance in the outcome due to differences between subjects. The remaining variance (1 – 
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ICC) is due to differences between observers. Fleiss and Cohen38 showed that for ordinal 
outcomes ICC and w are equivalent. 
Bland Altman Plot The aim of a Bland Altman plot is to demonstrate if two methods of 
measurement agree sufficiently for them to be used interchangeably or for one method of 
measurement to supersede an existing gold standard. Primarily designed to assess the 
difference between continuous measurements, a Bland Altman plot can also be used for 
categorical data39. The plot is of the average measurement against the difference between 
measurements40. 
1.3.3.4. Responsiveness 
The responsiveness of a scale describes its sensitivity to detect change over time within 
subjects in response to meaningful changes in clinical status34. A stroke scale should be able 
to detect changes in functional ability as the patient progress through rehabilitation and 
recovery.   
Where a scale is used to measure the magnitude of a therapeutic treatment effect, 
responsiveness is an important characteristic of the scale. The quantification of a scale’s 
responsiveness can be achieved by comparison to another external criterion using 
correlation or receiver operator characteristics (ROC) analysis41. 
Responsiveness is also sometimes described by use of a “minimal clinically important 
difference” or” minimal clinically important change”42. This concept attempts to quantify the 
degree of change required in a scale that is associated with a patient perception of benefit.  
However, there are as many as nine reported methods of generating these estimates42 and 
the lack of standardisation in development of these figures has undermined the utility of 
such a concept in clinimetrics43. The minimal degree of change that is significant will vary 
according to the trial. However even clinically modest improvements in function can have 
substantial meaning to patients and be important at a population level. Increasing 
responsiveness is by its nature often at the cost of increasing complexity. 
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The responsiveness of many scales is restricted by floor or ceiling effects. This describes the 
limits of a scale’s ability to detect change, beyond which no further improvement (or 
deterioration) can be described. Where a subject achieves “full marks” in a score relative to 
the specific scale items in question, yet has further recovery potential which could positively 
impact their function and quality of life, the scale is limited by a ceiling effect (and vice 
versa). Where a scale suffers from floor or ceiling effects the measure is not useful to assess 
or document further potential improvement or deterioration which may be attained by the 
next assessment in a study protocol. 
1.3.3.5. Acceptability 
Acceptability refers to the burden of administering the scale. An ideal scale will be quick to 
administer with minimal distress to participants and minimal disruption to other activities.   
1.3.3.6. Feasibility 
Feasibility also refers to the burden of administering a scale, however in this context it is 
considered in terms of the burden on assessors. Pressure of time, expense and disruption to 
other clinical care duties are particularly relevant in a clinical context. However, even within 
the realms of research, similar pressures are present and the choice of outcome scale must 
not be allowed to discourage trial enrolment or progression through undue effort placed 
upon assessors. 
1.3.3.7. Interpretability 
The scores generated should be meaningful and comparable to previous studies. Clearly in 
the generation of a novel outcome measure this is less relevant; however in choosing an 
outcome measure for a trial where a number of tools are used it is important to ensure that 
the choice of primary outcome measure will generate data that is meaningful in the context 
of existing literature. The landmark thrombolysis trials were comparable in an important 
pooled analysis due to the virtue of similar outcome measures facilitated through 
prospective collaboration44.  
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A recent analysis of outcome measures in contemporary stroke research has demonstrated 
use of 47 different outcome scales29. However, a significant majority of studies used one of a 
smaller group of favoured tools.  These tools are preferred because of increasing clinimetric 
data to support their use, both objectively (valid, reliable and responsive tools) but also 
subjectively; the practicality (acceptability, feasibility and interpretability) of the chosen 
tool(s) is crucial to the success of a trial. 
1.3.4. Commonly used stroke outcome measures 
The widespread development of stroke scales in recent decades has led to much confusion in 
the literature. There are scales designed to classify stroke syndromes (TOAST Classification, 
Oxford Classification, ICD 9/10, Physicians Health Study Stroke Subtypes etc.), scales 
developed to quantify stroke deficit and neurological examination (NIHSS, Canadian 
Neurological Scale, European Stroke Scale, Mathew Scale etc.) and scales developed to 
measure function and quality of life (Barthel Index, modified Rankin Scale, Stroke Impact 
Scale, Functional Independence Measure etc.). These scales have all been used and continue 
to be used in stroke trials; however a preference for certain measures has been noted29.  
1.3.4.1. National Institutes of Health Stroke Scale (NIHSS) 
The NIHSS is a measurement of physical impairment following stroke and is a common 
marker of stroke severity, allowing simple quantification of clinical examination findings. It 
was originally described in 1989 using components of several previous stroke scales (the 
Toronto Stroke Scale, the Cincinnati Stroke Scale, the Oxbury Initial Severity Scale and the 
Edinburgh-2 Coma Scale)45 and in its current form it assesses fifteen items with a 3 to 4 point 
scale (level of consciousness / extraoccular eye movements / visual fields / facial muscle 
function / arm and leg motor function / sensory disturbance / ataxia / language / dysarthria 
and inattention).  (Figure 2)  Construct validity of the NIHSS as a marker of stroke severity is 
favourable when compared to infarct volume on CT scanning45. Moderate to substantial 
inter-rater reliability has consistently been demonstrated for the complete scale in assessors 
of diverse backgrounds45, 46, 46-48. However, some specific items are noted to be less reliable; 
ataxia, facial weakness, dysarthria and level of consciousness; exhibiting unacceptable 
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agreement by kappa statistic46. A modified version of NIHSS (mNIHSS) was proposed in 2001, 
excluding these more contentious items. This version of the scale demonstrated slightly 
increased reliability but appeared to convey no advantage in statistical modelling49.  
Reliability and validity of the mNIHSS has also been demonstrated in a prospective sample50 
but the use of this version of the scale has not been adopted routinely in trial design. 
In its current form the NIHSS is frequently used as a research tool and in clinical practice.  
Measurement of NIHSS was included in 27.8% of recent trial procedures and it was used as a 
primary outcome measure in 11.9%29. In routine clinical practice it is also used commonly to 
aid treatment decisions and provide prognostic information at baseline51, 52. Widespread 
experience and knowledge of the scale is one of its great strengths in both stroke physicians 
and non specialists.   
However, the NIHSS does have accepted limitations. As a scale used to document physical 
impairments there is an acknowledged ceiling effect in its administration (see section 
1.3.3.3). The scale items favour left hemisphere events; of 42 possible marks there are seven 
directly related to language function where only two measure a degree of neglect / 
inattention. A study examining CT infarct volume has questioned the validity of NIHSS on this 
basis; the median volume of right hemisphere infarcts was found to be consistently higher 
than left hemisphere infarcts for the same NIHSS score53. Common clinical findings in 
posterior cerebral circulation events are also poorly reflected in the NIHSS. The development 
of hemisphere specific or stroke syndrome specific versions of NIHSS have been proposed54 
but have not been adopted. 
Overall, the NIHSS is a useful tool for acute clinical assessment and is acknowledged to 
accurately document stroke severity and predict outcome45, 51. For this reason it is widely 
accepted in stroke research. However, its usefulness as a functional outcome measure is 
questionable; recovery of a physical deficit may not translate to meaningful functional 
recovery. 
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1a. Level of Consciousness (LOC) 0= Alert; keenly responsive 
1= Not alert; but arousable by minor stimulation 
2= Not alert; requires repeated stimulation to attend 
3= Unresponsive; reflex movements only 
 
1b. LOC Questions 
Ask patient the month and his/her age 
0= Answers both questions correctly 
1= Answers one question correctly 
2= Answers neither question correctly 
 
1c. LOC Commands 
Open and close eyes 
Grip and release non paretic hand 
0= Performs both tasks correctly 
1= Performs one task correctly 
2= Performs neither task correctly 
 
2. Best Gaze 
Horizontal movements only 
0= Normal 
1= Partial gaze palsy 
2= Forced deviation not overcome by oculocephalic manoeuvre  
 
3. Visual Fields 0= Normal 
1= Partial Hemianopia 
2= Complete Hemianopia 
3= Bilateral Hemianopia (blind including cortical blindness) 
 
4. Facial Palsy 0= Normal 
1= Minor Paralysis (flattened nasolabial fold, asymmetry on smiling) 
2= Partial Paralysis (total or near total paralysis of lower face) 
3= Complete Paralysis of one or both sides, absence of facial 
movement in the upper and lower face 
 
5. Motor Function – Arm 0= Normal; holds limb 90 (or 45) degrees for 10 seconds without drift 
1= Drift; limb holds 90 (or 45) degrees but drifts down before full 10 
seconds but does not hit bed or other support 
2= Some effort against gravity 
3= No effort against gravity; limb falls 
4= No movement 
UN= Untestable; joint fused or amputated 
 
6. Motor Function – Leg 0= Normal; leg holds 30 degree position for 5 seconds without drift 
1= Drift; leg falls by end of the 5 second period but does not hit bed 
2= Some effort against gravity 
3= No effort against gravity; limb falls 
4= No movement 
UN= Untestable; joint fused or amputated 
 
7. Limb Ataxia 0= No ataxia 
1= Present in one limb 
2= Present in two limbs 
UN= Untestable; joint fused or amputated 
 
8. Sensory 0= Normal; no sensory loss 
1= Mild to moderate sensory loss, aware of touch 
2= Severe to total sensory loss 
 
9. Best Language 0= No aphasia 
1= Mild to moderate aphasia; loss of fluency or comprehension 
2= Severe aphasia; fragmented communication 
3= Mute, global aphasia; no useable speech or auditory comprehension 
 
10. Dysarthria 0= Normal 
1= Mild to moderate dysarthria; slurring of words, at worst can be 
understood with some difficulty 
2= Severe dysarthria; near unintelligible or unable to speak (out of 
proportion to aphasia) 
UN= Untestable due to intubation or physical barrier 
 
11. Extinction and Inattention 0= No abnormality 
1= Inattention or extinction to bilateral simultaneous stimulation in 
one sensory modality (visual, tactile, auditory, spatial or personal) 
2= Profound hemi-inattention or extinction to one or more modality 
 
Total Score   
Figure 2 The National Institutes of Health Stroke Scale (NIHSS)45 
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1.3.4.2. The Barthel Index of Activities of Daily Living 
The Barthel Index (BI) has been in common use for many years and is a familiar instrument in 
all areas of rehabilitation medicine. First described in the literature in 196555 the scale had 
been in clinical use locally for almost a decade. Initially proposed as a simple measure to 
quantify independence it was used as a score to document improvement in rehabilitation.  
The original scale describes ten tasks in the areas of personal care and mobility, scoring 0 to 
100 with 5 point increments. (Figure 3) As a general rehabilitation scale it does not contain 
any stroke specific domains such as communication / cognition.   
There are several variations of the original scale which are collectively described in the 
literature as the BI. Although the variations on the original scale are largely similar they 
include modifications such as change in scale items56 or definition57 / reordering of scale 
items58. These changes have potential to alter the clinimetric properties of the scale raising 
question over their validity in a research setting.   
The methods used to collect BI data also vary substantially across the literature. The original 
scale was designed to be administered through direct observation of scale tasks. However, 
validation of a scale for one purpose does not ensure that its validity will translate into a 
different clinical context or situation59. For ease of data collection centres have administered 
the scale via self reporting60, telephone interview61 or postal questionnaire62.  It must be 
recognised that a change in scale administration can alter its performance. 
The reliability of the BI has consistently been reported as good when administered in a 
general rehabilitation population63. Individual studies examining reliability in stroke patients 
are reassuring in their estimates64-66. A recent systematic review and meta-analysis found 
overall excellent inter-observer variability67, however there were discernible differences in 
the included studies; limited by small sample size, heterogeneous study population and 
diverse methodology. However, in an elderly cohort, systematic review of BI reliability found 
only fair to moderate interobserver agreement by kappa statistic in individual items, 
postulating that the use of this as a tool may be limited in an elderly population where 
cognitive impairment is prevalent68.   
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Feeding 0= Unable 
5= Needs help (cutting / spreading) 
10= Independent 
Transfers 
Bed to chair (or wheelchair) and back 
0= Unable, no sitting balance 
5= Major help (of one or two people), can sit 
10= Minor help (verbal or physical) 
15= Independent 
Grooming 
Face/Hair/Teeth/Shaving 
0= Needs help 
5= Independent, implements provided 
Toilet Use 
Handling clothes, on and off toilet, wipe, flush 
0= Dependent 
5= Needs some help but can do something alone 
10= Independent 
Bathing 0= Dependent 
5= Independent 
Mobility 
On surface level 
0= Immobile or < 50 yards 
5= Wheelchair independent, including corners, >50 yards 
10= walks with help of one person (verbal or physical), >50 yards 
15= Independent (but may use aid), > 50 yards 
Stairs 0= Unable 
5= Needs help (verbal, physical or carrying aid) 
10= Independent 
Dressing 
Includes buttons, zips, laces etc. 
0= Dependent 
5= Needs help but can do ≈50% unaided 
10= Independent, including fastenings 
Bowels 0= Incontinent (or requires enemas) 
5= Occasional accident 
10= Continent 
Bladder 0= Incontinent (or catheterised) 
5= Occasional accident 
10= Continent 
Total Score  
Figure 3 The Barthel Index (BI)55 
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The BI certainly has strengths as a stroke outcome measure which explains its use in several 
previous landmark stroke trials, including the thrombolysis trials. It has been used as an 
instrument in 40.5% of recent publications and was primary outcome measure in 7.9%. It is 
familiar to a wide range of clinicians both in clinical practice and as a research tool, aiding its 
use in multicentre trials. It has good intra and inter observer reliability and is a useful 
predictor of length of stay, discharge destination69 and of the likelihood of a patients return 
to independent community living70, 71. It also generates a standardised, numerical score 
which is easily comparable at various time points, aiding in statistical analysis and 
manipulation. 
However, there are widely acknowledged limitations in the use of BI as a functional outcome 
measure, which may explain increasing reluctance in contemporary trials to use it as a 
primary outcome measure. Heterogeneity in the use of various versions of the BI and 
diversity in methodology of administration adds complexity when interpreting and 
comparing trial results. As an ADL score the BI is not designed to assess many areas of 
neurological deficit or disability commonly reported in a stroke population (disorders of 
cognition, language, vision etc.) which may have significant impact upon function and quality 
of life. The primary limitations seen in the BI are the substantial “floor” and “ceiling” effects 
in scoring subjects at the extremes of the scale72-74 together with a U-shaped distribution in 
clinical practice. These limit the responsiveness of the BI, hindering the ability of the scale to 
detect meaningful change over time75 and requiring a large change shift in outcome in order 
for this to be detected statistically.   
1.3.4.3. The modified Rankin Scale / Oxford Handicap Scale 
The modified Rankin Scale is the most commonly used outcome measure in contemporary 
stroke research, used in 64% of recent stroke trials and as a primary outcome measure in 
26%29. An ordinal, hierarchical scale, it is used to measure disability across seven ranks. 
(Figure 4) There have been several variations of the scale since its inception in the 1950’s 
(including the alternatively named Oxford Handicap Scale - Figure 5) and it has been widely 
adopted in a standard form for use in trials. A detailed discussion of the modified Rankin 
Scale, its clinimetric properties and variations is found in section 1.4. 
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0 No symptoms 
1 No significant disability despite symptoms; able to carry out all usual duties and 
activities 
2 Slight disability; unable to carry out all previous activities, but able to look after own 
affairs without assistance 
3 Moderate disability; requiring some help, but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to attend 
to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant nursing care and 
attention 
6 Dead 
Figure 4 The modified Rankin Scale 
0 No symptoms 
1 Minor symptoms that do not interfere with lifestyle 
2 Minor handicap, symptoms that lead to some restriction in lifestyle but do not interfere 
with the patient’s capacity to look after himself 
3 Moderate handicap, symptoms that significantly restrict lifestyle and prevent totally 
independent existence 
4 Moderately severe handicap, symptoms that clearly prevent independent existence 
though not needing constant attention 
5 Severe handicap, totally dependent patient requiring constant attention night and day 
Figure 5 The Oxford Handicap Scale (OHS)76 
1.3.4.4. Stroke Impact Scale 
As a measure of stroke outcome across many domains, the Stroke Impact Scale (SIS) was 
developed in response to the criticism that the above common scales do not directly or 
adequately assess stroke survivors in a holistic or comprehensive manner. The SIS was 
developed using a patient centred approach involving feedback from patients, carers and 
therapists rather than trial investigators in the description of domains.  The scale includes 
measurement of changes in emotion, cognition, communication and social role / 
participation in addition to the expected physical attributes tested after stroke. The scale was 
originally developed in 199977 and was modified in 2003 to its current version78 although it 
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continues to be refined. Despite its careful description and development to ensure validity 
and reliability, the SIS has not been adopted widely in the stroke literature and its 
generalisability is questionable79. It was used in only 2.4% of recent stroke trials and was not 
utilised as a primary outcome measure in any29.   
1.3.5. Global Statistic Outcome Measures 
Because each stroke outcome scale is recognised to measure important but often very 
different parameters in stroke recovery a global statistical outcome measure has been 
proposed in some large trials to better describe the spectrum of outcome after intervention.  
Mathematical techniques can be used to combine several outcome measures, each of which 
measures a different but important domain in stroke recovery, such as neurological deficits, 
independent function and quality of life. The NINDS tPA Stroke trial, a landmark thrombolysis 
trial11, 80, utilised a global statistic incorporating the NIHSS, mRS, BI and Glasgow Outcome 
Scale (another hierarchical ranked scale used to measure outcome after brain injury – 
frequently traumatic head injury) as a primary outcome. As a successful method for the 
NINDS trial, a retrospective analysis of the ECASS I dataset using the NINDS statistical 
methodology altered the outcome of the intention to treat analysis from a negative study to 
one with a positive result. Clearly retrospective data analysis such as this has limitations and 
is methodologically flawed, however it highlights the importance of choosing the optimal 
outcome measure in trial results81. 
With the advent of more complex statistical analysis techniques the use of global statistics 
may be more widely adopted. Trial power may be enhanced with the use of a global statistic 
through reduction of the random variation seen in a single scale. However, there are 
disadvantages and the use of a global statistic and their use in place of a more recognisable 
primary outcome measure is discouraged by regulatory bodies. By mixing conceptually 
distinct recovery descriptors, ultimately such an approach provides an abstract result that is 
less intuitive than a single well defined outcome.  It must be recognised that any global 
outcome measure will be limited by the weakest performing tool involved and the resulting 
statistics are less interpretable than a single outcome measure. There are also statistical 
complexities in analysis. A global outcome may be able to provide an estimate of statistical 
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significance, but is less able to provide a meaningful measure of effect size.  Furthermore, 
analysis often includes the combination of several ordinal scales. In this situation global 
statistics are often analysed with multiple dichotomisation points with recognised statistical 
inefficiencies82. (See section 1.5) 
1.4. The modified Rankin Scale 
Originally described by Dr John Rankin in 1957 the Rankin Scale (RS)83 was designed to 
provide a method of describing the recovery of a group of stroke patients at discharge or 
transfer from hospital. Dr Rankin established an archetypal specialist “stroke unit”84 and the 
scale was designed to evaluate the effectiveness of this intervention. 
1.4.1. The Modified Rankin Scale (mRS) 
The original RS scale was modified in 1988 as part of the UK-TIA Aspirin Study85 to what is 
now accepted as the modified Rankin Scale (mRS). (Figure 4) Changes to the original scale 
included the addition of an extra category (Grade 0) and an alteration of the wording of 
grades 0, 1 and 2 to better accommodate disturbances of language and cognitive function86.  
1.4.1.1. The Oxfordshire Handicap Scale (OHS) 
Further modification was proposed in 1989 by the Oxfordshire Community Stroke Project 
with the alternative title of Oxfordshire Handicap Scale (OHS)76. In response to controversy 
surrounding the use of the functional terms in the mRS87, the OHS was reworded to 
standardise the use of the term “handicap” in place of “disability” and include the term 
“lifestyle” in scoring. (Figure 5) In addition to this change in semantics, the focus of the mRS 
on mobility was reduced by removing the ability to walk as an explicit grading criterion88.  
The OHS has been used in few studies89-91 and has not been adopted widely in the stroke 
literature.  
The mRS in its 1988 format86 (Figure 4) is widely accepted as the standard version of the 
scale. It is an ordinal hierarchical scale with grades from zero (no symptoms) to five (severe 
disability); an extra score of 6 is often added in clinical trials to signify death. It is important 
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to note that some studies describe the use of the mRS but cite alternative versions of the 
scale. It is important to clarify the specific instrument used in order to be confident of 
comparable trial results. 
1.4.2. Clinimetric properties of mRS 
The validity, reliability and responsiveness of the mRS are described in a broad literature.  
Although acknowledged as an imperfect scale, it has been demonstrated to meet the 
requirements of an outcome measure for use in randomised clinical trials and has been 
recommended for its brevity, simplicity and ease of interpretation in clinical trials89. The long 
term predictive value the mRS makes it an attractive scale for use in RCT’s. mRS data 
collected at 90 days are representative of the likely long term functional outcome92.   
1.4.2.1. Validity 
The mRS has been shown to correlate well with several other markers of stroke severity and 
outcome and can be considered a valid measurement of functional outcome. Convergent 
Validity has been shown with other outcome scales such as the NIHSS and BI72, 93 and with 
economic indices such as length of hospital stay and cost of patient care94. Construct validity 
has also been reported via association with arguably more objective and direct measures of 
stroke severity such as infarct volume95, 96 or recanalisation of affected vessels following tPA 
therapy97. 
1.4.2.2. Reliability 
Reliability has been reported across a wide and somewhat fragmented literature. Caution 
must be exercised in interpreting results of these studies as they are heterogeneous in 
methodology: patient selection, timescale after stroke, sample size, assessor number, 
background and training and number of centres vary throughout.   
In most cases reliability studies have been conducted using highly trained and motivated 
individuals in a single centre98. Systematic review has found wide estimates of inter-observer 
variability with overall good agreement (=0.61)99. Estimates range from =0.25100 to 
=0.72101 for a standard mRS interview. Only one mRS reliability study has a design that 
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attempts to emulate an active RCT; a multicentre study with several investigators of different 
clinical backgrounds100. The reliability of the traditional mRS in this study was of concern 
(=0.25) in the context of large multicentre studies. Substantial heterogeneity has been 
reported in mRS reliability amongst a large cohort of international observers102. Where our 
closest estimate of mRS reliability in a multicentre RCT shows substantial disagreement 
(=0.25) we might expect that this could be amplified in an international RCT. 
1.4.2.3. Responsiveness  
As a scale with only six potential categories, the mRS requires meaningful clinical 
improvement or deterioration to move between each point on the scale. This attribute 
makes it a poor tool for measuring change over short periods of time. However its advantage 
in clinical trials for the assessment of longer term follow up (e.g. at study completion) is 
recognised. A change in mRS score in response to treatment is very likely to be associated 
with a clinically meaningful change as perceived by both the patient and the investigator72, 
103.  No minimal clinically important change is reported for the mRS. 
The mRS scale distributes disability states meaningfully, in comparison with the NIHSS and 
Barthel Index which are troubled by floor and ceiling effects.  This is useful clinically and 
statistically.  Figure 6104 demonstrates the 90 day outcome measures for the NIHSS, BI and 
mRS. It is clear that the information provided by the mRS and distribution of mRS outcomes 
will allow more robust statistical analysis and interpretation. 
 
Figure 6 Typical Distribution of outcome with the NIHSS, BI and mRS at 90 days. 
[Final 90-day outcome scores in the 2 NINDS tissue-type plasminogen activator 
trials
104
]. 
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1.4.3. Challenges in the use of mRS 
Although it is the favoured outcome scale for use in contemporary stroke research, the mRS 
is acknowledged as an imperfect tool for several reasons. The perfect outcome measure is 
unlikely ever to exist and hence trialists must accept the limitations in the available tools and 
ensure that they are optimised in their administration. 
The mRS has been criticised due to the broad nature of each category and large potential 
change in function that is contained within each rank. The broad categories of the mRS are 
considered by some as subjective, ambiguous and poorly defined105. In contrast, the “global” 
nature of mRS is also considered one of its strengths, particularly through reduction in the 
floor and ceiling effects that limit many outcome measures. As a simple, time efficient 
measure it should be performed within around fifteen minutes and can be administered by a 
variety of health care professionals with similar validity and reliability in scoring106. 
The broad nature of the mRS may be to its advantage; however there is an argument that it 
lacks specificity, without explicit measurement of certain domains. The wording of the mRS 
may place undue reliance on predominantly physical attributes such as ambulation and 
continence. There is no direct focus within the assessment in areas such as cognition, 
communication, language disorders or other common post stroke syndromes (fatigue / pain / 
mood disorder) that can affect motivation and patient perception of function.  The “global” 
nature of the assessment allows implicit inclusion of these domains; an experienced assessor 
should consider physical and non physical characteristics in assessment of overall function 
and participation103.   
The influence of co-morbid conditions must be considered in assigning a score; arthritis, 
respiratory or cardiovascular disease, depression and many other confounding illnesses are 
common in the stroke population and can have an important impact upon the functional 
domains that are affected by stroke disease. Co-morbid illness is known to affect stroke 
survivors’ quality of life107 but the mRS should be used to assess the effect of stroke related 
limitations. Again, an experienced assessor should be able to disentangle the aetiology of a 
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patient’s limitations but the uncertainty that these factors bring to the allocation of mRS 
scoring may limit its utility.     
The timing of mRS administration is controversial. It is accepted that most stroke recovery 
occurs in the early phase of rehabilitation, however improvement can continue at a slower 
rate for up to six or twelve months. Administration of the mRS early in the recovery phase 
may be considered unreliable for outcome classification108. Prolonged admission is common 
after stroke for intensive rehabilitation and therapy. The effectiveness of the mRS in patient 
populations who have not returned home or had an opportunity to return to many aspects of 
previous function is questionable. The standard time point of mRS assessment in clinical trials 
is 90 days post ictus, a period recognised as a predictor of longer term outcome92. This 
prognostic information is useful clinically in planning rehabilitation goals or likely discharge 
destination; importantly in research it allows trial follow up to be completed within a 
reasonable timeframe.   
Across each boundary of the mRS there are controversies, due to both the inherent 
ambiguity of the scale and the potential misinterpretation of its wording by assessors. For 
example, the boundary between mRS 3 and mRS 4 largely relies on the ability to walk 
unaided. The use of aids and adaptations (such as a walking frame or cane) should not merit 
the term “assistance”; rather these are aids to allow independence88. However, if the 
assistance of another person, physical or supervisory, is necessary then this would warrant a 
score of four.  A similar dilemma exists in the use of a wheelchair; this aid can permit 
functional mobility without the ability to walk independently. Many wheelchair users would 
disagree that this modification leads to significant disability questioning the appropriateness 
of an mRS of four (Figure 4). Often a patient is capable of performing particular tasks but 
chooses not to because “assistance” is offered and this help is accepted, for example in the 
context of a caring relative who wishes to save the subject the time and energy required to 
complete tasks. In this case it is arguable whether they should they be scored based upon 
their potential capability or based upon their true function. The wording of the mRS does not 
clearly specify whether a subject should be scored on the basis of absolute loss of activity or 
chosen loss of activity for the sake of convenience or increased effort.  Examples of areas of 
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controversy are present at each level of the scale but are more prevalent in the middle 
ranges where classification of “good” or “bad” outcome often rests. Areas of controversy 
result in potential for variability in scoring; they will be discussed further in later chapters.  
Health related quality of life measures are important after stroke but are infrequently 
incorporated in trial design or used as a primary or secondary outcome109.  For this reason, 
translation of the functional ability with each rank on the mRS scale to a single index value 
for health status is necessary to assess the “value” of treatment in terms of evaluating health 
care provision and in health economics.  For this to be possible, a disease specific instrument 
such as the mRS must be expressed in a form comparable to universal generic health 
outcomes.  In the United Kingdom, generic outcomes provide utility values from which health 
related quality of life measures, such as a Quality Adjusted Life Year (QALY) must be derived. 
It is a challenge to express the mRS outcome scale in this format but there is some evidence 
to suggest that it is possible and valid.  
The mRS has been successfully mapped to EuroQol-5D110, a generic health outcome measure 
commonly used by health economists in evaluation of new treatment strategies.  An 
alternative method of expressing utility values is through the use of Disability Adjusted Life 
Year (DALY).  This measure is generated from WHO Global Burden of Disease (WHO-GBD) 
disability weights, a numeric value which reflects the severity of disease or disability on a 
scale from 0 (perfect health) to 1 (equivalent to death).  This spectrum of disability is 
intuitively similar to the mRS scale.  The mRS has been described using this spectrum by 
generating disability weights for each rank of the mRS scale111.  
Despite these challenges and pitfalls, the mRS is a well recognised scale which has been well 
studied with an established and acceptable clinimetric literature.  Its ease of administration 
and global nature is considered its great asset and in experienced hands it is used with 
confidence in large clinical trials93.  
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1.4.4. Variants of the standard mRS 
The standard mRS interview was developed as a face-to-face interview between assessor and 
patient. Several variants of the standard mRS interview have been proposed in an attempt to 
simplify administration, improve accessibility or improve reliability.   
1.4.4.1. Premorbid mRS score 
Traditional statistical analyses in acute stroke trials measure the proportion of participants 
achieving a “good” functional outcome, by whatever criterion that is defined in each trial.  
This concept is complicated by the inclusion of participants with considerable pre-stroke 
functional limitation. For this reason a pre-stroke mRS is often used as a measure of disability 
at entry to contemporary stroke trials. In clinical practice, a national audit programme is 
collecting data on outcomes at 6 months and one year, corrected for pre-stroke mRS112. In 
some centres, pre-stroke mRS is used as a measure of functional independence, upon which 
a decision to administer or withhold thrombolytic therapy may be based. 
The concept of pre-stroke mRS is difficult to define, as by its very definition, the modified 
Rankin scale describes the presence or absence of symptoms and limitations after stroke.  
However, the descriptions in terms of symptoms, limitations and the need for assistance are 
extrapolated to include all aetiologies of disability in this context. The validity and reliability 
of a pre-stroke mRS is moderate with some concerns raised regarding its use as an entry 
criteria to stroke trials113. A re-written mRS with the same structure but alternative wording 
regarding symptoms and limitations has been proposed. 
1.4.4.2. Acute mRS assessment 
Assessment of mRS in the acute phase is common in stroke trials but has been poorly studied 
in the hospital setting, where most participants are in the immediate phase after stroke. The 
wording of the scale concentrates on functional limitations and the need for assistance with 
activity. In the hospital setting this help is available but not always required and participants 
have often not had the opportunity to assess their abilities with extended ADLs such as 
shopping, cooking or managing their finances. The reliability of the mRS in the acute phase 
 31 
has been shown to be good, with acceptable inter-rater agreement.  However, the validity of 
the scale in this context, particularly with reference to the relevance and interpretation it is 
questionable114. 
1.4.4.3. Remote mRS assessment 
As there is no physical examination component to the mRS, remote assessment (via 
telephone or postal questionnaire) is an attractive prospect in circumstances where direct 
assessment is not possible or to limit the time and expense involved in patient visits.   
A postal based mRS questionnaire approach has been used in clinical trials. There are no data 
comparing postal versions of the mRS with traditional face-to-face assessment. A study 
compared differing postal mRS questionnaires and telephone assessment.  The authors 
concluded that telephone follow up may be preferable as response rate from the postal 
questionnaire was suboptimal115. Studies are available describing the properties of postal 
versions of alternative stroke assessment measures from which we can extrapolate. A postal 
version of the Glasgow Outcome Scale (GOS) in head injury patients was found to have good 
reliability in comparison to telephone assessment116. However, limitations in data collection 
due to the high risk of non-responders were highlighted as a disadvantage in a study of a 
postal version of the Stroke Impact Scale (SIS)117.   
There are more data pertaining to telephone versions of stroke outcome assessment. ADL 
based assessment such as the BI has been demonstrated to have good reliability by 
telephone118, 119. More severely affected patients are likely to yield less reliable results by 
telephone61 which may be a reflection of a patient’s propensity to overstate their ability or 
an indication of the important nonverbal cues that are gained by visualising a patient.  
Telephone mRS assessments have been assessed for both validity and reliability120, often in 
the form of a structured interview. Results are conflicting with inter-rater reliability reported 
from =0.30101 to =0.78121. The largest study of telephone mRS reports a weighted kappa 
statistic rather than a standard kappa statistic (w=0.71).  This makes direct comparison with 
other studies difficult but certainly reflects a significant degree of disagreement122.  At best 
we must interpret the result of a telephone mRS with caution. 
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Derivation of the mRS from outpatient case records has been proposed as an alternative 
method of collecting follow up data. Case record extraction has been shown to be reliable for 
impairment scales such as NIHSS123. However, a prospective study found poor reliability in 
case record derived mRS in comparison to standard mRS (=0.34) and between observers 
(=0.33)124. 
1.4.4.4. Proxy mRS assessment 
In some circumstances the mRS cannot be administered through direct patient interview. 
Communication or cognitive impairments are common and when severe can preclude a 
standard mRS assessment. The properties of a proxy mRS assessment have been assessed in 
a cohort of patients125. Family members, nurses and physiotherapists were used as proxy 
respondents and mRS scores were compared to direct patient assessment. Only moderate 
agreement between proxy and patient assessments was found (=0.4), encouraging caution 
in the interpretation of proxy assessments. The greatest variability was found in therapist 
assessments. There is evidence to suggest that systematic differences are present in the 
perception of overall function between different groups of respondents. Although not 
directly studies of the mRS, extrapolation from other stroke assessment scales suggests that 
proxy respondents may be less reliable. Patients are prone to self-report better function than 
their carers126. Proxies systematically report more dysfunction in aspects of quality of life 
measures than direct patient assessment, thought to be affected by proxy perception of 
burden127. Therapists report better functional scores than carers128.  This is perhaps a 
reflection of improved effort on the part of a patient when undergoing therapy assessment 
in comparison to home performance or that the nature of therapist training is in looking for 
rehabilitation potential. Systematic review of proxy responses to stroke assessments found 
that ADL measures were more suited to a proxy assessment and that less agreement is seen 
in quality of life measures129. No mRS studies were available for inclusion in this review but 
given the nature of the mRS assessment lies somewhere between an ADL impairment scale 
and global quality of life measure we must consider this when using proxy mRS assessments. 
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1.4.4.5. Structured mRS assessment 
Although it can be considered an inherent advantage of the mRS assessment, the open and 
global nature of the standard interview, risking subjective interpretation, increases potential 
for inter-observer variability. An experienced assessor should gather the appropriate 
information to grade patients successfully using a standard, unstructured mRS interview.  
However, in an attempt to widen the utility of the mRS and encourage more standardised 
results, a structured interview has been proposed.   
Several versions of a structured mRS assessment are available, most of which use a checklist 
format through various ADL’s and activities66, 100, 101, 105, 130-133. This is most appropriate for 
assessing mRS at the lower end of the scale (mRS 3-5) where basic ADL’s are an important 
element in scoring. The translation of ADL scoring (BI) to mRS scores has been shown to be 
an effective method of mRS assessment65, however, this is less effective at the top end of the 
mRS beyond the ceiling threshold of the BI. 
Reliability estimates of the structured interview are conflicting101, 105. In a multicentre trial 
with assessors of various healthcare backgrounds the use of a structured interview was 
found to be highly reliable100. However, the structured interview has been criticised as a 
complicated tool to implement. A Rankin Focused Assessment (RFA), a four page 
standardised assessment form is reported to be less cumbersome.  Designed as part of the 
FAST-MAG trial protocol it has been shown to have excellent inter-observer reliability133. It is 
important to note that although RFA scores showed substantial agreement between raters, 
this study was restricted to one centre and no comparison was made with mRS scores 
generated in a traditional manner to confirm validity. 
Even more focused mRS assessment has been described using a questionnaire methodology.  
Using the OHS version of the mRS scale a two question assessment (1. Do you feel that you 
have made a complete recovery from your stroke? and 2. Do you require help from another 
person for everyday activities?) was found to be sensitive in predicting BI and OHS scores of 
20 or 0 respectively (i.e no symptoms or limitations)134. In an era of dichotomised mRS 
outcomes as the common analysis technique (see section 5.3) this was considered an 
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advantage in terms of time and efficiency. However, current trial design would not support 
this method.  A more recent questionnaire based mRS assessment (Simplified modified 
Rankin Questionnaire smRSq) has been described using three questions each generating a 
binary yes / no response132.  This generates mRS results across the full ordinal scale and has 
been shown in a single study to have similar reliability to a standard mRS assessment 
between two raters132 and has been validated in comparison to stroke severity135, stroke 
size136 and quality of life measures137. The validity of the smRSq has been demonstrated in a 
study comparing its use to the standard mRS and the NIHSS in a cohort of Chinese stroke 
patients138. 
 
1.4.5. Adjudicated mRS outcomes 
Central adjudication of trial end points is routinely used in a variety of settings but has rarely 
been used in stroke. This is straightforward where the endpoint is based upon the 
assessment of paper records or images; however, adjudicated endpoints of participant 
function are more problematic. 
Group adjudication of mRS outcomes has been employed in some trial designs, including 
telephone mRS in the IMAGES139 and IST 1140 trials. In the HAMLET trial a written summary of 
the mRS assessment was provided for central review141. However, as discussed in section 
1.4.4.3, the reliability of remote mRS is debated.    
In order to evaluate mRS outcomes remotely in a format as close to current assessments as 
possible there are numerous barriers to overcome. First, this would require capture of the 
assessment, including both visual and audio components, in a format that can be 
subsequently reviewed ‘off-line’. Further, most trials are international, mutli-cultural and 
multilingual; meaning methods of handling these complexities including translation would 
need to be considered and should be demonstrated not to influence scoring.  Pilot data 
suggest that video based mRS assessment is valid and reliable142.  
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1.5. Improving statistical analysis in acute stroke trials 
The failure of many previous large RCTs in acute stroke has been attributed in part to trial 
design and statistical analysis. The detection of what is likely to be a small treatment effect 
requires statistically efficient methods to optimise the likelihood of demonstrating improved 
outcome with a realistic sample size. 
1.5.1. Choice of scale 
As previously discussed, the selection of outcome measure is crucial. It must be a reliable, 
robust and valid measure of what the treatment in question aims to achieve. The most 
common outcome measure is the mRS or its incorporation in a global endpoint statistic. 
Varying estimates of inter-rater reliability in the mRS have the potential to affect trial results.  
Most contemporary phase III trials are conducted internationally, with the potential for up to 
hundreds of investigators; therefore the scope for amplification of even small degrees of 
inter-observer variability is of concern. Endpoint misclassification, through incorrect or 
variable administration of the mRS, has the potential to introduce type II statistical error and 
compromise trial results through loss of power. In a trial of pneumococcal vaccine the 
recording of the endpoint was erroneously assumed to be infallible. It was demonstrated 
that a modest misclassification in the reported cause of death reduced the trial power by 
40%143. Analysis of data from a neurotrauma studies, with similar challenges to that of stroke 
recovery, confirmed that endpoint misclassification could have a significant effect upon the 
magnitude of treatment effect. With flawless classification the effect size was 7.5% (p=0.039) 
but this lost statistical significance and fell to 6% (p=0.102) and 4.5% (p=0.228) where there 
was 10% and 20% misclassification respectively144. A pattern of misclassification upwards, 
downwards or in both directions can attenuate the treatment effect found in clinical trials145. 
1.5.2. Training and Certification 
The requirement for large studies in stroke research demands international collaboration, 
multicentre trials and a considerable number of investigators to contribute data for analysis.  
Although all stroke scales are acknowledged to be imperfect, the consistent application of 
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even an imperfect tool is crucial in the collection of accurate, comparable and generalisable 
data146.  
The importance of investigator training was acknowledged when the mRS was originally 
described although at this stage was considered impractical in the context of a multicentre 
trial86. However, with technological advances this situation has changed.  
Training in application of the NIHSS was developed for the TOAST trial in 1994 and was found 
to be feasible, effective and inexpensive147. Improved reliability in scoring using a video 
training package was reported in the TOAST investigators (n=162)46. An early analysis of 
reliability using the original video NIHSS training package in a large cohort (n=7405) found 
less consistent results in scoring148. Subsequently the training package was updated to DVD 
technology48 and again to its current format as an online package. This has been robustly 
validated with good reliability in a large cohort from multiple venues (n=8214)149 and there is 
evidence to support its use in translated form150.  
A similar training resource is available to improve the application of the mRS in clinical 
trials151. Again this began as an instructional DVD with subsequent conversion to a web based 
package accessible internationally. This has also been validated with good reliability in a large 
cohort (n=2942) from several countries102. As a less structured tool than the NIHSS no studies 
to date have investigated the validity and reliability of a translated mRS assessment. 
Consistency in application of stroke scales requires a degree of quality control. This is best 
achieved through formal training and certification of investigators and a compulsory training 
process is now ubiquitous amongst contemporary stroke research where the NIHSS or the 
mRS are used.   
1.5.3. Statistical Analysis Techniques 
Following collection of outcome data, the analysis technique chosen to interpret it can 
significantly alter trial results. The relative advantages and disadvantages of different analysis 
techniques have been much debated in the stroke literature in recent years. 
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1.5.3.1. Dichotomised Analysis  
A popular method of analysing disability endpoints has been to dichotomise outcome data, 
separating participants into those with “favourable” and “non-favourable” outcomes and 
comparing proportions. With mRS a variety of cut offs have been used to define “favourable” 
outcome status. There is no consensus as to the level of mRS that best represents acceptable 
recovery and choice has been partially dependent on the expected benefit of the therapy 
and the baseline disability of the cohort. For example, in a trial of intervention in the often 
fatal condition of malignant middle cerebral artery infarction a “good” outcome was defined 
as mRS 3 (moderate disability), while in trials of thrombolysis, where better functional 
outcomes are expected, use of mRS 0-1 (no significant disability) defines treatment success.  
Dichotomisation of outcome data is attractive because it allows easy interpretation into 
“good” and “bad” outcome, simplifying statistical analysis and interpretation of results. 
Placing the threshold between “good” and “bad” outcome across one health state is less 
meaningful to participants and their families. A traditional dichotomisation point on the mRS 
would be 0-2 vs. 3-6, meaning that the transition from death to being able to walk on ones 
own would not be considered a successful treatment. In the Kansas City Stroke Study(n=459) 
it was noted that 65% of patients crossed one or more boundaries on the mRS by three 
month follow up.  Dichotomisation of the mRS at 0-1 or 0-2 resulted in only 15% or 42% of 
participants respectively being considered as having a “good” outcome152. The optimal cut 
off for dichotomisation of the mRS scale is debated153 and often chosen arbitrarily.   
Dichotomisation (or Trichotomisation) is now widely accepted as a suboptimal method of 
analysing acute stroke trials and is recognised as statistically inefficient154. Collection of data 
on an ordinal scale such as the mRS with a view to collapsing it into a binary outcome 
discards potentially useful information, risking a loss of statistical power.   
Of more concern is the possibility that we may fail to detect the harmful effects of treatment.  
Where the dichotomised threshold is set high (mRS 1 or 2) but the treatment (e.g. 
thrombolytic therapy) is in fact harmful to patients with more severe stroke the analysis will 
not detect a transition from moderate disability (mRS3) to severe disability or death (mRS 
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5/6). Perhaps dichotomising with a definition of “poor” outcome such as death or mRs above 
a certain cut off would be safer and more meaningful in this respect155. 
1.5.3.2. Responder Analysis  - Prognosis adjusted endpoints  
Stroke is a heterogeneous disease with a wide variety of outcomes.  Setting an arbitrary and 
identical target deemed to signify “recovery” or “good outcome” for this varied population 
will almost certainly miss important clinical effects in a large trial. The principle of using 
prognosis adjusted end points, also known as responder analysis or a sliding dichotomy, 
encourages judgement of a treatment effect in response to the severity of the initial stroke 
insult156, 157. This allows trialists to individualise end points to reflect the baseline 
characteristics and prognosis as assessed by factors such as age, stroke severity, 
classification, baseline NIHSS, blood pressure etc. 
This approach has been demonstrated to be effective in several types of study. Retrospective 
analyses of previous trial datasets (Tirilizad Head Injury Trials157, NINDS tPA trials158, Trial of 
Org 10172 in Acute Stroke Treatment TOAST trial and ECASS I and ECASS II159) statistical 
simulations using previous trial datasets (Glycine Antagonist in Neuroprotection GAIN 
International Trial160) and prospective phase III clinical trials (AbESTT-II161 and STITCH162). 
1.5.3.3. Shift Analysis – Ordinal Analysis 
Analysis of change in outcome distribution across the full ordinal range of a scale is an 
attractive prospect. This approach allows analysis of all functional transitions, both beneficial 
and harmful. A shift analysis technique is being employed in ongoing large phase III trials and 
has been used in analysis of previous RCT’s (Erythropoetin in Acute Stroke163, SAINT18, FAST-
MAG164 and IST3165). 
The advantage of shift analysis is the enhancement in statistical power that is gained by using 
all available information154. This is particularly important where the hypothesised treatment 
effect is seen uniformly across the spectrum of stroke severity. It may be even more 
important to use all available data where there are no assumptions or prior knowledge of 
where in the stroke severity spectrum a treatment effect may be of benefit166. A 
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collaboration of stroke academics re-analysed the datasets of 47 trials using techniques 
designed to examine the unprocessed ordinal data. In every case they found that shift 
analysis techniques performed better, were more efficient and reliable167. Stroke trial power 
can be substantially enhanced by the use of an ordinal shift analysis technique with test 
statistics such as the Cochran-Mantel-Haenszel Test104. 
1.5.4. Non-Expert Interpretation of Trial Analysis 
 
A change in mRS score at the top end of the scale is most often considered by physicians to 
represent a clinical or functional success168. However, economic analysis demonstrates 
benefit with a shift across each level in mRS score. A success in economic term is measured in 
terms of length of stay and institutional care94. Information about both ends of the spectrum 
is important in overall risk/benefit reporting of a new product after clinical trials. 
The use of shift analysis techniques is mathematically and computationally more complex 
than those using dichotomised data. This can be dealt with using most modern statistical 
computer packages but the important challenge is in converting this spectrum of non binary 
outcomes into terms that are easily understood and interpreted by clinicians and patients. In 
this situation the number needed to treat (NNT) or number needed to harm (NNH) is 
traditionally used. NNT and NNH are widely used and statistically valid measures of a 
treatment effect, the resulting figure is clinically meaningful and can be used to indicate to 
patients and their families how many patients would require treatment in order for one to 
have a beneficial or harmful outcome.  
Dichotomised analysis allows easy calculation of the NNT for each patient to cross the 
threshold to a “good” outcome. The calculation of NNT in a shift analysis is more complex; a 
transition across each grade in the scale may be associated with different magnitudes of 
clinical change (the scale is not linear). The degree of change across the entire population 
may not be uniform.  In some cases a small number of patients improve considerably, in 
others the treatment effect may improve outcome to a modest degree for a greater 
proportion of patients166. A method of estimating NNT in an ordinal analysis is available169 
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and allows the calculation of a figure that represents the NNT in order for one patient to 
improve by one or more point on the mRS scale. 
Overall there has been a marked change in attitudes to statistical techniques used in 
contemporary stroke research since the start of the twenty-first century. A greater 
understanding and appreciation of the various methods and their relative merits, even 
amongst non academic clinicians, has permitted this change in ideology168.  
1.6. Optimising Acute Stroke Trials 
Improvements in acute stroke trials have been ongoing for many years. Coherent 
international collaboration, well designed protocols, appropriate training and certification of 
study investigators, adequate sample sizes and shortened time to treatment are a selection 
of the advances that are now considered ubiquitous in contemporary stroke research. There 
is no one best approach for statistical analysis in all acute stroke trials and it is crucial that 
each study is designed with appreciation of the population of patients to be enrolled, the 
realistic effect size and therefore the necessary sample size156. Despite meticulous planning, 
an inefficient outcome measure and statistical strategy can jeopardise trial outcome. It is 
increasingly accepted by contemporary trialists that the choice of outcome measure and 
statistical analysis plan may be paramount to a study’s success104.  
1.7. Research questions 
This programme of research and thesis aims to investigate an alternative method of 
collecting outcome data and strategies to optimise analysis of these data.   
We present data exploring complementary themes, generated by the original research 
questions for the CARS study (Central Adjudication of modified Rankin Scale Assessments in 
Acute Stroke Trials):   
 What are the expected benefits in trial power and study sample size with improved 
reliability of mRS and/or multiple mRS assessments?  
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 Does Central Adjudication of video recordings of mRS assessments: 
a. Provide a feasible method of measuring outcome in a multicentre trial 
setting?  
b. Offer a more accurate measure of outcome?  
c. Allow measurement of more subtle effect on outcome through grading of 
outcomes within mRS categories?  
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Chapter 2  
Statistical Simulations: a 
study of the potential benefits 
of improved mRS reliability on 
study sample size.  
2.1. Introduction 
The global and unstructured nature of the mRs is a great advantage; without relying on 
individual activities of daily living there are no floor or ceiling effects in its application which 
are common to structured intsruments. Typically mRS assessment is based on a clinician’s 
rating of a patient interview. This subjectivity contributes to inter-observer variability, which 
can be considerable. In a recent systematic review and meta-analysis, the overall reliability 
seen in the traditional mRS interview was  0.46 (w 0.9)
99.   Few studies have quantified the 
extent and impact of this in a multicentre clinical trial but its reliability in this context is 
estimated to be poor ( 0.25)100.  Mandatory training in mRS assessment is employed in most 
trials to mitigate this151 but several issues persist in international randomised controlled 
trials; the large number of assessors and cultural differences in activity, treatment and 
rehabilitation of stroke patients.  Further, bias is possible with use of the mRs where 
observers are not or cannot be blinded to treatment allocation. Traditional dichotomised 
methods of outcome analysis disregard important differences between adjacent mRs 
groups94.  There are a number of ways in which our use of the mRs could be improved.  Inter-
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observer variability is associated with endpoint misclassification which in turn can affect trial 
power143 and treatment effect size144, 145.   
We aimed to describe the effect of varying magnitudes of mRS inter-observer variability and 
multiple mRS scores on required sample size for an acute stroke study using statistical 
modelling techniques. 
2.2. Methods 
We performed simulations to demonstrate the effect of increasing mRS reliability, 
considering both dichotomised and ordinal analysis approaches and using multiple raters to 
assign mRS scores. To do this we generated power estimates from simulated mRS studies 
under different combinations of sample size (N), effect size (δ), reliability  (unweighted  and 
quadratically weighted w ), dichotomised mRS outcomes, adjudication panel size (Nadj )  and 
method of summarising mRS across adjudicators (mode, mean and median). In order to test 
the robustness of our simulation findings across a variety of settings, we based the 
proportions in each mRS category and the underlying disability distribution on 3 different 
scenarios; 1) the tPA (NINDS 0-3hrs) study11, 2) the NXY059 study18 and 3) derived from the 
standard normal distribution. A fixed treatment effect (i.e. not based on the therapeutic 
intervention in the above mentioned studies) was chosen to give approximately 80% power 
across N at the lowest common variable (/w or Nadj). This treatment effect was subtracted 
from the disability value of the patients assigned to the treatment group. Power was defined 
as the proportion of simulated data sets where P < 0.05 in a test of equal mRS proportions 
between placebo and treatment groups (Mann-Whitney U test with continuity correction170).  
From each power estimate a proportion of the original sample size (the sample size needed 
at the lowest (/w or Nadj) required was generated.   
2.2.1. The effect of increasing mRS reliability 
To assess the effect of improving reliability, the degree of inter-observer error in assigning 
disability on mRS was varied. A range of reliability based on previous studies of mRS 
reliability were used. Kappa () / weighted kappa [w] of (0.25
100)/[0.74], (0.586)/[0.92], 
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(0.799)/[0.96], (0.9)/[0.99] and (1.0)/[1.0] was simulated by adding varying amounts of 
random statistical noise. Each combination of N, δ and /w was simulated 100,000 times.  
Software used was R (version 2.13.0 for Unix). Parameter combinations that yielded power 
estimates >99% were deemed uninformative and removed. 
2.2.2. The effect of using dichotomised outcomes 
To assess the effect of dichotomised mRS outcome at different levels the above reliability 
simulations were performed using mRS dichotomised at 0-1, 0-2 and 0-3. 
2.2.3. The effect of using multiple scores 
To assess the benefit of multiple mRS assessments, simulations were performed using 
summary statistics (mode/mean/median) of Nadj = 1,2,4 and 9. Each combination of N, δ and 
Nadj was simulated 10,000 times. Reliability ( / w) was represented by the agreement in 
modal mRS between two independent panels of size Nadj. When calculating the mode, ties 
were resolved randomly. Parameter combinations that yielded power estimates >95% were 
deemed uninformative and removed. 
2.3. Results 
All planned simulations were successfully completed. Results are described for a typical 
phase III RCT of n=2000 using the tPA (NINDS 0-3hrs) dataset. Results for each mRS 
distribution [tPA (NINDS 0-3 hrs) dataset, NXY059 dataset and the hypothetical normal 
distribution] are displayed in tabulated form. 
2.3.1. The effect of increasing mRS reliability 
Simulations using the using the tPA (NINDS 0-3hrs) dataset suggest that improving reliability 
in mRS scoring from  (w) 0.25 (0.74) to 0.5 (0.92), 0.7 (0.96), 0.9 (0.99) up to hypothetical 
perfect agreement at  1.0 (1.0) could reduce sample size by n=386, n=490, n=488 and n=484 
respectively. (Tables 2-4). There is a plateau seen at near perfect agreement beyond which 
there is no further potential reduction in sample size. This is seen in both the tPA (NINDS 0-
3hrs dataset and the NXY059 dataset but not in the standard normal distribution. 
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2.3.2. The effect of using dichotomised outcomes 
Simulations using the tPA (NINDS 0-3hrs) dataset suggest that the use of a dichotomised 
outcome at mRS 0-1, 0-2 or 0-3 increases the sample size required by n=843, n=230 or n=884 
at baseline reliability of  (w) 0.25 (0.74).  (Tables 2-4) 
2.3.3. The effect of using multiple scores 
Simulations using the tPA (NINDS 0-3hrs) dataset suggest that a mean mRS score of 2, 4 or 9 
adjudicators can reduce sample size by n=54, n=172 and n=318 respectively.  The use of the 
mode or median of multiple mRS assessments does not convey similar benefits.  The modal 
mRS of up to 9 adjudicators will reduce sample size by a maximum of n=18.  A median mRS 
performs slightly better with maximal reduction in sample size of n=60. (Tables 5-7) 
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Table 2 - Sample size simulations using tPA (NINDS 0-3hrs) study dataset: effect of 
increasing reliability in mRS and the use of dichotomised outcomes 
Total 
Sample 
Size 
(N) 
Effect 
Size 
(δ/SD) 
Power (SE) 
 
[Proportion of N required to match power at =0.25]b 
 
{Proportion of N required to match power at =0.25 with dichotomised outcomes (Fisher exact test)}c 
 
 = 0.25 
w = 0.74 
 = 0.50 
w = 0.92 
 = 0.70 
w = 0.96 
 = 0.9 
w = 0.99 
 = 1.0 
w = 1.0 
 
 
50 
 
 
0.83a 
0.621 (0.001) 
 
[100.0%]b 
 
{0-1 vs 2-6 115.4% 
0-2 vs 3-6 157.7% 
0-3 vs 4-6 638.5%}c 
0.761 (0.001) 
 
[76.9%] 
 
{0-1 vs 2-6 80.8% 
0-2 vs 3-6 134.6% 
0-3 vs 4-6 850.0%} 
0.792 (0.001) 
 
[69.2%] 
 
{0-1 vs 2-6 69.2% 
0-2 vs 3-6 134.6% 
0-3 vs 4-6 888.5%} 
0.797 (0.001) 
 
[69.2%] 
 
0-1 vs 2-6 65.4% 
0-2 vs 3-6 134.6% 
0-3 vs 4-6 896.2%} 
0.797 (0.001) 
 
[69.2%] 
 
0-1 vs 2-6 65.4% 
0-2 vs 3-6 134.6% 
0-3 vs 4-6 903.8%} 
 
 
200 
 
 
0.38a 
0.650 (0.001) 
 
[100.0%] 
 
{0-1 vs 2-6 125.5% 
0-2 vs 3-6 118.6% 
0-3 vs 4-6 229.4%} 
0.767(0.001) 
 
[76.5%] 
 
{0-1 vs 2-6 89.2% 
0-2 vs 3-6 89.2% 
0-3 vs 4-6 222.5%} 
0.800 (0.001) 
 
[70.6%] 
 
{0-1 vs 2-6 73.5% 
0-2 vs 3-6 87.3% 
0-3 vs 4-6 219.6%} 
0.800 (0.001) 
 
[70.6%] 
 
{0-1 vs 2-6 60.8% 
0-2 vs 3-6 85.3% 
0-3 vs 4-6 218.6%} 
0.800 (0.001) 
 
[70.6%] 
 
{0-1 vs 2-6 59.8% 
0-2 vs 3-6 85.3% 
0-3 vs 4-6 218.6%} 
 
 
1000 
 
 
0.17a 
0.675 (0.001) 
 
[100.0%] 
 
{0-1 vs 2-6 136.3% 
0-2 vs 3-6 113.8% 
0-3 vs 4-6 156.1%} 
0.774 (0.001) 
 
[79.6%] 
 
{0-1 vs 2-6 107.4% 
0-2 vs 3-6 85.4% 
0-3 vs 4-6 130.3%} 
0.800 (0.001) 
 
[74.5%] 
 
{0-1 vs 2-6 88.0% 
0-2 vs 3-6 83.8% 
0-3 vs 4-6 125.3%} 
0.800 (0.001) 
 
[74.5%] 
 
{0-1 vs 2-6 69.1% 
0-2 vs 3-6 82.4% 
0-3 vs 4-6 124.4%} 
0.798 (0.001) 
 
[74.7%] 
 
{0-1 vs 2-6 68.1% 
0-2 vs 3-6 82.4% 
0-3 vs 3-6 124.2%} 
 
 
2000 
 
 
0.12a 
0.685 (0.001) 
 
[100.0%] 
 
{0-1 vs 2-6 141.7% 
0-2 vs 3-6 115.2% 
0-3 vs 3-6 144.2%} 
0.776 (0.001) 
 
[80.7%] 
 
{0-1 vs 2-6 113.8% 
0-2 vs 3-6 87.4% 
0-3 vs 4-6 117.5%} 
0.802(0.001) 
 
[75.5%] 
 
{0-1 vs 2-6 93.1% 
0-2 vs 3-6 85.3% 
0-3 vs 4-6 112.2%} 
0.802 (0.001) 
 
[75.6%] 
 
{0-1 vs 2-6 71.5% 
0-2 vs 3-6 84.2% 
0-3 vs 4-6 110.7%} 
0.801 (0.001) 
 
[75.8%] 
 
{0-1 vs 2-6 70.6% 
0-2 vs 3-6 84.1% 
0-3 vs 3-6 110.9%} 
 
Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ) and reliability 
(unweighted kappa  and quadratically weighted w).  The mRS proportions and underlying disability distribution were based on 
the tPA (NINDS 0.3hrs) study.  Each combination of N, δ and  was simulated 1e+05 times.  Power is defined as the proportion of 
simulated data sets where P<0.05 in a test of equal mRS proportions between placebo and treatments groups (Mann Whitney U 
test with continuity correction).  Parameter combinations that yielded power estimates >99% were deemed uninformative and 
removed. 
 
aEffect size chosen to give approximately 80% power across N at  = 1.0 (not related to the effect size seen in the original trial) 
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline level of 
interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved interobserver reliability is 
noted in each column as a percentage of the original sample size 
c
Proportion of n required (expressed as percentage of original sample size at baseline interobserver reliability (=0.25) with use 
of dichotomised endpoint (0-1 vs 2-6 / 0-2 vs 3-6 / 0-3 vs 4-6) 
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Table 3 - Sample size simulations using NXY059 study dataset: effect of increasing 
reliability in mRS and the use of dichotomised outcomes 
Total 
Sample 
Size 
(N) 
Effect 
Size 
(δ/SD) 
Power (SE) 
 
[Proportion of N required to match power at =0.25] b 
 
{Proportion of N required to match power at =0.25 with dichotomised outcomes (Fisher exact test)} c 
 = 0.25 
w = 0.74 
 = 0.50 
w = 0.92 
 = 0.70 
w = 0.96 
 = 0.9 
w = 0.99 
 = 1.0 
w = 1.0 
 
 
50 
 
 
0.80a 
0.622 (0.001) 
 
[100.0%]
 b
 
 
{0-1 vs 2-6 130.8% 
0-2 vs 3-6 165.4% 
0-3 vs 3-6 273.1%}
 c
 
0.787 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 92.3% 
0-2 vs 3-6 123.1% 
0-3 vs 3-6 238.5%} 
0.808 (0.001) 
 
[73.1%]
 
 
 
{0-1 vs 2-6 84.6% 
0-2 vs 3-6 115.4% 
0-3 vs 3-6 234.6%} 
0.804 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 80.8% 
0-2 vs 3-6 115.4% 
0-3 vs 3-6 234.6%} 
0.799 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 80.8% 
0-2 vs 3-6 115.4% 
0-3 vs 3-6 234.6%} 
 
 
200 
 
 
0.38a 
0.660 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 125.5% 
0-2 vs 3-6 131.4% 
0-3 vs 3-6 164.7%} 
0.787(0.001) 
 
[74.5%]
 
 
 
{0-1 vs 2-6 86.3% 
0-2 vs 3-6 90.2% 
0-3 vs 3-6 125.5%} 
0.811 (0.001) 
 
[70.6%]
 
 
 
{0-1 vs 2-6 80.4% 
0-2 vs 3-6 83.3% 
0-3 vs 3-6 118.6%} 
0.807 (0.001) 
 
[70.6%]
 
 
 
{0-1 vs 2-6 77.5% 
0-2 vs 3-6 81.4% 
0-3 vs 3-6 116.7%} 
0.804 (0.001) 
 
[71.6%]
 
 
 
{0-1 vs 2-6 77.5% 
0-2 vs 3-6 81.4% 
0-3 vs 3-6 116.7%} 
 
 
1000 
 
 
0.17a 
0.654 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 127.2% 
0-2 vs 3-6 119.6% 
0-3 vs 3-6 138.0%} 
0.783 (0.001) 
 
[74.2%]
 
 
 
{0-1 vs 2-6 90.0% 
0-2 vs 3-6 81.0% 
0-3 vs 3-6 99.2%} 
0.808 (0.001) 
 
[69.8%]
 
 
 
{0-1 vs 2-6 83.4% 
0-2 vs 3-6 74.6% 
0-3 vs 3-6 93.2%} 
0.806 (0.001) 
 
[70.0%]
 
 
 
{0-1 vs 2-6 81.6% 
0-2 vs 3-6 73.0% 
0-3 vs 3-6 91.4%} 
0.804 (0.001) 
 
[70.6%]
 
 
 
{0-1 vs 2-6 81.6% 
0-2 vs 3-6 72.8% 
0-3 vs 3-6 91.2%} 
 
 
2000 
 
 
0.12
a
 
0.655 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 128.3% 
0-2 vs 3-6 118.3% 
0-3 vs 3-6 131.8%} 
0.781 (0.001) 
 
[74.4%]
 
 
 
{0-1 vs 2-6 90.9% 
0-2 vs 3-6 80.6% 
0-3 vs 3-6 95.0%} 
0.806(0.001) 
 
[70.1%]
 
 
 
{0-1 vs 2-6 84.1% 
0-2 vs 3-6 73.9% 
0-3 vs 3-6 89.2%} 
0.805 (0.001) 
 
[70.0%]
 
 
 
{0-1 vs 2-6 82.1% 
0-2 vs 3-6 72.1% 
0-3 vs 3-6 87.3%} 
0.803 (0.001) 
 
[70.5%]
 
 
 
{0-1 vs 2-6 81.8% 
0-2 vs 3-6 72.0% 
0-3 vs 3-6 87.1%} 
Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ) and reliability 
(unweighted kappa  and quadratically weighted w).  The mRS proportions and underlying disability distribution were based on 
the NXY059 study.  Each combination of N, δ and  was simulated 1e+05 times.  Power is defined as the proportion of simulated 
data sets where P<0.05 in a test of equal mRS proportions between placebo and treatments groups (Mann Whitney U test with 
continuity correction).  Parameter combinations that yielded power estimates >99% were deemed uninformative and removed. 
 
aEffect size chosen to give approximately 80% power across N at  = 1.0 (not related to the effect size seen in the original trial) 
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline level of 
interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved interobserver reliability is 
noted in each column as a percentage of the original sample size 
c
Proportion of n required (expressed as percentage of original sample size at baseline interobserver reliability (=0.25) with use 
of dichotomised endpoint (0-1 vs 2-6 / 0-2 vs 3-6 / 0-3 vs 4-6) 
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Table 4 - Sample size simulations using the standard normal distribution: effect of 
increasing reliability in mRS and the use of dichotomised outcomes 
Total 
Sample 
Size 
(N) 
Effect 
Size 
(δ/SD) 
Power (SE) 
 
[Proportion of N required to match power at =0.25] b 
 
{Proportion of N required to match power at =0.25 with dichotomised outcomes (Fisher exact test)} c 
 = 0.25 
w = 0.74 
 = 0.50 
w = 0.92 
 = 0.70 
w = 0.96 
 = 0.9 
w = 0.99 
 = 1.0 
w = 1.0 
 
 
50 
 
 
0.86a 
0.646 (0.001) 
 
[100.0%]
 b
 
 
{0-1 vs 2-6 153.8% 
0-2 vs 3-6 176.9% 
0-3 vs 3-6 238.5%}
 c
 
0.760 (0.001) 
 
[80.8%]
 
 
 
{0-1 vs 2-6 119.2% 
0-2 vs 3-6 142.3% 
0-3 vs 3-6 192.3%} 
0.781 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 115.4% 
0-2 vs 3-6 134.6% 
0-3 vs 3-6 184.6%} 
0.790 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 111.5% 
0-2 vs 3-6 134.6% 
0-3 vs 3-6 180.8%} 
0.790 (0.001) 
 
[76.9%]
 
 
 
{0-1 vs 2-6 111.5% 
0-2 vs 3-6 130.8% 
0-3 vs 3-6 180.8%} 
 
 
200 
 
 
0.42a 
0.667 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 156.4% 
0-2 vs 3-6 156.4% 
0-3 vs 3-6 181.2%} 
0.775(0.001) 
 
[78.2%]
 
 
 
{0-1 vs 2-6 122.8% 
0-2 vs 3-6 122.8% 
0-3 vs 3-6 145.5%} 
0.794 (0.001) 
 
[75.2%]
 
 
 
{0-1 vs 2-6 116.8% 
0-2 vs 3-6 116.8% 
0-3 vs 3-6 140.6%} 
0.801 (0.001) 
 
[74.3%]
 
 
 
{0-1 vs 2-6 114.9% 
0-2 vs 3-6 115.8% 
0-3 vs 3-6 138.6%} 
0.802 (0.001) 
 
[73.3%]
 
 
 
{0-1 vs 2-6 114.9% 
0-2 vs 3-6 114.9% 
0-3 vs 3-6 138.6%} 
 
 
1000 
 
 
0.19a 
0.669 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 154.7% 
0-2 vs 3-6 145.5% 
0-3 vs 3-6 161.3%} 
0.779 (0.001) 
 
[77.4%]
 
 
 
{0-1 vs 2-6 120.4% 
0-2 vs 3-6 113.6% 
0-3 vs 3-6 127.7%} 
0.798 (0.001) 
 
[73.9%]
 
 
 
{0-1 vs 2-6 115.0% 
0-2 vs 3-6 108.6% 
0-3 vs 3-6 122.8%} 
0.805 (0.001) 
 
[72.7%]
 
 
 
{0-1 vs 2-6 113.6% 
0-2 vs 3-6 106.6% 
0 – 3 121.0%} 
0.806 (0.001) 
 
[72.5%]
 
 
 
{0-1 vs 2-6 113.6% 
0-2 vs 3-6 106.4% 
0-3 vs 3-6 120.4%} 
 
 
2000 
 
 
0.13a 
0.676 (0.001) 
 
[100.0%]
 
 
 
{0-1 vs 2-6 152.1% 
0-2 vs 3-6 145.2% 
0-3 vs 3-6 156.5%} 
0.786 (0.001) 
 
[77.3%]
 
 
 
{0-1 vs 2-6 120.0% 
0-2 vs 3-6 112.9% 
0-3 vs 3-6 124.4%} 
0.804 (0.001) 
 
[73.9%]
 
 
 
{0-1 vs 2-6 115.1% 
0-2 vs 3-6 108.0% 
0-3 vs 3-6 119.3%} 
0.811 (0.001) 
 
[72.6%]
 
 
 
{0-1 vs 2-6 113.2% 
0-2 vs 3-6 106.2% 
0-3 vs 3-6 117.7%} 
0.812 (0.001) 
 
[72.5%]
 
 
 
{0-1 vs 2-6 112.9% 
0-2 vs 3-6 106.1% 
0-3 vs 3-6 117.8%} 
Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ) and reliability 
(unweighted kappa  and quadratically weighted w).  The mRS proportions and underlying disability distribution were derived 
from the standard normal distribution.  Each combination of N, δ and  was simulated 1e+05 times.  Power is defined as the 
proportion of simulated data sets where P<0.05 in a test of equal mRS proportions between placebo and treatments groups (Mann 
Whitney U test with continuity correction).  Parameter combinations that yielded power estimates >99% were deemed 
uninformative and removed. 
 
a
Effect size chosen to give approximately 80% power across N at  = 1.0  
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline level of 
interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved interobserver reliability is 
noted in each column as a percentage of the original sample size 
c
Proportion of n required (expressed as percentage of original sample size at baseline interobserver reliability (=0.25) with use of 
dichotomised endpoint (0-1 vs 2-6 / 0-2 vs 3-6 / 0-3 vs 4-6) 
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Table 5 - Sample size simulations using tPA (NINDS 0-3hrs) study dataset: effect of 
multiple scores (mode / mean / median) 
 
Total 
Sample 
Size 
(N) 
 
Effect 
Size 
(δ/SD) 
 
Summary 
Statistic 
Power (SE) 
 
[Proportion of N required to match power at Nadj = 1]
 b 
 
 Nadj = 1 
 = 0.7 
w = 0.96 
Nadj = 2 
 = 0.7 
w = 0.96 
Nadj = 4 
 = 0.78 
w = 0.97 
Nadj = 9 
 = 0.86 
w = 0.98 
 
 
50 
 
 
0.81a 
Mode 
 
Mean 
 
Median 
 
0.789 (0.004) 
[100.0%] b  
0.789 (0.004) 
[100.0%]  
0.789 (0.004) 
[100.0%]
 
 
0.778 (0.004) 
[100.0%]  
0.808 (0.004) 
[92.9%]  
0.808 (0.004) 
[92.9%]
 
 
0.786 (0.004) 
[96.4%]  
0.840 (0.004) 
[85.7%]  
0.804 (0.004) 
[92.9%]
 
 
0.786 (0.004) 
[96.4%]  
0.868 (0.004) 
[82.1%]  
0.786 (0.004) 
[96.4%]
 
 
 
 
200 
 
 
0.40a 
Mode 
 
Mean 
 
Median 
0.838 (0.004) 
[100.0%]  
0.838 (0.004) 
[100.0%]  
0.838 (0.004) 
[100.0%]  
0.834 (0.004) 
[101.0%]  
0.849 (0.004) 
[96.2%]  
0.849 (0.004) 
[96.2%]  
0.842 (0.004) 
[99.0%]  
0.874 (0.004) 
[90.4%]  
0.852 (0.004) 
[96.2%]  
0.841 (0.004) 
[99.0%]  
0.901 (0.004) 
[83.7%]  
0.841 (0.004) 
[99.0%]  
 
 
1000 
 
 
0.18
a
 
Mode 
 
Mean 
 
Median 
0.821 (0.004) 
[100.0%]  
0.821 (0.004) 
[100.0%]  
0.821 (0.004) 
[100.0%]  
0.820 (0.004) 
[99.8%]  
0.829 (0.004) 
[97.0%]  
0.829 (0.004) 
[97.0%]  
0.828 (0.004) 
[98.6%]  
0.856 (0.004) 
[90.9%]  
0.832 (0.004) 
[96.4%]  
0.823 (0.004) 
[99.0%]  
0.881 (0.004) 
[83.9%]  
0.823 (0.004) 
[99.0%]  
 
 
2000 
 
 
0.13a 
Mode 
 
Mean 
 
Median 
0.806 (0.004) 
[100.0%]
 
 
0.806 (0.004) 
[100.0%]  
0.806 (0.004) 
[100.0%]  
0.804 (0.004) 
[100.0%]
 
 
0.815 (0.004) 
[97.3%]  
0.815 (0.004) 
[97.3%]  
0.807 (0.004) 
[99.1%]
 
 
0.840 (0.004) 
[91.4%]  
0.815 (0.004) 
[97.0%]  
0.811 (0.004) 
[99.2%] 
0.867 (0.004) 
[84.1%] 
0.811 (0.004) 
[99.2%] 
 Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ), 
adjudication panel size (Nadj ) and associated reliability  (unweighted  and quadratically weighted w ), and method of 
summarising mRS across adjudicators (mode, mean and median).  The mRS proportions and underlying disability 
distribution were based on the tPA (NINDS 0-3hrs) study.  Each combination of N, δ and Nadj was simulated 10,000 
times.  Power is defined as the proportion of simulated data sets where P < 0.05 in a test of equal mRS proportions 
between placebo and treatment groups (Man-Whitney U test with continuity correction).  Reliability represents the 
agreement in modal mRS between two independent panels of size Nadj.  When calculating the mode, ties were 
resolved randomly.  Parameter combinations that yielded power estimates >95% were deemed uninformative and 
removed. 
 
a
Effect size chosen to give approximately 80% power across N at Nadj = 1(not related to the effect size seen in the 
original trial) 
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline 
level of interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved 
interobserver reliability is noted in each column as a percentage of the original sample size 
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Table 6 - Sample size simulations using NXY059 study dataset: effect of multiple 
scores (mode / mean / median) 
 
Total 
Sample 
Size 
(N) 
 
Effect 
Size 
(δ/SD) 
 
Summary 
Statistic 
Power (SE) 
 
[Proportion of N required to match power at Nadj = 1]
 b 
 
 Nadj = 1 
 = 0.7 
w = 0.96 
Nadj = 2 
 = 0.7 
w = 0.96 
Nadj = 4 
 = 0.78 
w = 0.97 
Nadj = 9 
 = 0.86 
w = 0.98 
 
 
50 
 
 
0.81a 
Mode 
 
Mean 
 
Median 
 
0.810 (0.004) 
[100.0%] b 
0.810 (0.004) 
[100.0%] 
0.810 (0.004) 
[100.0%] 
0.810 (0.004) 
[100.0%] 
0.816 (0.004) 
[100.0%] 
0.816 (0.004) 
[100.0%] 
0.811 (0.004) 
[100.0%] 
0.825 (0.004) 
[96.3%] 
0.811 (0.004) 
[100.0%] 
0.808 (0.004) 
[103.7%] 
0.836 (0.004) 
[96.3%] 
0.808 (0.004) 
[103.7%] 
 
 
200 
 
 
0.40a 
Mode 
 
Mean 
 
Median 
0.841 (0.004) 
[100.0%] 
0.841 (0.004) 
[100.0%] 
0.841 (0.004) 
[100.0%] 
0.845 (0.004) 
[101.0%] 
0.842 (0.004) 
[96.2%] 
0.842 (0.004) 
[96.2%] 
0.843 (0.004) 
[100.0%] 
0.843 (0.004) 
[99.0%] 
0.840 (0.004) 
[100.0%] 
0.839 (0.004) 
[100.0%] 
0.851 (0.004) 
[97.1%] 
0.839 (0.004) 
[100.0%] 
 
 
1000 
 
 
0.18a 
Mode 
 
Mean 
 
Median 
0.838 (0.004) 
[100.0%] 
0.838 (0.004) 
[100.0%] 
0.838 (0.004) 
[100.0%] 
0.839 (0.004) 
[99.8%] 
0.836 (0.004) 
[100.4%] 
0.836 (0.004) 
[100.4%] 
0.840 (0.004) 
[99.6%] 
0.841 (0.004) 
[99.6%] 
0.838 (0.004) 
[100.2%] 
0.840 (0.004) 
[100.0%] 
0.848 (0.004) 
[97.8%] 
0.840 (0.004) 
[100.0%] 
 
 
2000 
 
 
0.13
a
 
Mode 
 
Mean 
 
Median 
0.841 (0.004) 
[100.0%] 
0.841 (0.004) 
[100.0%] 
0.841 (0.004) 
[100.0%] 
0.840 (0.004) 
[99.9%] 
0.840 (0.004) 
[100.2%] 
0.840 (0.004) 
[100.2%] 
0.844 (0.004) 
[99.6%] 
0.842 (0.004) 
[99.5%] 
0.839 (0.004) 
[100.2%] 
0.842 (0.004) 
[99.9%] 
0.849 (0.004) 
[97.6%] 
0.843 (0.004) 
[99.9%] 
 Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ), 
adjudication panel size (Nadj ) and associated reliability  (unweighted  and quadratically weighted w ), and method of 
summarising mRS across adjudicators (mode, mean and median).  The mRS proportions and underlying disability 
distribution were based on the NZY059 study.  Each combination of N, δ and Nadj was simulated 10,000 times.  Power 
is defined as the proportion of simulated data sets where P < 0.05 in a test of equal mRS proportions between placebo 
and treatment groups (Man-Whitney U test with continuity correction).  Reliability represents the agreement in modal 
mRS between two independent panels of size Nadj.  When calculating the mode, ties were resolved randomly.  
Parameter combinations that yielded power estimates >95% were deemed uninformative and removed. 
 
aEffect size chosen to give approximately 80% power across N at Nadj = 1 (not related to the effect size seen in the 
original trial) 
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline 
level of interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved 
interobserver reliability is noted in each column as a percentage of the original sample size 
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Table 7 - Sample size simulations using the standard normal distribution: effect of 
multiple scores (mode / mean / median) 
 
Total 
Sample 
Size 
(N) 
 
Effect 
Size 
(δ/SD) 
 
Summary 
Statistic 
Power (SE) 
 
[Proportion of N required to match power at Nadj = 1]
 b 
 
 Nadj = 1 
 = 0.7 
w = 0.96 
Nadj = 2 
 = 0.7 
w = 0.96 
Nadj = 4 
 = 0.78 
w = 0.97 
Nadj = 9 
 = 0.86 
w = 0.98 
 
 
50 
 
 
0.81a 
Mode 
 
Mean 
 
Median 
 
0.736 (0.004) 
[100.0%] b 
0.736 (0.004) 
[100.0%] 
0.736 (0.004) 
[100.0%] 
0.739 (0.004) 
[100.0%] 
0.748 (0.004) 
[96.3%] 
0.748 (0.004) 
[96.3%] 
0.741 (0.004) 
[100.0%] 
0.756 (0.004) 
[96.3%] 
0.746 (0.004) 
[96.3%] 
0.745 (0.004) 
[96.3%] 
0.758 (0.004) 
[96.3%] 
0.746 (0.004) 
[96.3%] 
 
 
200 
 
 
0.40
a
 
Mode 
 
Mean 
 
Median 
0.752 (0.004) 
[100.0%] 
0.752 (0.004) 
[100.0%] 
0.752 (0.004) 
[100.0%] 
0.752 (0.004) 
[100.0%] 
0.760 (0.004) 
[98.0%] 
0.760 (0.004) 
[98.0%] 
0.760 (0.004) 
[99.0%] 
0.769 (0.004) 
[96.1%] 
0.762 (0.004) 
[98.0%] 
0.762 (0.004) 
[98.0%] 
0.773 (0.004) 
[95.1%] 
0.762 (0.004) 
[98.0%] 
 
 
1000 
 
 
0.18a 
Mode 
 
Mean 
 
Median 
0.743 (0.004) 
[100.0%] 
0.743 (0.004) 
[100.0%] 
0.743 (0.004) 
[100.0%] 
0.747 (0.004) 
[100.0%] 
0.757 (0.004) 
[97.6%] 
0.757 (0.004) 
[97.6%] 
0.748 (0.004) 
[99.0%] 
0.761 (0.004) 
[96.2%] 
0.756 (0.004) 
[97.8%] 
0.753 (0.004) 
[98.0%] 
0.763 (0.004) 
[95.8%] 
0.753 (0.004) 
[98.0%] 
 
 
2000 
 
 
0.13
a
 
Mode 
 
Mean 
 
Median 
0.755 (0.004) 
[100.0%] 
0.755 (0.004) 
[100.0%] 
0.755 (0.004) 
[100.0%] 
0.756 (0.004) 
[100.1%] 
0.765 (0.004) 
[97.8%] 
0.765 (0.004) 
[97.8%] 
0.763 (0.004) 
[99.0%] 
0.773 (0.004) 
[96.4%] 
0.766 (0.004) 
[97.7%] 
0.765 (0.004) 
[98.4%] 
0.777 (0.004) 
[95.5%] 
0.765 (0.004) 
[98.4%] 
 Power estimates from simulated mRS studies under different combinations of sample size (N), effect size (δ), 
adjudication panel size (Nadj ) and associated reliability  (unweighted  and quadratically weighted w ), and method of 
summarising mRS across adjudicators (mode, mean and median).  The mRS proportions and underlying disability 
distribution were derived from the standard normal distribution.  Each combination of N, δ and Nadj was simulated 
10,000 times.  Power is defined as the proportion of simulated data sets where P < 0.05 in a test of equal mRS 
proportions between placebo and treatment groups (Man-Whitney U test with continuity correction).  Reliability 
represents the agreement in modal mRS between two independent panels of size Nadj.  When calculating the mode, 
ties were resolved randomly.  Parameter combinations that yielded power estimates >95% were deemed 
uninformative and removed. 
 
aEffect size chosen to give approximately 80% power across N at Nadj = 1 
bFor each example sample size (n=50, 200, 1000 and 2000) the proportion of that sample size required at the baseline 
level of interobserver reliability (=0.25)  is noted as 100%; the proportion of n that is required with improved 
interobserver reliability is noted in each column as a percentage of the original sample size 
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2.4. Conclusions 
We found significant potential for reducing required trial sample size and / or increasing trial 
power through improving reliability of mRs assessments. A reduction in sample size of 20% to 
25% was seen in each simulation with improvement of mRS reliability from baseline  0.25 to 
 0.5 or  0.7.  
Previous studies assessing the inter-rater reliability of the mRS have predominantly been 
conducted in small, single centre studies with highly motivated individuals. Inter-observer 
reliability in a large scale clinical trial with the associated challenges; multicentre / 
multicultural / assessors from different professional backgrounds and level of experience; is 
likely to be poorer.   
Simulations using real life mRS distributions from previous phase three clinical trials suggest 
that improving inter-rater reliability in mRS assessment may have positive effects on sample 
size. The use of multiple mRS assessments has similar beneficial effects in simulation.  
Interestingly we see a plateau in this improvement at near perfect agreement ( (w) 0.9 
(0.99)  and  1.0).  This is not seen in the simulations using a hypothetical normal 
distribution.  We propose that this is due to a statistical phenomenon; stochastic 
resonance171:  small levels of variability or noise are present in the “real life” mRS 
distributions that are not present in the smooth normal distribution which lowers the 
agreement threshold at extremes of the scale.   
The potential loss of valuable mRS information where a dichotomised mRS outcome is used is 
well documented154. Our simulations quantify the increase in sample size that would be 
required with dichotomisation at mRS boundaries 0-1, 0-2 and 0-3. The optimal cut off for 
dichotomisation is debated and often chosen arbitrarily153 and our data further support the 
assertion that dichotomised mRS outcomes offer a sub optimal method of analysing acute 
stroke data and is statistically inefficient.   
Studies with a sample size larger than necessary are economically and ethically unjustified.  
The potential reduction in sample size seen in these simulations may have a substantial 
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positive financial implication but may also deliver important ethical benefits.  We must 
involve as few participants in research as necessary to provide the evidence required to 
confirm or refute our hypotheses.  In a standard phase III RCT of n=2000 the potential saving 
might run to millions of pounds if the required sample size is cut by 25%.  
We have demonstrated through simulations that there are benefits to be reaped if the use of 
the mRS as an outcome measure can be optimised.  There are strengths and weaknesses to 
this analysis.  We used two trial datasets to assess generalisability and found broad 
agreement between results. However, although based on real life trial datasets, simulations 
are no comparison to real life data.  They allow us to speculate that there may be 
improvements in required sample size but it remains to be seen if these benefits might 
translate into real life economic and ethical savings in the future.   
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Chapter 3  
The methodology, design and 
conduct of the CARS trial: 
Central Adjudication of 
modified Rankin Scale 
disability assessments in 
acute stroke trials. 
3.1. Introduction 
The importance of a robust functional outcome measure in acute stroke trials is evident. As 
we have discussed, the use of consistent and reproducible outcome scales has become a 
mandatory element of good trial design6, the most commonly used outcome measure being 
the modified Rankin scale (mRS)29  
For many years, aided by the development of fast and easy data transfer through secure 
electronic means, trialists in all medical fields have preferred to include electronic data 
collection and remote adjudication of their chosen study outcome where possible. Central 
reading of electrocardiograms, radiological images or mortality data is common practice in 
randomised controlled trials (RCTs) and is encouraged where the data is in a format that is 
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easily transferred to an independent central adjudicator or adjudication committee. This 
conveys several benefits including standardisation, quality control and reliable blinding.  
There is also a reduction in the number of trial investigators responsible for assigning 
outcome, likely to reduce the variability in scoring (reduced endpoint misclassification) and 
limit the chance of the study suffering the effects of type II error in data analysis. Despite the 
trend towards the use of a functional outcome as the primary endpoint in acute stroke trials, 
the concept of central adjudication of functional outcome has not been explored. We sought 
to investigate the feasibility, acceptability, validity and reliability of central adjudication of 
modified Rankin scale (mRS) assessments in a multicentre trial setting.  
3.2. The CARS study - Central Adjudication of modified Rankin Scale disability 
assessments in acute stroke trials. 
A “virtual” multicentre acute stroke trial was performed to assess the practicalities of using 
centrally adjudicated outcomes as a primary trial endpoint.  The study was designed and 
conducted to emulate a typical contemporary acute stroke trial but there was no 
randomisation or intervention.  We aimed to clarify the extent of possible endpoint 
misclassification and establish the validity and reliability of mRS outcomes assigned centrally.  
Ethical approval for all study procedures was granted by Scotland A Research Ethics 
Committee (08/MRE00/72) and Essex 2 Research Ethics Committee (08/H0203/147) for study 
sites in Scotland and England/Wales respectively.  The study was funded by the Chief 
Scientist Office (CSO reference number CBZ/4/595) and was supported by the UK Stroke 
Research Network. 
3.3. Primary Research Questions 
Our primary research questions were as follows; 
Does central adjudication of video recordings of mRS assessments: 
1. Provide a feasible method of measuring outcome in a multicentre trial setting? 
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2. Offer a more accurate measure of outcome? 
i.e.  Does outcome from central adjudication correlate better than on site raters’ assessments 
with factors known to influence outcome (such as baseline NIHSS, glucose and blood 
pressure) 
3. Allow measurement of more subtle effects on outcome?  
i.e. Through grading of outcomes within mRS categories? 
3.4. Trial Design 
3.4.1. Study Population 
Participants with a diagnosis of acute stroke of any aetiology who presented within 48 hours 
of ictus and with a demonstrable deficit on the National Institutes of Health Stroke Scale 
(NIHSS) were considered for inclusion in the study. Participants who had prior disability were 
excluded from the study in line with standard practice for acute stroke treatment trials.   
Inclusion and exclusion criteria are detailed in Figure 7.  
Inclusion Criteria: 
 
1. Diagnosis of Acute Stroke (ischaemic or haemorrhagic) 
2. Recruitment within 48 hours of stroke onset 
3. Demonstrable deficit on NIHSS (greater than 1) 
Exclusion Criteria: 1. Pre-morbid mRS score of ≥3 
Figure 7 CARS study Inclusion and Exclusion Criteria 
We aimed to recruit a minimum of 300 participants. This sample size was chosen as it reflects 
the minimum number of participants likely to be required in a phase III acute stroke trial of a 
reperfusion strategy and could provide sufficient video assessments to enable us to evaluate 
 57 
the technique and its impact upon trial design. We expected over 240 final assessments after 
accounting for mortality and withdrawals. 
3.4.2. Consent Procedure 
Participants were identified by a member of the treating clinical team as soon as possible 
after admission to the stroke unit. Suitable participants and/or their nearest relative were 
approached by a member of the clinical team with a brief description of the study. Where an 
interest in participation was noted, a research team member explained the study fully and 
obtained informed consent. Consent was sought as soon as possible after the stroke event in 
order to assess the practicalities of recruitment to a study of this nature. However, as no 
study specific procedures were involved within the initial days of admission, participants and 
relatives were given up to 48 hours within which to decide. 
Research trials in acute stroke are frequently specifically designed to assist adults who are 
unable to consent for themselves. This is because the inherent nature of stroke disease often 
affects communication or cognitive abilities. For this reason, where individuals were unable 
to consent for themselves, assent from a relative / welfare guardian was sought. In practical 
terms the early procedures were indistinguishable from normal clinical care and only the 
later study procedures were considered more intrusive. If a participant subsequently 
regained the ability to provide their own consent they were asked to do so at future follow 
up visits and were given the opportunity to discontinue participation in the study if desired.   
3.4.3. Study Centres 
The study was co-ordinated from the University of Glasgow, based in the Institute of 
Cardiovascular and Medical Sciences, Western Infirmary. Fourteen centres were involved in 
the study, six in Scotland and eight in England/Wales.  The study was adopted by the UK 
Stroke Research Network.  Study centres are detailed in Figure 8. 
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Scotland 
Scotland A REC (08/MRE00/72) 
Aberdeen Royal Infirmary 
Glasgow Royal Infirmary 
Ninewells Hospital, Dundee 
Southern General Hospital, Glasgow 
Stobhill Hospital, Glasgow 
Western Infirmary, Glasgow 
England / Wales 
Essex 2 REC (08/H0203/147) 
Countess of Chester Hospital, Chester 
Cumberland Infirmary, Carlisle 
Harrogate District General Hospital 
Leeds General Infirmary 
Royal Devon and Exeter Hospital 
Royal Glamorgan Hospital 
Wakefield (Pinderfields) Hospital 
York Hospital 
Figure 8 CARS study centres 
3.4.4. Study Investigators 
Investigators at each site included medical staff, research nursing staff and allied health 
professionals involved in the care of acute stroke patients. A delegation log of investigators 
was held at each site and copied to the co-ordinating centre. All investigators were trained 
and certified in the use of the mRS and NIHSS assessment through trainingcampus©, an 
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internet based training and certification resource172, 173. Investigators were visited at each 
centre by a member of the co-ordinating study team to initiate the site and provide training 
in the study procedures and equipment.  Written guidance was prepared and provided to all 
investigators. (See Appendix 1) 
3.4.5. Study Procedures 
Baseline data were collected at the time of recruitment including demographics, stroke 
subtype, NIHSS, medications, blood pressure, blood results and imaging results. No 
intervention or change to normal routine clinical care occurred during the study. Endpoint 
assessments were performed as they would be in an interventional trial (mRS, NIHSS, Serious 
Adverse Events (SAE), medications and home time). Two endpoint assessment visits were 
carried out at 30 and 90 days following the stroke event. The sequence of study procedures is 
outlined in Figure 9.  Data were recorded locally on paper case report forms and also entered 
into an electronic case report form (eCRF) for remote access by the co-ordinating centre. 
 
 
 
 
 
 
 
 
Recruitment Day 30 Day 90 
Demographic Data 
Stroke subtype 
Baseline NIHSS 
Medications 
Blood Pressure 
Blood results 
Imaging results 
Clinical Review 
mRs Assessment 
NIHSS 
Home Time 
Medications 
SAE 
 
Clinical Review 
mRs Assessment 
NIHSS 
Home Time 
Medications 
SAE 
 
Figure 9 - CARS study procedure flowchart 
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3.4.5.1. Baseline Factors know to affect stroke outcome 
Baseline stroke severity is well recognised as a predictor of functional outcome after stroke.  
Measurement of stroke severity using the NIHSS is the most useful marker to predict poor 
functional outcome174, 175. Hypertension is common in the stroke population and often 
diagnosed only after presentation with a stroke event. Regardless of whether hypertension 
has been previously diagnosed or is found only at the time of admission, there is a well 
documented association between baseline blood pressure and poor functional outcome176, 
177. Diabetes is a recognised risk factor for stroke and similarly raised admission blood glucose 
level, whether previously diagnosed as diabetes / glucose intolerance or an incidental finding 
is associated with poor functional outcome178-180.  
We collected these data at baseline in order to compare local and centrally adjudicated mRS 
as an outcome measure relative to these factors previously known to be associated with 
functional outcome.  
 
3.4.5.2. The modified Rankin scale assessment 
The mRS assessment was performed in standard fashion according to normal practice at each 
centre. Assessments were performed in hospital wards, outpatient clinics or in participants’ 
homes depending upon their location at the time of follow up. The mRS was recorded using a 
digital video camera. Where a participant was unable to be involved in an interview, due to 
significant disability or communication difficulties, a proxy was used. The chosen proxy was a 
relative, friend or health care provider with a good knowledge of the participant’s functional 
capabilities.  
The mRS video clip contained an image of the participant and/or their proxy.  The assessor 
was not seen in the clip but their voice was audible.  Anonymity was otherwise preserved.  
The recommended position of the camera in relation to the participant and assessor is 
demonstrated in Figure 10. 
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Figure 10 - Recommended position of participants, camera and microphone for 
mRS video assessment 
The local investigator assigned a mRS score for the patient and entered this into the eCRF 
(the standard / local mRS score).  Where possible the investigator remained constant across 
the follow-up period for a given patient, although we recognised that this was not possible in 
all cases, particularly in smaller sites with fewer investigators.  In centres where it was 
standard practice to perform a structured mRS interview, an area was made available in the 
eCRF for entry of this score. The recorded mRS interview was uploaded to the eCRF through 
an internet based portal. These assessments were then reviewed by the co-ordinating centre 
according to a standard procedure, resulting in entry of the adjudicated mRS score (see 
section 3.4.6.2). 
3.4.5.3. The NIHSS assessment 
NIHSS assessments were performed in the standard fashion at each site. All investigators 
were trained and certified in the administration of this assessment tool. 
 
Participant 
Investigator 
 
External Boundary 
Microphone 
Camera 
[Canon Camera 
demonstrated] 
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3.4.5.4. Home Time Assessment 
As a relatively novel but previously validated stroke outcome measure181, 182 we included 
assessment of “Home Time” as a further comparative outcome measure. Home time is a 
measurement of the duration of time that a patient lives independently in the community 
following a stroke event. This is more useful than a simple measure of inpatient stay as 
shorter hospital stay does not always reflect a good outcome and in many cases may be 
associated with a poor outcome, for example death or early transfer to a long term 
institutional care facility. We collected Home Time data at 30 and 90 day follow up visits.   
3.4.5.5. Recording of Serious Adverse Events 
As an observational trial, recording of adverse events was not a legal requirement in line with 
good clinical practice (GCP) guidelines. However we aimed to co-ordinate the study in a 
similar manner to a clinical intervention trial and therefore in order emulate the practicalities 
of this as closely as possible we included collection of serious adverse events (SAE) in our 
case report form. An additional aim of SAE reporting was to help us to better identify 
individuals where the video technique was unsuitable or problematic. A serious adverse 
event was defined as an event that: a) results in death, b) is life threatening, c) requires 
hospitalisation or prolongation of existing hospitalisation, d) results in persistent or 
significant disability or incapacity or e) consists of a congenital anomaly or birth defect.  
3.4.5.6. Study Withdrawal / Completion 
Study completion was indicated to the co-ordinating centre via the eCRF after the 90 day 
visit. Where a participant chose not to return for follow up they were withdrawn from the 
study. The date of last contact with the participant and a reason for withdrawal (where 
available) was detailed in the eCRF. In this case participants were asked if they were happy 
for the data collected prior to withdrawal to be used in analysis.  If they chose to withdraw 
consent entirely their data was not used in future analysis - this was clearly documented in 
the eCRF. 
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3.4.6. Review of Video mRS assessments 
The review of mRS video assessments was co-ordinated through the web based portal by the 
study outcomes manager. 
3.4.6.1. Handling of mRS clips 
After initial upload of a video clip through the CARS web portal (see section 3.4.6.3) the study 
outcomes manager was notified by automated email. The clip was assessed for technical 
adequacy and anonymity. 
If the clip was deemed inadequate, either because of technical difficulties (e.g. poor sound 
quality) or deficiencies in the mRS interview (e.g. inadequate information / questioning of 
participant) a repeat was requested from the local investigator by automated email. Any 
participant-identifying information was removed by the outcomes manager using Windows 
Movie Maker© (Microsoft, USA) video editing software. No other editing of video clips was 
performed.  The nature of any editing performed and the reasons for this was recorded in 
the eCRF.  
3.4.6.2. The CARS Endpoint Committee 
The CARS endpoint committee was composed of seven experienced mRS assessors. All were 
physicians with a clinical and academic interest in stroke medicine (three professors, two 
clinical lecturers and two clinical research fellows). 
Adequate mRS video assessments were distributed by the outcomes manager to a minimum 
of four endpoint committee members for independent, blinded mRS scoring. Video 
assessments were scored fully blinded to all other participant information. Where these 
scores agreed, the collective endpoint committee mRS score was assigned for that clip.  
Where there was a disagreement, the clip was “misclassified” and forwarded to the full 
endpoint committee for group review and consensus scoring where possible. The mRS clip 
review protocol is summarised in Figure 11. 
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Figure 11 mRS  Video review process 
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3.5. Technical Specifications 
3.5.1. Video Equipment 
The mRS assessment was recorded using a high definition video camera. Two camera 
systems were used during the study.   
Initially a Canon© high definition camera was used (Canon HF10©, Canon HF100©, Canon 
HF200©). This system required the use of an external omni-directional condenser boundary 
microphone (ATR97, Audio-technica©. Frequency response 50-1500Hz). A portable desk 
tripod was used to mount the video camera (Hama Photo Traveller Compact Tripod©). The 
camera files were transferred to PC using an external USB cable. The total cost of this 
equipment was £700. (See Figure 12) 
 
 
Figure 12 Canon
©
 Camera Equipment 
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Later in the study we began to trial the use of a FLIP© Mino camera. This smaller and more 
portable model included an in built microphone and USB connection allowing greater ease of 
file transfer. The total cost of this equipment was £130. (See figure 13)  
 
Figure 13 Flip
©
 Camera Equipment 
Twelve centres used the original Canon© equipment and two centres trialled the FLIP© 
equipment. 
3.5.2. Video Conversion Software 
In planning the study, we anticipated from prior pilot work that video clips would be 5-10 
minutes in length and around 7-15 MB in size in MPEG format. More modern camera 
equipment was purchased for the CARS study which recorded video footage with higher 
resolution in MTS format. These MTS format video clips ranged from 150-250 MB for a 
similar length of mRS assessment. Allowing for NHS and University network speeds these files 
were too large to be uploaded over the internet in an acceptable time frame and therefore a 
video conversion step was included with the initial Canon camera. We used AVS Video 
Converter© Software, Online Media Technologies Ltd. UK. This allowed conversion of MTS 
files to WMV files which were 5-15 MB in size and were easily viewed on any Windows 
personal computer (PC) (Microsoft©, USA) with Windows Media Video© software. 
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Later in the study, with the addition of the FLIP camera technology the file format was 
updated. We began to receive AVI files which were of greatly increased size (100-200MB). In 
response to this we undertook re-programming of the web portal with the Robertson Centre 
for Biostatistics and all files were able to be transferred in a non-converted format. This 
allowed direct upload of the camera files to the co-ordinating centre with much greater ease 
and without the requirement for conversion software. 
3.6. The CARS web portal 
The CARS web portal was developed with technical assistance from the Robertson Centre for 
Biostatistics (RCB), University of Glasgow. The functionality of the web portal was planned 
and designed by the study team and then constructed by the web design team at the RCB.  
The RCB were responsible for the administration of the many functions of the portal under 
instruction from the study team. All study documentation and links to training materials were 
accessible to investigators. After enrolment, the portal was used to generate an electronic 
case report form (eCRF) for each study participant. This facilitated remote entry of 
participant details, NIHSS assessment scores, standard mRS assessment scores and upload of 
mRS video assessments for review by the co-ordinating centre. Secure access to the portal 
was granted through the use of username and password, provided to authorised 
investigators by the RCB, University of Glasgow (Figure 14). On first use, users were 
prompted to change their password.  Smart passwords were required. 
3.6.1. Investigator access to CARS web portal 
Different functions of the web portal were available to study investigators allocated by their 
role within the trial. This was designed to ensure that data were kept secure, accessible by 
the minimal number of investigators and to allow full blinding of outcomes assessment. The 
various components of the portal and degree of access available to each study role are 
detailed in figure 15. 
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Figure 14 - The CARS Web Portal 
Portal function Access available to: 
Study documents 
Study Protocol 
Participant and Relative information sheets 
Consent documents 
Paper case report forms 
 
 All users 
Electronic Case Report forms (eCRF) 
Electronic entry of participant data 
 Outcomes manager  
 - able to view all sites 
 Local investigators  
 - able to view local site 
Endpoints 
Assessment of mRS video clips 
Diary to prospectively record periods when 
unavailable  
 Outcomes manager 
- able to see all clips 
 Endpoint committee members 
- able to see clips for individual review 
and group review if misclassified 
Training 
Links to internet based training and certification 
modules in NIHSS and mRS 
 All users 
Profile 
Link to change password 
 All users 
Figure 15 CARS web portal. Functions and User Access. 
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3.6.2. Electronic Case Report form (eCRF) 
Standard paper case report forms were used for each study participant, stored locally and 
completed at the time of the study visit by the investigator. These data were also entered 
into the eCRF, available to all local investigators through the CARS web portal. This allowed 
automatic entry of source data to our database, held by the RCB. As far as possible all data 
were entered using drop down menus or tick boxes to minimise possible responses, limit 
human error and aid data analysis. Where free text was more practical or necessary this was 
available. Any change / correction made to the data after initial entry was archived and the 
investigator making the change was required to state a reason for this in line with standard 
data monitoring practice. 
3.6.3. Endpoint Assessment 
Endpoint assessment was performed by a committee of academics with a clinical and 
academic interest in stroke. All had extensive experience in administration of the mRS 
assessment and many had been involved in prior mRS reliability research. 
One member of the endpoint committee had a dual role as outcome manager. After initial 
review of each clip for technical adequacy this member distributed the clips to a minimum of 
four endpoint committee members. This was done in an unsystematic manner. Where 
endpoint committee members were unavailable to review clips for any period of time they 
could note this in the web portal to ensure that they did not appear on the list of potential 
reviewers at the time of distribution. The aim of this was to ensure timely review of all clips, 
our target was to ensure all clips were adjudicated within 7 days of upload to allow for repeat 
assessment or further information where clips were contentious. 
After allocation of an mRS clip, endpoint committee members were alerted by automated 
email. They were prompted to log in to the web portal to view and score the clip. Once all 
four reviews were in place the portal was programmed to recognise any discrepancy in 
scoring among the four endpoint committee opinions. If all scores agreed then the clip and 
corresponding scores were archived securely in the database. If there was any disagreement, 
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the clip was deemed “misclassified” and this prompted a further automated email to all 
seven members of the endpoint committee to alert them all to log in and review the clip.   
Regular endpoint committee meetings were arranged by the outcomes manager as a forum 
to discuss the misclassified clips and reach a consensus score where possible. At the endpoint 
committee meetings each member attended with a note of their scores and comments for 
discussion. Access to the CARS web portal was available for entry of scores and comments.  
The misclassified clips were available via the portal for review if the committee members 
wished to review the clip collectively in order to facilitate discussion and scoring.   
As the study progressed we expanded the facility to store endpoint committee scores in 
order to facilitate endpoint committee discussion. Initially the portal had the facility to 
accept only the four original committee scores and a consensus score. We expanded this to 
allow all seven members to enter a score at the stage of full committee review and also 
provided a comments box for each committee member to use if there were specific details 
about the clip that were contentious or guided their scoring decision.  In the later stages of 
the study all of these details were available through the portal for endpoint committee 
meetings.  These alterations were devised to help facilitate remote discussion in cases where 
endpoint committee members were not available to attend. 
Where a score was allocated after committee discussion it was noted if this score was 
allocated with unanimous or non-unanimous committee agreement in order to highlight the 
most controversial clips.  Where no score could be allocated due to inadequate technical 
quality or inadequate interview consideration was given to request further information from 
the local site or a repeat assessment. There was a link next to each assessment in the web 
portal to email the investigator directly in the case of any queries. 
3.7. Conclusions 
The CARS study was designed to emulate a typical phase III RCT in acute stroke, similar to 
recent large studies investigating reperfusion or neuroprotectant agents.  We have designed 
a facility to incorporate central adjudication of mRS assessments within an acute stroke trial 
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and a process for providing adjudicated endpoint blinded to the original / local mRS 
assessment.  We aim to examine the benefits of such an outcome strategy.  The results of the 
study programme are presented in the following chapters.  We aimed to assess the benefits 
of central adjudication of mRS outcomes in terms of feasibility of collecting this data (Chapter 
4) together with an assessment of the reliability (Chapter 5) and validity (Chapter 6) of the 
outcomes recorded. 
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Chapter 4  
Feasibility: is a central 
adjudication model feasible? 
4.1. Introduction 
As a novel method of collecting modified Rankin outcome data, we aimed to establish 
whether central adjudication of locally recorded mRS assessments can be performed in a 
multicentre trial setting. In this chapter we will discuss the practical details of conducting the 
CARS study. It will detail the recruitment, data collection and central adjudication processes 
to examine the feasibility and acceptability of using this model in future stroke trials. 
4.2. Results 
4.2.1. Study Sample 
We set up a “virtual” acute stroke trial across UK hospitals. Fourteen study centres were 
included in the CARS study; six in Scotland (ethical approval granted by Scotland A Research 
Ethics Committee on 12th November 2008) and eight in England / Wales (ethical approval 
granted by Essex 2 research ethics committee on 28th January 2009).     
4.2.1.1. Recruitment 
Three hundred and seventy three participants were recruited to the study. Recruitment 
began at the co-ordinating centre and extended to all fourteen sites as each centre received 
training and achieved local research and development approval. Recruitment commenced on 
17th December 2008 and completed on 22nd September 2010. Table 8 details the date each 
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centre commenced the study, the majority joined in a six month period between May and 
October 2009. The final day 90 follow up visits were completed in January 2011.  The number 
of participants recruited by month as the trial progressed is detailed in Figure 16.  Total 
recruitment at each site is detailed in Figure 17. 
Of 373 participants recruited, 3 were excluded from analysis. One was later found to have a 
diagnosis other than stroke (demyelinating disease) and two withdrew their consent and 
asked to have their data removed from analysis. 
Table 8 Date for first participant recruited at each site 
 
Site 
 
Date first participant recruited 
SCOTLAND  
Aberdeen Royal Infirmary 15.07.09 
Glasgow Royal Infirmary 10.02.09 
Ninewells Hospital, Dundee 19.01.10 
Southern General Hospital, Glasgow 22.12.09 
Stobhill Hospital, Glasgow 08.05.09 
Western Infirmary, Glasgow 17.12.08 
ENGLAND AND WALES  
Countess of Chester Hospital, Chester 28.06.09 
Cumberland Infirmary, Carlisle 19.03.10 
Harrogate District General Hospital 10.09.09 
Leeds General Infirmary 21.08.09 
Royal Devon and Exeter Hospital 28.07.09 
Royal Glamorgan Hosptal 16.10.09 
Wakefield (Pinderfields) Hospital 01.10.09 
York Hospital 19.08.09 
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Figure 16 Number of participants recruited by month 
 
 
Figure 17 Total Recruitment by site 
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4.2.1.2. Consent 
All participants provided written informed consent or where a participant was unable to do 
so, proxy consent from their nearest relative was used. 46 participants were included with 
proxy consent. Participants included with proxy consent were slightly older than those who 
gave their own consent (mean 70.5 years versus 67.4 years). Stroke was more severe in the 
group who were included with proxy consent (mean baseline NIHSS (bNIHSS) 4.8 versus 
11.8), indicating communication difficulties or other incapacitating symptoms at the time of 
the index event.   
Of the 46 included with proxy consent, 30 completed the study. Seven were withdrawn due 
to a serious adverse event. In this group we see the most severe strokes (mean bNIHSS 18.3).  
The nine participants who chose to withdraw from the study after initial proxy consent were 
younger than those completing (66.1 years versus 70.6 years). One of the participants 
included with proxy consent actively withdrew consent for use of data during the study. Age 
and stroke severity of the participants included with proxy consent are detailed in Table 9. 
Table 9 Age and Stroke Severity of participants included with own consent / proxy 
consent 
 N Range Mean (SD) Median (IQR) 
Age (years)     
All 373 22 – 99 67.8 (13.0) 69 (60-77) 
Own consent 327 22 – 99 67.4 (13.2) 69 (59-77) 
Proxy Consent (All) 46 37 – 88 70.5 (10.6) 71 (67-76) 
          Proxy Consent (Completed) 30 45 – 88 70.6 (9.6) 72 (67-76) 
          Proxy Consent (Withdrew)  9 37 – 86  66.1 (15.2) 68 (66-71) 
          Proxy Consent (SAE) 7 67 – 83 75.6 (6.4) 77 (72-80) 
Baseline NIHSS     
All 373 0 - 23 5.6 (4.8) 4 (2-7) 
Own consent 327 0 – 21 4.8 (3.8) 3 (2-6) 
Proxy Consent (All) 46 2 – 23 11.8 (6.4) 11 (7-17) 
          Proxy Consent (Completed) 30 2 – 22 10.8 (6.2) 10 (6-17) 
          Proxy Consent (Withdrew)  9 3 – 22 10.3 (6.0) 9 (6-13) 
          Proxy Consent (SAE) 7 15 – 23 18.3 (3.1) 18 (16-20) 
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4.2.2. Demographics and Baseline Characteristics 
61.4% (227/370) of participants were male with a mean (SD) age of 67.8 (13.2) years. The 
participants ranged from 22 years to 99 years old.   
Most participants had an excellent functional status prior to involvement in the study. The 
majority had a premorbid mRS of 0 (75.5%, 269/370). There were ten participant recruited 
with a pre-morbid mRS of 3 and two participants recruited with a pre-morbid mRS of 4 in 
violation of the protocol. 
Stroke severity in the study population was mild. Baseline NIHSS ranged from 1 to 23 with a 
mean (SD) of 5.6 (4.8). Median baseline NIHSS was 4, IQR 2-7. The distribution of stroke 
severity by the Oxford Classification was as follows: Total Anterior Circulation Stroke (TACS) 
12.7%, Partial Anterior Circulation Stroke (PACS) 41.6%, Posterior Circulation Stroke (POCS) 
14.9% and Lacunar Stroke (LACS) 30.8%. Stroke side was equally distributed, left hemisphere 
affected in 50.2%, right hemisphere affected in 49% and both sides affected in 0.8%.  
Stroke risk factors were widespread. 14.9% (55/370) had a history of previous stroke. 20.3% 
had a pre-existing history of atrial fibrillation or were found to be in atrial fibrillation at the 
time of presentation. A history of smoking (65.1%, 240/370), hypertension (55.6%, 205/370), 
hyperlipidaemia (39.2%, 145/370) ischaemic heart disease (21.6%, 80/370) or diabetes 
(14.1%, 52/370) was highly prevalent in the study population. 21.6% (80/370) of participants 
had a family history of stroke. 
The baseline blood pressure ranged from 96/45 mmHg to 232/140 mmHg with an average 
reading of 152/81mmHg.  There were 29 missing values for admission blood glucose.  The 
mean (SD) glucose level was 6.7 (1.4) mmol/l, ranging from 3.1 – 20.7.  Demographic details 
are summarised in Table 10. 
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Table 10 Baseline Demographic Characteristics of CARS study participants 
Baseline Demographics of CARS study participants   (n=370) 
Age (years) Mean (SD) 67.8 (13.2) 
 Median (IQR) 69 (60-77) 
 Range 22-99 
Sex Male 227 (61.4%) 
 Female 143 (38.6%) 
Oxford Classification TACS 47 (12.7%) 
 PACS 154 (41.6%) 
 POCS 55 (14.9%) 
 LACS 114 (30.8%) 
Side of Stroke Right 187 (50.2%) 
 Left 180 (49%) 
 Both 3 (0.8%) 
Pre Morbid mRS Mean (SD) 0.9 (1.25) 
 Median (IQR) 0 (0 – 0.25) 
 Range 0 – 4 
Baseline NIHSS Mean (SD) 6.2 (4.8) 
 Median (IQR) 4 (2 – 7) 
 Range 1-23 
Blood Pressure (mmHg) Mean (SD) 152/81 (33/18)  
 Median (IQR) 150/80 (132/70-170/92) 
 Range 96/45 – 232/140 
Blood Glucose (mmol/l) Mean (SD) 6.7 (1.4) 
 Median (IQR) 6.0 (5.2-7.1) 
 Range  3.1 – 20.7 
Risk Factors (n= (%)) Smoking     Current 124 (33.5%) 
                      Former 117 (31.6%) 
                      Never 129 (34.9%) 
 Alcohol Excess 26 (7.0%) 
 Hypertension 207 (55.9%) 
 Hyperlipidaemia 145 (39.2%) 
 Previous Stroke 55 (14.9%) 
 Peripheral Vascular Disease 20 (5.4%) 
 Atrial Fibrillation 75 (20.3%) 
 Family History 80 (21.6%) 
 Diabetes 52 (14.1%) 
 Ischaemic Heart Disease 80 (21.6%) 
4.2.3. Trial Termination 
A considerable proportion of the study population did not complete all follow up visits. Of 
the 370 participants included in analysis, 267 completed 90 days of follow up. 65 participants 
did not return for 30 day follow up. In 10 cases this was due to a serious adverse event (SAE).  
38 further participants withdrew after 30 day follow up, six due to an SAE. Figure 18 and 
Table 11 describe the flow of participants through the study and detail the reasons for trial 
termination. 
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Figure 18  - Flow diagram of participant follow up 
 
 
Death n=9, PTE n=1 
Death n=6 
 79 
 Table 11 Trial Termination Details for participants who attended at day 30, day 90 
or did not attend either visit 
Trial Termination Day 30 visits  
(n= 296) 
Day 90 visits  
(n=267) 
No visits  
(n=68) 
Total 
Study Completion 258 267 0 267 
Subject unwilling to continue 21 0 39 60 
Lost to follow up 6 0 10 16 
SAE 6 0 10 16 
Non Compliance 2 0 3 5 
Subject violated protocol 0 0 1 1 
Investigator terminated participation 0 0 0 0 
Subject withdrawn consent for use of data 0 0 2 2 
Investigator absence 3 0 3 6 
Total 296 267 68 373 
Six participants were withdrawn from the study due to investigator absence. A single 
investigator at one site was unavailable for several months due to ill health leading to a 
number of follow up visits being omitted.   
Stroke severity and baseline demographic characteristics were similar in participants who 
completed versus participant chosen withdrawals. Tables 12 and 13. 
Table 12 Stroke severity of participants at baseline, 30 days and 90 days in each 
follow up group 
  Follow up Complete  
(n=267) 
No visits 
 (n=52) 
30 day visit only  
(n=29) 
Baseline mRS Mean (SD) 0.37 (0.76) 0.5 (0.92) 0.79 (1.11) 
Median (IQR) 0 (0-0) 0 (0-1) 0 (0-1) 
Range 0-4 0-3 0-4 
Baseline NIHSS Mean (SD) 5.39(4.53) 4.63 (3.36) 5.83 (5.43) 
Median (IQR) 4 (2-7) 4 (2-6) 4 (2-6) 
Range 0-22 1-17 0-22 
30 day mRS Mean (SD) 2.24 (1.21)  2.21 (1.26) 
Median (IQR) 2 (1-3)  2 (1-3) 
Range 0 – 5  0-4 
30 day NIHSS Mean (SD) 2.83 (3.64)  1.5 (1-4.25) 
Median (IQR) 2 (1-3)  2.50 (2.41) 
Range 0 – 22  0-8 
90 day mRS Mean (SD) 1.91 (1.20)   
Median (IQR) 2 (1-3)   
Range 0 – 5   
90 day NIHSS Mean (SD) 2.14 (2.83)   
Median (IQR) 1 (0–3)   
Range 0 – 19   
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Table 13 Baseline Demographic Characteristics of participants in each follow up 
group 
 
 
 Both Visits  
(n=267) 
No visits  
(n=52) 
30 day visit only 
(n=29) 
Age (years) Mean (SD) 67.7 (12.7) 69 (12.4) 65 (15) 
 Median (IQR) 69 (60-77) 68 (60.8-70.5) 63 (56-79) 
 Range 22-99 43-92 37-90 
Sex  Male 163 (61.0%) 28 (53.8%) 21 (72.4%) 
 Female 104 (39.0%) 24 (46.2%) 8   (27.6%) 
Oxford 
Classification 
TACS 31   (11.6%) 7   (13.5%) 2   (6.9%) 
 PACS 106 (39.7%) 21 (40.4%) 16 (55.2%) 
 POCS 45   (16.9%) 8   (15.4%) 3   (10.3%)   
 LACS 86   (32.2%) 16 (30.8%) 8   (27.6%) 
Side of Stroke Right 134 (50.2%) 24 (46.2%) 22 (75.9%) 
 Left 131 (49.1%) 28 (53.8%) 6    (20.7%) 
 Both 2      (0.7%) 0    (0%) 1    (3.4%) 
Blood Pressure 
(mmHg) 
Mean (SD) 153/81 (27/16) 150/83 (27/17) 148/81 (28/17) 
 Median (IQR) 158/80 (133/70 - 
170-90) 
143/80 (130/68 – 
167-95) 
 143/80 (129/71 – 
161/92) 
 Range 98/45 – 232/140 96/47 – 226/118 97/49 – 230/119 
Blood Glucose 
(mmol/l) 
Mean (SD) 6.7 (2.4) 6.6 (2.9) 6.4 (2.5) 
 Median (IQR) 6.7 (5.2-7.1) 5.6 (5.2-6.6) 5.8 (5.3 – 6.5) 
 Range  3.1 – 19.9 3.8 – 20.7 4 – 15.3 
Risk Factors Smoking   Current 86   (32.2%) 22 (42.3%) 15 (51.7%) 
                    Former 81   (30.3% 13 (25%) 16 (55.2%) 
                    Never 100 (37.5%) 17 (32.7%) 8   (27.6%) 
 Alcohol Excess 15   (5.6%) 4   (7.7%) 5   (17.2%) 
 Hypertension 147 (55.1%) 31 (59.6%) 23 (79.3%) 
 Hyperlipidaemia 108 (40.4%) 21 (40.4%) 12 (41.4%) 
 Previous Stroke 43   (16.1%) 9   (17.3%) 3   (10.3%) 
 Peripheral Vascular 
Disease 
13   (4.9%) 5   (9.7%) 3   (10.3%) 
 Atrial Fibrillation 54   (20.2%) 12 (23.1%) 7   (24.1%) 
 Family History 60   (22.5%) 11 (21.2%) 6   (20.7%) 
 Diabetes 45   (16.9%) 4   (7.7%) 3   (10.3%) 
 Ischaemic Heart 
Disease 
58   (21.8%) 12 (23.1%) 7   (24.1%) 
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4.2.3.1. Serious Adverse Events (SAEs) 
As stroke severity was mild in the study population SAEs were infrequent. There were fifteen 
deaths. Sixteen participants were withdrawn due to an SAE. Thirteen patients (3.5%) had a 
recurrent cerebrovascular event during the study period. The recorded SAEs are detailed in 
Table 14. 
Table 14 Serious Adverse Events 
Serious Adverse Events 
Death 15 
DVT/PTE 5 
Elective Procedure 2 
Endarterectomy 5 
Fall 6 
Unrelated Illness requiring admission 18 
MI/CCF/AF 7 
Pneumonia 9 
TIA/Stroke/New Neurology 13 
Pt’s withdrawn due to SAE 16 
Total 80 
4.2.4. Imaging 
All patients had brain imaging. 96.8% (358/370) had initial CT scanning and 13.2% (49/370) 
had MRI.  The majority of participants had ischaemic stroke (94.9%, 351/370).  27.3% 
(101/370) of participants had normal imaging on CT and in 10 cases this was confirmed with 
a normal MRI scan.  
Carotid Doppler studies were performed in 73.2% of participants (271 / 370).  In some cases 
an alternative modality of carotid imaging was performed (CT or MR angiography) and in the 
remainder no carotid imaging was done.  We did not collect data regarding carotid imaging 
other than Doppler ultrasound.  Severe carotid stenosis was found in 26 participants, in 14 
cases these were symptomatic stenoses.  Five carotid endarterectomies were recorded 
during the study period. Details of imaging are described in Table 15. 
 
 82 
Table 15 Imaging – Frequency of CT, MRI and Carotid Doppler Ultrasound studies 
and Results 
CT Brain 
(n=358 [96.8%]) 
Normal 101  (28.2%) 
Primary Intracerebral Haemorrhage 18     (5.0%) 
Subcortical Infarction 95     (26.5%) 
Cortical Infarction 95     (26.5%) 
Posterior Circulation Infarction 48     (13.4%) 
Other 32     (8.9%) 
MRI Brain  
(n=49 [13.2%]) 
Normal 10     (20.4%) 
Primary Intracerebral Haemorrhage 1       (2.0%) 
Subcortical Infarction 11     (22.4%) 
Cortical Infarction 14     (28.6%) 
Posterior Circulation Infarction 11     (22.4%) 
Other 11     (22.4%) 
Carotid Doppler USS        Right 
(n=271 [73.2%]) 
 
 
 
                                       
 
 Left 
 
[Grading of severity of carotid 
stenosis was at the discretion 
of each investigating team 
based upon local protocols] 
Normal 196  (72.3%) 
Mild Stenosis 33    (12.2%) 
Moderate Stenosis 18    (6.6%) 
Severe Stenosis 10    (3.7%)   
(Symptomatic Side n= 3) 
Occlusion 14    (5.2%) 
Normal 200 (73.8%) 
Mild Stenosis 35    (12.9%) 
Moderate Stenosis 14    (5.2%) 
Severe Stenosis 16    (5.9%)  
(Symptomatic Side n=11) 
Occlusion 6      (2.2%) 
 
4.2.5. Medications 
Consistent with the high prevalence of stroke risk factors in the study population, a 
substantial proportion of participants were prescribed primary preventative medications at 
baseline. At the time of recruitment 41.4% (153/370), 55.4% (205/370) and 44.3% (164/370) 
of the study population were taking aspirin, antihypertensive treatment and statin treatment 
respectively. At follow up there were increased rates of prescription of all secondary 
preventative treatment. The rate of antiplatelet prescription with aspirin and dypiridamole 
dual therapy was greatest at 30 days.  At 90 days the proportion of participants taking 
monotherapy with clopidogrel was greater. The rate of warfarin prescription increased from 
7.3% (27/370) at baseline to 27% (72/267) at 90 days. We did not collect data regarding rates 
of new atrial fibrillation at follow up. The rate of antihypertensive prescription and statin 
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prescription increased at each follow up visit. A summary of secondary preventative 
medication is detailed in table 16. 
Table 16 Frequency of secondary preventative medication prescription at each 
study visit 
 Baseline (n=370) 30 days (n=289) 90 days (n=267) 
Aspirin 
 
153 (41.4%) 188 (65.1%) 155 (58.1%) 
Dypiridamole 
 
20 (5.4%) 108 (37.4%) 89 (33.3%) 
Clopidogrel 
 
19 (5.1%) 45 (15.6%) 46 (17.2%) 
Warfarin 
 
27 (7.3%) 63 (21.8%) 72 (27.0%) 
LMWH 
 
1 (0.3%) 8 (2.8%) 2( 0.8%) 
Thrombin Inhibitor 
 
0 (0%) 1 (0.3%) 1 (0.4%) 
Antihypertensives 
 
205 (55.4%) 194 (67.1%) 190 (71.2%) 
Statins 
 
164 (44.3%) 241 (83.4%) 229 (85.8%) 
 
4.2.6. Home Time 
Home time was recorded at 30 and 90 days. Home times were clustered at high and low 
levels, a reflection of the mild stroke population being discharged very early with a small 
proportion having a more prolonged length of stay in hospital for rehabilitation after more 
severe stroke. 
The average home time at 30 and 90 days was 16.5 and 65.8 days respectively. In each case 
there was a full range of possible home time (0 -30 days or 0 – 90 days) and the median (IQR) 
was 22 (0 – 26) and 82 (59 – 86). Cumulative Frequency distribution of 90 day home time is 
displayed in Figure 19. 
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Figure 19 Cumulative Frequency Distribution of Home Time (90 days) 
 
4.2.7. mRS assessment Videos 
Five hundred and sixty three mRS video assessments were uploaded for review. Twelve 
centres used the original Canon HF100© camera and two centres used the Flip Mino© 
camera. Interview duration ranged from under one minute to 24 minutes; mean (SD) 5mins 
32 seconds (3mins 20seconds), median (IQR) 4mins 47seconds (3mins 9 seconds – 7mins 6 
seconds). Figure 20. 
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Figure 20 - mRS video length (minutes) 
File sizes ranged from 1920KB to 116095KB (113MB); mean (SD) 18230KB (16453KB). (Table 
17)  Smaller files were received where the original Canon camera was used; these files were 
converted to a compressed file type prior to upload.  Five hundred and thirty eight clips were 
scored by the adjudicating committee. The reasons for missing adjudicated scores will be 
discussed in section 4.2.8.1. 
Table 17 File size and duration of video mRS assessments 
File Size (KB) Mean (SD) 18230 (16453) 
Median (IQR) 13152 (8510 – 20635) 
Range 1920 – 116095 
Clip Duration 
(mins:secs) 
Mean (SD) 05:29 (0:14) 
Median (IQR) 04:45 (03:09 – 07:03) 
Range 00:52 – 23:51 
 
Editing for anonymity was required in thirty nine (7.2%) mRS assessments due to mention of 
participants forename, surname or date of birth. A proxy was used in the assessment in 106 
(19.3%) assessments. In the majority of these clips both the participant and a proxy were 
used to provide the interview for clarity and corroboration of details. The full interview was 
provided by a proxy in only 22 (4.1%) cases. In 14 of these the mRS interview was conducted 
 86 
with a member of the clinical team involved in the participant’s daily care (nurse / 
physiotherapist / occupational therapist / doctor) and in 8 the mRS interview was conducted 
with the participant’s relative or informal carer. There was language disorder noted in 145 
(20.7%) assessment videos. The majority of assessments were filmed in an outpatient clinic 
setting (389 clips, 72.3%). Eighty six assessments (16.0%) were filmed in the participants 
home and sixty three (11.7%) were filmed in a ward setting prior to discharge. To assess the 
level of pre-morbid disability in line with the pre-morbid mRS score it was noted how many 
clips involved a discussion of prior disability. There was no mention of previous functional 
limitations in 415 clips (77.1%). In 14 clips there was mention of previous stroke (43 
participants who attended both follow up visits had a documented history of prior stroke). In 
109 clips there was mention of other co-morbidity affecting pre-morbid function (arthritis, 
respiratory or other cardiovascular illness).  Details of video clips scored are shown in Table 
18.   
Table 18 Details of video mRS assessments 
Proxy No proxy  
Participant provides full interview 
432 (80.3%) 
Proxy provides full interview  
Clinical staff 
14 (2.6%) 
Proxy provides full interview  
Relative 
8 (1.5%) 
Participant and proxy  
Both provide interview together 
84 (15.6%) 
Language Disorder Yes 145 (27.0%) 
No 393 (73.0%) 
Discussion of prior 
disability 
None 415 (77.1%) 
Yes – previous stroke 14 (2.6%) 
Yes – other co-morbidity 109 (20.3%) 
Location Hospital Study Visit / Clinic 389 (72.3%) 
Inpatient / Care facility 63 (11.7%) 
Patient’s home 86 (16.0%) 
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4.2.8. Adjudication of mRS videos by Endpoint Committee 
96% (538/563) of study visits resulted in an adjudicated mRS score.  
The majority of mRS assessments were performed using a traditional, unstructured 
approach.  45 structured mRS scores were recorded at 30 days and 28 structured mRS scores 
were recorded at 90 days. Structured mRS scores were limited to six sites, in four of these all 
study visits recorded an mRS score at 30 and 90 days, in two sites there were structured mRS 
scores recorded in some study visits only.  One site recorded structured mRS at 30 days only 
in 8.2% (4/49) of participants.  One site recorded structured mRS at 30 and 90 days in 30.4% 
(7/23) and 26.1% (6/23) of participants at each time point.  An adjudicated mRS score was 
available in 88.9% (40/45) and 92.9% (26/28) of mRS assessments where a structured mRS 
was recorded at 30 and 90 days respectively.   
4.2.8.1. Missing adjudicated scores 
Technical failures were responsible for the majority of missing adjudicated scores. The clips 
where technical failure precluded scoring were recorded early in the study; median (IQR) 159 
(111-221) days into study [Total study days Median (IQR) 510 (458-558)].   
Poor audio was encountered in nineteen clips (3.4%), rendering scoring impractical in seven 
(1.2%). A repeat assessment was requested by the adjudicating centre in 15 cases (2.7%). In 
six cases a duplicate clip was uploaded in error. In two cases an accessory file (.exe) was 
uploaded instead of the video file. At one centre there were a number of video clips stored 
on the camera which were not uploaded to the co-ordinating centre immediately.  These 
assessments were lost when the camera malfunctioned. In two cases the camera or 
microphone battery died during the assessment interview, resulting in an incomplete 
assessment.  The reasons for missing adjudicated scores are detailed in Table 19.  
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Table 19 Reason mRS video unable to be scored by endpoint committee 
Reason (n) Day 30 (Total n = 296)) Day 90 (Total n= 267) 
Poor Audio 5 2 
Duplicate Clip uploaded in error 1 5 
Camera Malfunction – data lost 5 - 
Incorrect (assessory) File type uploaded in error 2 - 
Incomplete Assessment (battery failure) 1 1 
Committee Unable to reach consensus 2 1 
Total 16 9 
 
4.2.8.2. Time to adjudicated mRS score 
The time taken to complete the adjudication process varied substantially during the study.  
We were unable to meet our target of timely mRS adjudication within 7 days. Each 
committee member (C1-C7) entered scores at their convenience and in many cases 
committee members waited for several clips to be ready for scoring before assigning mRS via 
the web portal. Committee members C1, C2 and C3 chose to score clips as they were 
allocated. Committee members C6 and C7 saved large numbers for scoring in batches, 
resulting in a considerable delay in scoring some clips. The median number of days to scoring 
for each committee member is displayed in Figure 21.  Once misclassified, the adjudication 
committee assigned a final score within a median (IQR) of 21 (13-37) days. 
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Figure 21 Number of days (median and IQR) to mRS score entry  (Committee 
members C1 to C 7 and final adjudicated mRS score) 
4.3. Discussion 
4.3.1. The “CARS” web portal 
The central adjudication model relies upon the appropriate IT infrastructure to support 
transfer and timely scoring of local mRS assessments. As an exploratory trial designed in part 
to assess the feasibility of the central adjudication model, we were prepared to make 
changes as challenges arose. During the course of the trial we modified aspects of the trial 
protocol and data collection processes in response to initial experience.   
4.3.2. The “CARS” web portal – experience of investigators 
Each centre received face to face training in the use of the video equipment and web portal.  
Written material (See Appendix A) was also provided together with remote advice and 
assistance from the trial outcomes manager by email and telephone.  We encountered very 
few problems and in general received very positive feedback from investigators.   
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4.3.2.1. Data entry changes 
During the course of the trial the outcomes manager had several meetings with the web 
design team at RCB in order to discuss experience of the portal design and make changes to 
improve data collection. Given the large amount of data collected in the CARS portal we 
encountered very few issues and made only minor changes to the collection of laboratory, 
imaging and home time data. 
4.3.2.2. Laboratory results 
In the initial design we entered limits for each laboratory value which were considered 
physiologically plausible as a safeguard against data entry error. As an observational study 
we did not specifically request that certain blood tests were done in the protocol. We 
expected that the laboratory parameters that were included in the CARS study would be 
tested ubiquitously in all centres, however this was not the case and in some centres there 
were no values available for certain fields in the web page (most commonly blood glucose).  
We also found that our physiological limits were too narrow for the blood glucose field, 
where a patient had a blood glucose result at the extremes of physiological parameters these 
data could not be entered.  
The web page had originally been designed so that the page could not be saved until all fields 
were complete, again to safeguard against error and missing data.  However, we quickly 
found that this feature was in fact reducing the completeness of data collection as some 
investigators were unable to save and progress though the form where there were missing 
data.  We made changes to widen the data entry limits for blood glucose and to allow any 
data entered to be saved.  We also included an option “not done” so that the empty fields 
could be acknowledged as complete despite missing data.   
Each form of the eCRF was colour coded in the summary view for each centre. Once a form 
was “complete” the link to that form changed from green to blue. This colour change served 
as a visual prompt to investigators to ensure that data entry was complete. The colour of the 
box which was selected for each form on the eCRF did not change to “complete” until all 
fields were filled, either with a value or “not done”.   
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4.3.2.3. Imaging results 
In the initial design of the web portal we had not considered the heterogeneous design of 
radiology services across various sites. Based upon our local experience we anticipated that 
most imaging results would be available within a fairly short time frame. Delays in accessing 
imaging services and reporting of examinations varied considerably among sites. Imaging 
results were included in the baseline eCRF, usually completed within the first 24-72 hours of 
enrolment. Again, as an observational study we did not stipulate that reports must be 
available for enrolment. Participants could be enrolled on the basis of a clinical diagnosis 
without imaging. We made changes to allow entry of imaging data retrospectively at future 
follow up visits and again to allow the form to be saved at an early stage with data awaited or 
the “not done” field selected if no results would be expected. This was most common in the 
carotid Doppler section due to varied practices in frequency and modality of carotid imaging. 
4.3.2.4. Home Time 
Home time is the number of nights that a participant spends back in their own home 
between enrolment and the follow up visit; in CARS at day 30 or day 90181. In many cases this 
was simply the number of nights between discharge and follow up, however in some cases it 
was more complex and collection of these data in a standardised fashion within the eCRF was 
challenging.   
The following is an example of how home time is calculated for illustrative purposes.  A 
participant is enrolled on day 0 and followed up on day 30 and day 90.  If they are discharged 
from hospital on day x and remain at home then home time would be (30 – x) or (90 – x) at 
each follow up visit.  However, if that participant is re-admitted to hospital for any reason or 
spends time in any other institutional care (eg. Nursing home for respite), then the number 
of nights (y) that they spent in this care environment must be subtracted.  Home time is 
expressed as (30 – (x + y)) or (90 – (x + y)).  We felt that leaving this calculation to individual 
centres was open to error and would not provide enough certainty that the data was entered 
accurately.   
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Initially the web portal was designed to calculate the difference between the discharge date 
and the date of the follow up visit. We soon discovered that this method made two 
assumptions which jeopardised the home time data. The first was that participants were not 
readmitted. The second was that the follow up visit always occurred at exactly 30 or 90 days 
after enrolment. This was not practical given the necessary flexibility that was required to 
account for weekends, holidays and availability of participants and investigators.    
We made changes to the web portal to allow entry of each portion of the above equation 
and to standardise the limit of the calculation as 30 or 90 days after enrolment. Investigators 
were prompted to answer the following questions detailed in Figure 22. 
 
Figure 22 - Data collection screen for home time data 
4.3.2.5. NIHSS assessment 
Initially we planned to include a video recording of the NIHSS assessment at 90 days for 
additional adjudication. Our initial experience, having completed 90 days of follow up in the 
first 10 participants demonstrated that there were considerable technical problems with 
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adequate recording of NIHSS. The NIHSS scale requires a view of the participant from several 
angles and with varying degrees of proximity to the camera – i.e. in order to view large 
movements from a distance (such as limb power) and fine movements at close range (such as 
eye movements). In order to do this successfully appropriate accommodation and a 
dedicated camera operator was necessary. The video footage required substantial editing to 
produce a single clip for upload and scoring.  Investigator numbers were not sufficient at 
local sites to facilitate this process and to avoid this affecting future recruitment we chose to 
remove this video assessment from the protocol. Ethical approval for this amendment was 
granted in June 2009 in light of the fact that this did not impact upon the overall aims of the 
study. 
4.3.2.6. mRS assessment and video upload 
In most cases local investigators were able to deliver mRS assessments of high quality and 
negotiate their upload through the web portal with little difficulty. Written guidance and 
remote assistance via telephone or email was available from the trial outcomes manager 
throughout.  
In seven clips the sound quality was too poor to enable scoring. The use of an external 
boundary microphone with the Canon camera added multiple opportunities for error; 
connecting the microphone, switching the microphone on and ensuring adequate battery 
power. At the end of each interview the microphone had to be switched off to ensure that 
the battery did not run flat between interviews. 
The Canon camera required an external USB cable to upload clips. There were four steps to 
access the correct folder once the camera was recognised by the computer. Once the correct 
clip was identified it then had to be converted using the AVS converter software and re-saved 
to the investigators “CARS” folder with the appropriate file name for that visit. Again, these 
complexities increased susceptibility for error. In six cases a duplicate file was uploaded 
incorrectly, presumably due to error in re-naming the video files. In one centre five clips were 
lost when their Canon camera had a fault. Investigators were encouraged to upload each clip 
on the day of filming, however, due to the time taken to connect, convert, save, rename and 
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upload each clip some investigators found it time efficient to save the clips up for upload in 
batches.  
In the planning stages of the trial there were concerns regarding the capabilities of the 
existing NHS IT infrastructure to handle video files. For data protection reasons our ethical 
approval was granted on the understanding that secure NHS networks were used for file 
manipulation and delivery. We found that local IT departments were very helpful in setting 
up the required video conversion software. We were also pleased to find that the NHS 
network speed coped well with video upload in all centres. These were not barriers to using 
this technology in clinical practice.   
Each of these steps rendered the process more susceptible to error. Despite these 
complexities, it is important to emphasise that over 95% of clips were uploaded successfully 
and scored by the adjudicating committee. The newer Flip camera system together with 
technical advances in the two years that the study progressed simplified and substantially 
improved the upload process. Large files could be uploaded, mitigating the need for file 
conversion with either camera system. The direct access to upload with the Flip camera’s 
integrated USB stick encouraged prompt upload.   
In a small minority of cases (n=23, 4.2%) there were significant technical problems which 
precluded scoring of the mRS clips (See table 19, section 4.2.8.1). The majority of these 
occurred early in the study and were related to the use of the original Canon camera system. 
A learning effect was seen in investigators as the study progressed in both mRS interviews 
and technical skills.  It is important to note that had this been a real intervention trial there 
would have been a backup outcome measure in these cases in the form of the local mRS 
score. 
4.3.3. The “CARS” web portal – experience of the outcome manager and 
endpoint committee members 
The trial outcome manager had access to all areas of the portal to enable informal study 
monitoring and to keep track of enrolment, data entry and video upload. This was achieved 
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through several tabs at the top of the web page to enable the outcome manager to switch 
between rolls easily (See figure 15, Section 3.6). 
Automated emails were generated to the outcome manager to inform them of new video 
upload. This enabled timely review of clips for anonymity, technical adequacy and 
completeness of interview. 
4.3.3.1. Anonymity 
Editing for anonymity was required in a small number of clips (n=39, 7.2%).  Clips were edited 
if there was any mention of patient identifying information such as forename, surname or 
date of birth. Editing was minimised to avoid disruption of the interview and did not affect 
the content of the mRS assessment except where the investigator had mentioned their score 
at the end of the clip. In these cases the score was removed to ensure blinding. 
Anonymity was an important component in the ethical considerations in this study and 
details of this were incorporated in the protocol and patient information sheets to reassure 
participants of our commitment to data protection.  
4.3.3.2. Interview content and quality  
In general, the interview quality in all video clips was very high.  Very few centres performed 
a structured or semi-structured interview (structured mRS score recorded in 75/563 
assessments; 13.0%).  In four centres a structured mRS score was recorded as standard.  In 
two centres there was a structured mRS score recorded in some participants only.  There was 
no clear pattern in which participants had a structured mRS score recorded suggesting that 
this was not part of standard practice.   
As this was an exploratory study of feasibility we were liberal in accepting most interviews 
unless there were stark omissions in the discussion regarding mRS grade. No clips were 
considered inadequate on interview content alone. In two cases there was a failure of 
microphone battery midway through the interview which precluded scoring. In three cases 
endpoint committee adjudication requested further details from the local investigator to 
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clarify the adjudicated score. In three cases the committee were unable to reach consensus 
but scoring was delayed to a point where a request for further information was not practical. 
There was heterogeneity in the length and content of each interview. The majority of clips 
were under 10 minutes long, most were between 4 and 6 minutes long (mean duration 
5minutes 32seconds (SD 3minutes 20seconds). This heterogeneity is a function of all 
traditional mRS interviews (face to face or video) and reflects the complexities of some 
stroke survivors disability, particularly where there are co-morbidities or non-stroke related 
limitations.  These complexities are present in all traditional mRS scores; including non-video 
mRS interviews and are not a function of the central adjudication model per se. We 
encouraged local investigators to complete their interview as per their usual practice with no 
expectation that the video clip should be deliberately succinct.  
As our intent in the CARS study was to assess the variation in scores between local 
investigators and video based scoring; we deliberately designed the trial such that we were 
blinded to the local score at the time of consensus meeting. In practice, cases where there 
were omissions in the interview or disagreements at a committee level a reasonable 
approach would be to contact the local site evaluator for further information.  Such contact 
has both scientific and educational value unless the local rater may be prejudiced through 
knowledge of treatment assignment.  
4.3.3.3. Time to adjudicated mRS scores 
The different approaches to scoring misclassified clips were a limitation in the conduct of this 
study. As each endpoint committee member was scoring clips in their own time there was 
considerable delay in discussion of each clip at an endpoint committee meeting for a 
consensus score to be recorded. This did reduce the availability of further information from 
local centres if there were queries regarding the content of the interview. Adjudicated scores 
were recorded a number of months after the original mRS interview was uploaded in 
extreme cases.   In two cases the endpoint committee could not reach consensus but were 
unable to ask for further information due to the significant delay in committee discussion. 
There were also a number of clips where an adjudicated score was reached but without 
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unanimous committee agreement in scoring (See chapter 5), in these cases the ability to ask 
further details of the local investigator may have clarified points causing controversy. 
4.3.3.4. Co-ordination of endpoint committee activity 
Endpoint committee members were based in the same city (Glasgow) but worked in various 
centres across the city. The co-ordination of endpoint committee activity was achieved 
predominantly using email.  As clips were allocated to endpoint committee members for 
scoring an automated email would alert them that there was a clip for review. Once a clip 
was scored by the original four endpoint committee members an automated email would be 
generated to the outcome manager in the case of any disagreement (misclassified clips) and 
this clip would become available for all committee members to view prior to committee 
meeting discussion. End point committee meetings were arranged via online meeting 
scheduling software, Doodle©.   
Our target was that each clip would be viewed and adjudicated within 7 days of upload, to 
allow further information or repeat assessment to be requested from local investigators 
where required. Unfortunately this was not possible due to the time taken by some endpoint 
committee members to score their allocated clips (see section 4.3.3.3). Most committee 
members did not have dedicated time for the study and were scoring clips at their 
convenience around other clinical and academic commitments. 
As the study progressed it became clear that with each contentious clip there were often 
similar reasons for a committee member to choose a particular score or swing to one or 
other side of a controversial boundary. These thought processes are important in assigning 
the initial score and in subsequent discussion of each clip. We felt that allowing committee 
members to document comments pertaining to these scoring decisions would help to 
facilitate endpoint committee meetings.  We arranged to have the web portal changed and 
allow each committee member to input comments together with their score if they wished.  
These comments and scores were then available at each committee discussion.     
This alteration had multiple benefits.  In the CARS study endpoint committee meetings were 
held face to face.  Due to competing commitments it was not always possible for all 
 98 
committee members to be present. The availability of comments from each member allowed 
their thoughts to be considered when assigning an adjudicated score. An extrapolation of this 
might allow committee discussion to occur remotely, via email or video/teleconferencing; 
facilitating more timely adjudication, improving access to further information from local 
investigators and allowing involvement of endpoint committee members from geographically 
disparate areas.  
4.3.4. Study Completion 
The majority of participants completed the study, attending for three study visits with two 
mRS video assessments. We experienced a greater proportion of withdrawals than might be 
expected in an active treatment trial (17% visits missed). The completeness of video 
recordings was excellent; in 96% of cases where a local mRS was recorded an adjudicated 
mRS was reached. 
 A small number of participants were withdrawn following a serious adverse event; 15 deaths 
and one following pulmonary embolism. The majority of withdrawals were recorded as 
“subject unwilling to continue” or “lost to follow up”. Only two participants actively withdrew 
consent for the study, one of whom had originally been included with proxy consent.   
Our study population had a large proportion of participants with mild stroke. Investigators 
favour participants able to give their own consent in observational research therefore 
emulating a true acute stroke interventional trial is challenging.   
4.3.4.1. Withdrawals 
In any clinical trial there are opposing goals; it is important to collect sufficient data but also 
to minimise participant burden as far as possible by minimising frequency and intensity of 
intervention. At the point of consent it is important that the participant understands what is 
involved in the study to the point of completion. Attrition of participants is a threat to the 
quality of all data collected and losses of 20% or greater are considered a considerable threat 
to the validity of trial data183.  One of the cornerstones of ethical research is that participants 
can withdraw at any time, for any reason and without any detrimental effect on their care.  
 99 
Some argue that this may jeopardise clinical research and that a non-exploitative and 
autonomous “contract” might be reasonable prior to enrolment to ensure that participants 
understand the wider effects should they choose to withdraw184, 185.  
Withdrawals are a common phenomenon in clinical research and the rates of non-
completion in trials varies considerably depending upon the nature of the medical condition 
in question, the study population, the intervention and the study procedures. In studies 
involving psychiatric disorder186-188 or dementia189-191 there are high rates of attrition. It is 
well recognised that the elderly are more likely to dropout from research than other 
populations191-193. Randomisation is frequent in clinical research and best practice would 
blind treatment allocation and outcome to both the participant and investigator. The act of 
randomisation can affect consent to participate and remain in clinical research194. In 
unblinded trials it is recognised that participants allocated to a control group have increased 
rates of withdrawal195. There is a reasonable perception that participation in clinical research 
is less attractive in a placebo group or where there has been no intervention, such as in our 
observational study.      
Several techniques are used to optimise participant retention despite these issues. In many 
areas of the world where access to healthcare is limited and expensive; involvement in 
research is an incentive in itself as it ensures provision of treatment and follow up. In areas 
where there is publicly funded universal health care this is less important. Remuneration for 
participants directly is ethically unsound, however payment of expenses for travel and time 
from work are often utilised. Remuneration of investigators is more widely accepted, not 
only for enrolment but for follow up visits as well. Academic studies are more susceptible to 
participant withdrawal; modest funding budgets are less likely to extend to generous site 
remuneration for follow up and close data monitoring.  
The larger than expected proportion of withdrawals in our study may be attributable to the 
observational nature of the study and the mild clinical deficits. The mild nature of stroke 
events allowed the majority of participants to return to their usual active lives within the 
study period, reducing their motivation for participation in research. In a study of risk factor 
management in stroke patients, recruiting at a similar time point to the CARS study found 
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that 48% of patients did not attend for follow up at one year, often due to lack of interest196. 
As there was no intervention in our study there may also have been a perception amongst 
participants that they would not be impacting on valid research by not attending.    
Withdrawals might be considered an important endpoint in themselves197, particularly if they 
are due to poor tolerability of a study drug or unacceptability of study procedures. The 
majority of withdrawals in our study occurred before the first follow up assessment and 
therefore before any active intervention. There were fewer withdrawals between the 30 and 
90 day visits which could arguably be attributable to study procedures. The video 
adjudication process was acceptable to the substantial majority of investigators and 
participants.  
4.4. Conclusions 
In stroke trials, mRS outcome data can be collected using a central adjudication model. The 
use of patient interview videos to assign mRS grades is used in mRS training and 
certification151 and so is familiar and acceptable to most investigators.  Across 14 sites, we 
initiated and trained investigators, in many cases with limited stroke research experience.   
Recruitment was fast and exceeded our target of n=300.   
The use of video technology (see section 3.5) and the “CARS” adjudication web portal (see 
section 3.6) were the main focus in the investigation of feasibility. Both video systems and 
the web adjudication portal were very successful. An adjudicated score was available for 96% 
of study visits. We have demonstrated a high rate of technical success for assessment upload 
with the majority of failures occurring early in the study. A learning effect was seen in 
investigators as the study progressed and it is important to note that had this been a real 
intervention trial there would have been a backup outcome measure in these cases in the 
form of the local mRS score.      
We were able to utilise technological advances as the study progressed and incorporate 
these into our central adjudication model. It is important to emphasise that video and 
computer technology advance very quickly; with the advent of tablet computers with video 
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and internet capabilities this process could be simplified further without greater expense.  
The cost of the original Canon camera system was £700 in this study; current tablet 
computers with internet access and integrated video cameras are substantially cheaper than 
this. Recording a brief video clip and uploading this to the internet is familiar to any user of 
social media. We have demonstrated that using analogous technology in clinical trials is 
possible with the necessary data protection security. 
We have developed and assessed a system for central adjudication of mRS endpoints that is 
feasible; data collection is simple, inexpensive and acceptable to participants.  Technical 
handling of video recording and uploads and committee review has been successful.  Further 
technical advances and the use of the portal review comments may help facilitate faster 
remote adjudication, increasing the usefulness of local investigating teams to answer queries 
and provide clarification. 
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Chapter 5  
Reliability: is a central 
adjudication model reliable? 
5.1. Introduction 
Previous studies assessing the inter-rater reliability of the mRS have predominantly been 
conducted in small, single centre studies with highly motivated individuals. Inter-observer 
reliability in a large scale clinical trial with the associated challenges is likely to be poorer.    
No prior study has assessed measures of mRS reliability in a large multicentre and 
multinational study with observers from varied professional backgrounds and with varied 
levels of experience; a design which parallels a contemporary stroke RCT in practice.  
In our 14 centre study we collected multiple mRS scores for each study visit, as detailed in 
the methods section (Chapter 3). Each mRS interview was initially scored by a local 
investigator and was subsequently scored by four adjudication panel members.  A clip was 
designated as “misclassified” where there was disagreement amongst panel members, these 
clips were then forwarded for full adjudication committee review to reach a consensus score.  
At the close of this process each clip had a final adjudicated score, either taken from an 
agreed score at initial review (classified clips) or based upon the consensus decision taken at 
committee review (misclassified clips).  
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5.2. Method - Statistical Analysis 
5.2.1. Inter-Observer reliability 
Agreement between assessors was measured using kappa statistics ( / w Fleiss-Cohen 
Weights [1-[(i-j)/(1-)]2), intraclass correlation coefficient (ICC) and Bland Altman plot.  
Agreement was assessed for the following comparisons: local mRS versus final adjudicated 
panel mRS, local mRS versus mean panel mRS, local mRS versus a random panel mRS 
(generated using R statistical software). We also assessed agreement between the mean of 
two paired panel mRS scores, between all individual panel mRS scores and between the 
individual panel mRS scores and the local score together.   
We assessed for any differences in reliability as the study progressed to quantify any 
“learning” effect in the adjudication committee by measuring reliability in clips scored early 
or late in the study. Each participant had video clips assessed at various times during the 
study (local mRs assignment immediately, four endpoint committee mRS scores in the 
following weeks and finally the adjudicated mRS score assigned later still). We grouped the 
early and late assessments by splitting the participants into those assessed early and late 
around the median of the mean assessment dates. Agreement in clips scored early and late 
( and w ± 95% confidence interval) was calculated for the difference between groups 
(based on 10000 bootstrap samples).   
5.2.2. Measurement Error among observers 
It is important to quantify if there is any error (systematic bias or inconsistency) in the scores 
of individual raters, both to ensure that individual scores do not skew the panel process but 
also as a measure of quality control of individual assessors. We cannot quantify the “true” 
level of disability on the mRS; neither the local or adjudicated mRS scores are an accurate 
gold standard. For this reason we used statistical modelling techniques to quantify 
measurement error among observers. We used only day 90 mRS clips to avoid including 
repeated measures in the model. 
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We examined the error among individual raters using a mixed model designed to estimate 
the error between observers, measured as variance in mRS scores. This included a measure 
of each adjudicators bias (or accuracy) and consistency (or precision).  Bias was quantified in 
comparison to a surrogate gold standard mRS score, the mean of all mRS scores for each clip. 
Consistency was modelled as the individual error of each score entered by an individual 
rater. 
ICC was estimated using linear mixed effects models with normally distributed random 
effects fitted by restricted maximum likelihood (REML). Variance in mRS was decomposed 
into components due to: variation between patients (VP) and between study centres (VC), 
which together comprise the real variation in disability that we want to measure; consistent 
differences (bias) between observers relative to the mean of all observers (VO); and residual 
error (VE), which quantifies the measurement error, or inconsistency, of an individual 
observer. The square root of VE can be interpreted as an observer’s “inconsistency standard 
deviation (SD)” measured in mRS units.  
ICC is the proportion of variance that is due to differences between patients, that is:  
 
 
ICC=    Vpatient + V centre 
      (Vpatient + Vcentre) + (V0[bias] + Ve[Error inconsistency] 
 
 
Specific hypotheses were tested using likelihood ratio tests of REML models refitted using 
maximum likelihood. We tested for bias among observers, which is a test of the null 
hypothesis VO = 0, and for heterogeneity of inconsistency SD between observers and groups 
of patients. We compared reliability between local and panel-derived mRS scores by 
The real variation in disability that we aim to 
measure 
The real variation in disability that we aim to 
measure + unobserved noise term (bias and 
error) 
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estimating the inconsistency SD separately for local and panel mRS scores and testing for a 
difference. We did not include observer bias in this comparison of reliability because, in the 
absence of a gold standard mRS score, absolute bias cannot be estimated.  
5.2.3. Predicted Reliability with multiple mRS scores 
To estimate the predicted reliability that would be delivered by combining multiple ratings 
we used the Spearman Brown prediction formula198. 
            np 
    1 + (n-1))p 
 
We used the observed reliability of a single panel member (ICC) at day 90 to predict the likely 
improvement in reliability (ICC) with groups of up to ten raters. Using our data we compared 
our observed figure for reliability in two raters to the predicted figure. The observed 
reliability for two raters was calculated by selecting at random (using R statistical software) 
two pairs of panel mRS scores from each subject without replacement, taking the means of 
each pair and estimating the ICC between the two mean mRS scores. 
A summary of the mRS reliability analysis and the sample of mRS clips used for each 
component of the analysis is shown in figure 23 
 
 
 
 
 
 
n = Number of raters 
p = Reliability of a single rater 
pp 
Predicted Reliability = 
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Figure 23 - Summary of reliability analysis and sample of mRS video clips used for each component of 
analysis. 
Day 30 mRS 
clips 
(n=280) 
Day 90 mRS 
clips 
(n=258) 
Misclassified 
Clips 
(n=282) 
Classified 
Clips 
(n=256) 
Inter-observer 
Reliability at 
each mRS 
boundary* 
/
 ** 
Statistical 
Modelling of 
measurement 
error between 
observers* 
Bias / 
Consistency
Predicted 
Reliability with 
multiple mRS 
scores * 
(Spearman 
Brown 
Formula)
Inter-observer reliability*  
Inter-observer reliability 
early and late in study** 
* Where a random panel score is used this was generated using R statistical software 
** 95% Confidence Interval generated using 10000 bootstrapped samples 
All mRS 
clips 
(n=538) 
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5.3. Results 
5.3.1. Misclassified mRS assessments 
Clips were misclassified if there was disagreement among the four scoring members of the 
adjudication committee. At 30 and 90 days respectively, 57.5% (161/280) and 50.8% 
(131/258) of clips were misclassified.  See figure 24 
 
Figure 24 - mRS video clip adjudication process: classified / misclassified clips at 
Day 30 ad Day 90 
 
Misclassified clips were forwarded to the entire endpoint committee for review and 
discussion. The endpoint committee met on 12 occasions during the study to discuss 
misclassified clips. Details of the endpoint committee meetings are described in section 3.6.3. 
n=538 
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Unanimous committee agreement was reached after panel review in 89.4% (261/292) of 
mRS assessments. A non-unanimous committee decision was reached in 9.2% (27/292). In 
only three cases were the committee unable to reach consensus (0.5%). The distributions of 
local and adjudicated mRS at 30 and 90 days are shown in figure 25.   
Of the clips that resulted in complete agreement in end point committee scores (“classified”) 
there was disagreement with the local score in a proportion of cases.  At 30 days, 31/119 
(26.1%) classified clips disagreed with the local score.  At 90 days, 40/127 (31.5%) clips 
disagreed with the local score. Again there was no clear pattern or systematic bias in these 
disagreements. The local versus “classified” adjudicated mRS scores are cross tabulated in 
Table 20.   
5.3.2. Inter-Observer Reliability in mRS assessments 
Agreement between the adjudicated panel score and local mRS score at 90 days was good;  
0.48 (95% CI 0.40-0.55), w 0.80 ((95% CI 0.75-0.84) and ICC 0.8.  The use of the mean panel 
mRS score improved reliability at 90 days;  0.50 (95% CI 0.42-58), w 0.83 ((95% CI 0.78-
0.87) and ICC 0.84. The use of a single random panel score did not result in a benefit in 
reliability;  0.43 (95% CI 0.34-0.50), w 0.78 ((95% CI 0.78-0.83) and ICC 0.79. Agreement 
amongst panel members was very good at 90 days;  0.59 (95% CI 0.53-0.63), w 0.86 ((95% 
CI 0.82-0.88) and ICC 0.87. The addition of the local mRs score did not reduce reliability;  
0.55 (95% CI 0.51-0.60), w 0.84 ((95% CI 0.80-0.87) and ICC 0.84. Agreement at 30 days was 
similar to that seen at day 90.  Table 21. 
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mRS 0            mRS 1            mRS 2            mRS 3            mRS 4            mRS 5   
 
Common Adjudicated Score 119 
Adequate assessment with unanimous committee agreement 138 
Adequate assessment with non-unanimous committee decision 20 
Inadequate assessment - scored with additional info from centre 3 
Clip unable to be scored 16 
Total 296 
A Day 30 
  mRS 0            mRS 1            mRS 2            mRS 3            mRS 4            mRS 5 
 
Common Adjudicated Score 127 
Adequate assessment with unanimous committee agreement 123 
Adequate assessment with non-unanimous committee decision 7 
Inadequate assessment - scored with additional info from centre 1 
Clip unable to be scored 9 
Total 267 
B Day 90 
Figure 25 - Distribution of mRS Scores and committee outcomes at (A) Day 30 and 
(B) Day 90. 
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Table 20 - Cross tabulation of mRS scores where “classified” (agreement among 
committee members) scores disagree with local score 
 
Table 21 - Inter observer reliability in mRS scores at Day 30 and Day 90. 
[Agreement between local score and various methods of generating adjudicated 
score; agreement amongst panel members and agreement amongst all available 
scores] 
 Number of scores 
compared 
(n) 
Kappa  
() 
(95% CI) 
Weighted Kappa 
 (w) 
(95% CI) 
Intraclass 
Correlation 
Coefficient (ICC) 
Day 30     
Adjudicated Panel vs Local 2 0.53 (0.45-0.60) 0.84 (0.80-0.88) 0.85 
Mean Panel vs Local 2 0.51 (0.42-0.58) 0.84 (0.79-0.88) 0.87 
Mean of Paired Panel Scores 2 0.63 (0.56-0.70) 0.92 (0.89-0.94) 0.92 
Random Panel vs Local 2 0.46 (0.38-0.53) 0.82 (0.77-0.86) 0.82 
Individual Panel Scores 4 – 7 0.55 (0.50-0.60) 0.85 (0.81-0.88) 0.86 
Individual Panel and Local Scores 5 – 8 0.53 (0.48-0.58) 0.84 (0.81-0.87) 0.85 
Day 90    
Adjudicated Panel vs Local 2 0.48 (0.40-0.55) 0.80 (0.75-0.84) 0.8 
Mean Panel vs Local 2 0.50 (0.42-0.58) 0.83 (0.78-0.87) 0.84 
Mean of Paired Panel Scores 2 0.65 (0.57-0.71) 0.92 (0.89-0.94) 0.92 
Random Panel vs Local 2 0.43 (0.34-0.50) 0.78 (0.78-0.83) 0.79 
Individual Panel Scores 4 – 7 0.59 (0.53-0.63) 0.86 (0.82-0.88) 0.87 
Individual Panel and Local Score 5 – 8 0.55 (0.51-0.60) 0.84 (0.80-0.87) 0.84 
 Day 30 mRS scores 
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) 
Local mRS Score 
 0 1 2 3 4 5 Total 
0  2     2 
1 2  2    4 
2 2 9  1   12 
3  1 2  1  4 
4   1 4  1 6 
5     3  3 
Total 4 12 5 5 4 1 31 
 Day 90 mRS scores 
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) 
Local mRS Score 
 0 1 2 3 4 5 Total 
0  9     9 
1 3  3 1   7 
2 2 9  3   14 
3   3  2  5 
4    4  1 5 
5       0 
Total 5 18 6 8 2 1 40 
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Bland Altman plots demonstrating the agreement between local and adjudicated mRS clips is 
demonstrated in Figure 26.  
Inter-rater reliability varied across different mRS boundaries. The proportion of clips with 
disagreement at each level of mRS score was as follows (mRS 0: 51%, mRS 1: 53%, mRS 2: 
65%, mRS 3: 54%, mRS 4: 41%, mRS 5: 31%).  Greatest agreement was seen across the mRS 
2-3 boundary ( 0.81 95% CI 0.74-0.87) with poorer agreement seen at 0-1 (=0.66 95% CI 
0.53-0.75), 1-2 (=0.70 95% CI 0.64-0.76) and 4-5 (=0.75 95% CI 0.60-0.84).  Reliability 
around the 4-5 boundary was not assessed because too few participants were assigned a 
score of 5 to allow  to be estimated. Table 22 
Table 22 -  Reliability of dichotomised mRS scores at each mRS boundary at day 
90. Inter-rater reliability () with 95% CI derived from 10 000 bootstrapped 
samples.  
mRS boundary 0-1 1-2 2-3 3-4 
 (95% CI) 0.66 (0.53 – 0.75) 0.70 (0.64 – 0.76) 0.81 (0.74 – 0.87) 0.75 (0.60 – 0.84) 
  
There was no significant difference in agreement in day 90 clips that were scored early (w 
0.876) versus late (w 0.824) in the course of the study (p=0.146).  This applied also for 30 day 
assessments (w 0.876 early versus w 0.824 late p=0.146). Table 23 
 
Table 23 – Inter-Observer agreement of clips scored early and late in study. 
Participants divided by those assessed early and late around the median of the 
mean assessment dates  (* 95% CI for difference derived from 10 000 bootstrap 
samples)  
Visit Early (w) Late (w) 95% CI for 
difference * 
P 
Day 30 0.856 0.841 -0.081 – 0.057 0.344 
Day 90 0.876 0.824 -0.134 – 0.013 0.146 
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Figure 26 -Bland Altman Plot and cross tabulation of day 30 and 90 Local and 
Adjudicated mRS scores. Bland Altman Plot: [Difference in mRS (local – 
adjudicated) with mean mRS] 
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5.3.3. Measurement error among observers 
The magnitude of disagreement among raters is demonstrated in Figure 27. Very small levels 
of variability on the mRS scale are seen; typically less than a tenth of an mRS grade.  When 
comparing measurement error / consistency of panel members against performance of local 
raters there was no significant difference when using a single panel score (adjudicated score 
or random panel score). Where a mean panel score was used the panel score was more 
consistent than the local mRS (p=0.025). Table 24. 
 
 
Table 24 - Inconsistency standard deviation (SD) estimates for panel and local mRS 
scores at day 90.  P-values are presented from tests of the null hypothesis of 
homogeneity of inconsistency SD across adjudicators. 
Scores compared Panel Inconsistency SD Local Inconsistency 
SD 
Heteroscedasticity  P-
Value 
Random panel score 
and local score 
0.53 0.57 0.696 
Consensus panel score 
and local score 
0.45 0.58 0.194 
Mean panel score and 
local score 
0.33 0.56 0.025 
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Adjudicator bias (95% CI) in mRS at 90 days 
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Figure 27 - Magnitude of disagreement among mRS scores 
(L=local, C1-7=seven adjudication committee members) 
 
Bias (± 95% CI) in the seven individual panel scores and local score at visit 3 estimated as 
the adjudicator-level residuals in a mixed model where the outcome is mRS (n = 1322) 
and the random effects are study site (n = 14), patient within study site (n = 258), and 
adjudicator crossed with patient (n = 8). 
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5.3.4. Predicted Reliability with multiple mRS scores 
Using the estimated reliability of a single panel member (ICC) at day 90 of 0.87 (Table 22) and 
the Spearman Brown prediction formula we can estimate the reliability of the mRS with 
multiple raters. The observed reliability with two raters (ICC 0.92) was similar to the 
predicted figure (ICC 0.93). Increasing the number of raters to four is predicted to increase 
reliability to ICC 0.96. Table 25 
 
Table 25 - Spearman-Brown predicted mRS reliability at day 90 based on single 
panel rater reliability (ICC) 0.87. 
N raters Reliability (ICC) 
Spearman-Brown prediction for 
ICC = 0.870 
Observed 
2 0.930 0.923 
3 0.952 - 
4 0.964 - 
5 0.971 - 
6 0.976 - 
7 0.979 - 
8 0.982 - 
9 0.984 - 
10 0.985 - 
 
5.3.5. Reliability where a structured mRS approach was recorded 
A small number of assessments were accompanied by a structured mRS score. Each site was 
able to enter a mRS score based upon a structured interview where this was available. There 
was no formal protocol within the study to advise upon the use of a structured approach and 
therefore the scores are based upon various structured mRS instruments with substantial 
local variation. 45 structured mRS scores were recorded at 30 days and 28 structured mRS 
scores were recorded at 90 days. These assessments were limited to certain sites (see section 
4.2.8).  Structured mRS scores were accompanied by longer clips; mean (SD) 7mins 28secs 
(3mins 49 secs), median (IQR) 6mins 30 secs (5mins 4secs to 8mins 52secs). An adjudicated 
mRS score was available in 88.9% (40/45) and 92.9% (26/28) of mRS assessments where a 
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structured mRS was recorded at 30 and 90 days respectively.  There were more misclassified 
clips amongst the group that had a structured mRS score recorded; 65.0% (26/40) of 
structured mRS assessments at 30 days and 61.5% (16/26) of structured mRS assessments at 
90 days. The local (structured) mRS scores and adjudicated mRS scores are cross tabulated in 
Table 26. There was more disagreement between structured mRS scores and local 
adjudicated scores at the higher end of the mRS score. 
 
Table 26 - Cross tabulation of structured mRS interviews: local (structured) mRS 
scores and adjudicated mRS scores  
 
 
Agreement between structured mRS score (based upon varied structured mRS approaches) 
and adjudicated score was comparable to the results seen in the whole CARS sample.  At 30 
days  / w (95% confidence interval) was 0.64 (0.48 – 0.80) / 0.88 (0.58 – 1.19).  At 90 days  
/ w (95% confidence interval) was 0.52 (0.33 – 0.70) / 0.86 (0.47 – 1.23).  ICC at 30 and 90 
days was 0.88 and 0.86 respectively. 
 Day 30 mRS scores 
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 0 1 2 3 4 5 Total 
0 1      1 
1 1 5 2    8 
2 1 5 9    15 
3  1  2   3 
4    1 10  11 
5      2 2 
Total 3 11 11 3 10 2 40 
 Day 90 mRS scores 
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e Local (Structured) mRS Score 
 0 1 2 3 4 5 Total 
0 3 1     4 
1  2 1    3 
2 2  3 3   8 
3   1 2   3 
4    1 6 1 8 
5        
Total 5 3 5 6 6 1 26 
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5.4. Conclusions 
Intra-rater reliability has been previously reported99, 199; we considered only inter-rater 
reliability in this study with a “virtual trial” design. In the context of a multicentre clinical trial 
where endpoints will be assessed only once, inter-observer variability is most relevant.  
Comparing local and remote mRS scores gives some measure of the inherent variation in 
scoring across a multicentre study. 
A considerable proportion of mRS assessments were misclassified, meaning that there was 
disagreement among committee members. A further proportion of mRS assessments 
demonstrated disagreement between the local score and the agreed panel score. Inter-
observer variation was considerable (=0.48), albeit not as pronounced as in a previous 
smaller study (=0.25)100.The endpoint committee scores performed favourably in 
comparison to the local mRS score and inter-observer variability within the endpoint 
committee was excellent ( 0.59, w 0.86). Panel scores demonstrated a trend to suggest less 
disability overall than those allocated by the local investigator, but this “bias” represents a 
very small change in the mRS score (typically one tenth of an mRS rank).  It is important to 
recognise that in terms of interpretation, the mean difference in mRS scores created by a 
therapy such as rtPA may well be less than one mRS grade and when  dealing with late 
treatment, this could be a very small difference.  One tenth of an mRS grade may represent a 
meaningful proportion of the anticipated treatment effect.  
Our figures are comparable to those seen in systematic review of mRS reliability ( 0.46, w  
0.90)99. In their three centre study, Wilson et al reported inter-observer variability of  0.25, 
w 0.71
100.  Thus, with the addition of centrally adjudicated mRS scores we delivered in a 14 
site study an outcome substantially more reliable than the nearest prior estimate of mRS 
reliability in a multicentre study. 
There is a perception that there is less disagreement at the extremes of the scale (0-1 and 4-5 
boundaries); possibly because there can only be a disagreement in one direction, because no 
disability or severe disability are less complex to identify or because there are fewer 
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participants at these points in the scale. In fact our work has found substantial disagreement 
at all levels of the scale.    
The agreement between a single random panel score and the local score is less favourable 
than that seen between the adjudicated panel score, a mean panel score or the mean of 
paired panel scores. This suggests that there is an advantage with multiple scores. The 
advantage of multiple scores is supported further by the Spearman Brown prediction 
formula. Multiple mRS scores may be desirable but without added inconvenience to 
participants are unlikely to be achievable without the use of a remote scoring model such as 
that used in a central adjudication model. 
There was no significant difference in scores generated early or late in the study. This 
emphasises the complexity of scoring mRS assessments and the need to evaluate each 
participant individually. As the study progressed, the members of the end point committee 
had frequent opportunity to discuss controversies and difficulties in scoring clips; including 
discussion of several issues that recurred. Examples of these issues include how to score a 
patient who has chosen not to return to an activity, who receives help with activities that 
may not be necessary or who had prior disability that complicated the assessment of post 
stroke function. Despite reaching consensus on each of these issues for individual clips, these 
discussions did not improve reliability as the study progressed. 
Structured mRS assessment tools, including the recent Rankin Focussed Assessment133, have 
been proposed to improve mRS reliability. The comprehensive mRS structured inverview was 
originally developed by Wilson et al105 and has been adapted to the Rankin Focussed 
Assessment (RFA) by Saver et al133. This structured assessment form is designed to be 
completed in conjunction with interview of the participant, relative or caregiver and review 
of participant medical records. The RFA reports excellent inter observer reliability (w 0.99) in 
a sample of 50 paired mRS assessments and has been prospectively validated as part of the 
ongoing FAST-MAG trial. A simplified modified Rankin questionnaire (smRSq) has found good 
reliability (w 0.82) with a very fast administration time (average 1.67 minutes) in a sample of 
50 paired mRS assessments132 and has been validated in comparison to stroke severity135, 
stroke size136 and quality of life measures137. The validity of the smRS has been demonstrated 
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to that of the standard mRS and NIHSS138. It has also been validated for use via telephone 
consultation137.   
Compared to our group adjudication system, it could be argued that these structured tools 
offer an economical and simplified method of improving use of the mRS in stroke trials. It is 
worth noting that in the small sample of mRS assessments with structured mRS scores in our 
study we found increased frequency of misclassification at committee review, suggesting 
more variability in scoring. However, each of these structured assessments demonstrated 
heterogeneity in the approach taken with local variation between instruments. For this 
reason we must exercise caution in drawing conclusions from this small sample of structured 
mRS assessments.  The agreement between a structured mRS score and the adjudicated 
score was comparable. Few of the tools have been independently validated or assessed in a 
contemporary randomised controlled trial context. In meta-analysis, subgroup analysis 
comparing structured and unstructured approaches did not affect reliability99 and previous 
data suggest that questionnaire based mRS assessments confer no advantage when used in a 
“real world” setting199. The global and unstructured nature of the traditional mRs is a great 
advantage; without relying on individual activities of daily living there are no floor or ceiling 
effects in its application which are common to structured instruments.   
Further study of each approach to mRS assessment is required in large multicentre trials and 
is necessary to determine if the limitations placed upon mRS outcomes by either a structured 
interview approach or central adjudication model may diminish its value as an outcome 
measure. 
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Chapter 6  
Validity: is a central 
adjudication model valid?  
6.1. Introduction 
Functional outcome after stroke is highly variable and reflects the heterogeneity in the 
location and extent of the neurological insult. However, there are several factors that are 
known to predict functional outcome regardless of the nature and classification of the stroke 
event. In assessing a novel outcome assessment method it is important to ensure that it is 
both feasible (chapter 3), reliable (chapter 4) and valid in comparison to the current accepted 
method of outcome assessment.   
As discussed in section 1.4.2.1, the mRS has demonstrated good convergent validity (with 
NIHSS and Barthel Index) and construct validity (with infarct volume / recanalisation rates).  
The aim of this chapter is to investigate the validity of a centrally adjudicated mRS by two 
means. First, we assessed criterion validity in comparison to the current “gold standard”; the 
local mRS. Second, we assessed construct validity in comparison to independent factors 
known to predict functional outcome after stroke. 
As discussed in Chapter 4, adjudicated mRS scores show a trend to suggest less disability than 
their local counterparts, we sought to quantify this to ensure that there is no significant or 
systematic bias in adjudicated mRS scores.    
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6.2. Methods 
6.2.1. Criterion Validity 
Criterion validity describes the performance of a test in comparison to a criteria already held 
to be valid.  We sought to compare the current accepted method of collecting mRS outcome 
data (local investigator interview) with our novel method of collecting outcome data 
(centrally adjudicated video interview).  We analysed the local and committee adjudicated 
scores for any systematic differences using the Kruskal Wallis test of distributions for non 
parametric data (StatsDirect software). We included all mRS assessments with both a local 
and adjucated mRS score (n=538) 
6.2.2. Construct Validity 
Construct validity refers to a tests relationship to other accepted indicators of measuring the 
desired attribute.  This can be used in developing a novel outcome assessment tool by 
correlating the test result with other known prognostic indicators. We sought to assess the 
performance of adjudicated mRS outcomes in comparison to local mRS scores by comparing 
each method of scoring with factors known to affect functional outcome after stroke.  We 
collected data regarding several factors predictive of functional outcome after stroke, as 
described in section 3.4.5.1.   
The predictors used were baseline NIHSS (bNIHSS), Systolic Blood Pressure (SBP), blood 
glucose and home time. 
Spearman Rank correlation coefficients were generated for each variable with each method 
of assigning mRS outcome to demonstrate a simple test of association.  The Spearman Rank 
correlation coefficient is a non parametric measure and takes into account the ordinal nature 
of the mRS scale. 
To further assess the nature of the relationship we performed (adjusted and unadjusted) 
proportional odds ordinal logistic regression.  The software used was SAS (Version 9.3).  The 
significance of the association in ordinal logistic regression models using the mRS can be 
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tested using the the non-parametric Cochran mantel Haenszel (CMH) test which accounts for 
confounders in analysis200. 
6.2.2.1. Ordinal Logistic Regression and the Cochrane-Mantel-Haenszel Test 
Each of these analyses was performed using ordinal logistic regression with the proportional 
odds model.  Originally described by McCullagh in 1980201, this model provides a useful 
extension of binary logistic regression (with a yes:no response variable) to situations such as 
the mRS with a response variable using ordered categorical variables202.   
Ordinal logistic regression allows an analysis of how a predictive value is associated with a 
response variable; for example: for every point increase in bNIHSS or systolic blood pressure 
there is a tendency to worse mRS outcome with a quoted odds ratio.  This enables an 
assessment of how a local or adjudicated mRS outcome score is related to other factors 
known to affect stroke outcome (baseline NIHSS, systolic blood pressure, blood glucose and 
home time) and to determine if either method of assigning mRS is more closely related to 
these factors.    Ordinal logistic regression can also be performed with adjustment for the 
other covariates. 
Intrinsic to the proportional odds model is an assumption of ordinality. In simple terms, this 
assumes that each level of mRS is affected equally by the predictor, that is the odds ratio for 
a better or worse outcome is identical at each level of the scale203. This assumption is often 
not met and therefore a conservative measure of significance testing is required. The 
Cochrane-Mantel-Haenszel Test can be used to test the significance of the association 
between the predictor and outcome variable (or in clinical trials the treatment and outcome 
variables200). 
6.3. Results 
6.3.1. Criterion Validity 
We analysed for any systematic difference between local and committee scores. The mRS 
distributions of local and adjudicated scores were similar. There was a trend for local scores 
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to be higher than committee scores (i.e describing more disability) but this was not 
statistically significant (p=0.160).  Figures 28 and 29 display the distribution of mRS scores 
from local investigators and the adjudication committee (mean and median of initial n=4 
committee scores and the final adjudicated score).  
 
Figure 28 -mRS Distribution of Local and Committee Scores (Median / IQR). p-
values represent the Kruskal Wallis test of difference between distributions. 
n=538 
Min – (lower quartile-median-upper quartile) - max 
Adjudicated mRS 
Local mRS 
Median Committee mRS (n=4) 
Mean Committee mRS (n=4) 
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Figure 29 - mRS Distribution of Local and Committee Scores (Mean / 95% CI) p- 
values represent the Kruskal Wallis test of difference between distributions. 
n=538 
6.3.2. Construct Validity 
6.3.2.1. Spearman Rank Correlation 
Initially we performed simple Spearman Rank correlation coefficients to determine any 
simple relationship among variables known to be associated with stroke outcome (bNIHSS, 
Blood Pressure, Blood Glucose and Home Time). There were similar results with local and 
adjudicated mRS outcomes with any variable. All were found to be significantly associated 
with mRs outcome; except  SBP with 90 day adjudicated mRS which did not reach statistical 
significance (p=0.068). Table 27. 
Table 27 - Spearman Rank correlation coefficients (p value) for bNIHSS, SBP and 
Glucose with each mRS outcome 
mRS method n bNIHSS SBP Glucose 
Day 30 Local mRS 280 0.508 (<0.0001) 0.140 (0.014) 0.205 (0.005) 
Day 30 Adjudicated mRS 280 0.509 (<0.0001) 0.132 (0.027) 0.188 (0.003) 
Day 90 Local mRS  258 0.508 (<0.0001) 0.140 (0.014) 0.205 (0.001) 
Day 90 Adjudicated mRS 258 0.417 (<0.0001) 0.113 (0.068) 0.176 (0.006) 
 
   
0 1 2 3 4 5 
Local mRS 
Mean Committee mRS (n=4) 
 
Median Committee mRS (n=4) 
 
Adjudicated mRS 
min -[ mean ± 95% confidence interval ]- max 
p >0.99 
p >0.99 
p =0.23 
p =0.25 p =0.16 
p >0.99 
p =0.24 
Adjudicate  mRS 
Local mRS 
Median Committee RS (n=4) 
Mean Committee RS (n=4) 
Min – (mean ± 95% confidence interval) - max 
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6.3.2.2. Unadjusted Proportional Odds Ordinal Logistic Regression 
Unadjusted proportional odds logistic regression was then performed for each of the above 
predictors with each method of mRS outcome. Again bNIHSS was a strongly significant 
predictor of outcome with either method of assigning mRS.  SBP and Blood Glucose were not 
found to be consistently significantly associated with outcome. There was no significant 
difference between local and adjudicated mRS scores.  Table 28 and figure 30.  
 
Table 28 - Unadjusted proportional odds logistic regression of relationship between bNIHSS, 
SBP and blood glucose with each method of mRS assessment. 
Outcome n Odds Ratio 
(OR) 
95% CI for OR P 
 (CMH test) 
Baseline NIHSS 
Day 30 Local mRS 280 1.315 1.248 – 1.385 <0.0001 
Day 30 Adjudicated mRS 280 1.343 1.267 - 1.423 <0.0001 
Day 90 Local mRS 258 1.260 1.198 – 1.325 <0.0001 
Day 90 Adjudicated mRS 258 1.275 1.204 – 1.350 <0.0001 
Systolic Blood Pressure 
Day 30 Local mRS 280 1.009 1.002 – 1.016 0.670 
Day 30 Adjudicated mRS 280 1.008 1.000 – 1.016 0.303 
Day 90 Local mRS 258 1.008 1.000 – 1.016 0.558 
Day 90 Adjudicated mRS 258 1.007 0.999 – 1.015 0.581 
Blood Glucose 
Day 30 Local mRS 280 1.178 1.074 – 1.293 0.071 
Day 30 Adjudicated mRS 280 1.169 1.059 – 1.289 0.005 
Day 90 Local mRS 258 1.178 1.075 – 1.291 0.099 
Day 90 Adjudicated mRS 258 1.105 1.005 – 1.216 0.143 
 
6.3.2.3. Adjusted Proportional Odds Ordinal Logistic Regression 
Repeat proportional odds logistic regression was then performed, adjusted for each baseline 
predictor. Again, only bNIHSS was consistently significantly associated with outcome and 
there was no significant difference between local or adjudicated mRS scores. The CMH test 
was not possible in the adjusted analysis because of the nature of the variables, there were 
too many values for this be calculated.  Table 29 and Figure 31. 
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1.18 (1.09, 1.29) 
Figure 30 - Unadjusted proportional odds logistic regression 
of relationship between bNIHSS, SBP and Blood glucose with 
each method of mRS outcome (Odds Ratio and 95% CI) 
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Table 29 - Adjusted proportional odds logistic regression of relationship between 
bNIHSS, BP and blood glucose with each method of mRS assessment. 
Outcome Odds Ratio 
(OR) 
95% CI for OR P 
 (CMH test) 
Day 30 Local mRS (n=280) 
Baseline NIHSS 1.302 1.233 – 1.375 Not calculated 
Systolic Blood Pressure 1.014 1.005 – 1.023 Not calculated 
Blood Glucose 1.097 0.997 – 1.208 Not calculated 
Day 30 Adjudicated mRS (n=280) 
Baseline NIHSS 1.336 1.257 – 1.420 Not calculated 
Systolic Blood Pressure 1.014 1.005 – 1.024 Not calculated 
Blood Glucose 1.125 1.017 – 1.245 Not calculated 
Day 90 Local mRS (n=258) 
Baseline NIHSS 1.256 1.191 – 1.325 Not calculated 
Systolic Blood Pressure 1.015 1.005 – 1.024 Not calculated 
Blood Glucose 1.115 1.015 – 1.224 Not calculated 
Day 90 Adjudicated mRS (n=258) 
Baseline NIHSS 1.276 1.201 – 1.355 Not calculated 
Systolic Blood Pressure 1.015 1.005 – 1.026 Not calculated 
Blood Glucose 1.058 0.959 – 1.167 Not calculated 
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Figure 31 - Adjusted proportional odds logistic regression of the relationship 
between bNIHSS / SBP / blood glucose with each method of mRS assessment.          
Odds Ratio (95% CI) 
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6.3.2.4. Home Time 
Home time is not a baseline predictor of outcome but is validated as a useful measure of 
functional outcome181, 182. We repeated the previous analysis using home time as an 
independent surrogate marker of functional outcome and then as a further predictor in the 
adjusted proportional odds model. 
Initial Spearman Rank correlation coefficients confirmed the significant relationship between 
home time and functional outcome as measured using the mRS scale. There were no 
differences between local and adjudicated mRS scores. Table 30   
Table 30 - Spearman Rank correlation coefficients (p value) for Home Time with 
each mRS outcome 
mRS method n Home Time  
(Day 30) 
Home Time  
(Day 90) 
Day 30 Local mRS 280 -0.585 (<0.0001) -0.619 (<0.0001) 
Day 30 Adjudicated mRS 280 -0.605 (<0.0001) -0.642 (<0.0001) 
Day 90 Local mRS 258 -0.547 (<0.0001) -0.599 (<0.0001) 
Day 90 Adjudicated mRS 258 -0.578 (<0.0001) -0.607 (<0.0001) 
 
Unadjusted proportional odds logistic regression was performed with home time at day 30 or 
day 90 as a predictor for mRS outcome.  Again, home time was found to be a consistently 
significant predictor of mRS outcome and there was no significant difference between local 
and adjudicated mRS scores. Table 31 and figure 32  
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Table 31 - Unadjusted proportional odds logistic regression of relationship 
between Home Time and each method of mRS assessment. 
Outcome Odds Ratio 
(OR) 
95% CI for OR P 
 (CMH test) 
Home Time Day 30 (n=280)   
Day 30 Local mRS 0.871 0.850 – 0.893 <0.0001 
Day 30 Adjudicated mRS 0.861 0.839 – 0.885 <0.0001 
Day 90 Local mRS 0.887 0.866 – 0.909 <0.0001 
Day 90 Adjudicated mRS 0.868 0.844 – 0.892 <0.0001 
Home Time Day 90 (n=258)   
Day 30 Local mRS 0.933 0.922 – 0.944 <0.0001 
Day 30 Adjudicated mRS 0.929 0.916 – 0.941 <0.0001 
Day 90 Local mRS 0.947 0.938 – 0.957 <0.0001 
Day 90 Adjudicated mRS 0.934 0.921 – 0.947 <0.0001 
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Home Time Day 30 
0.5 1 
Day 90 Adj mRS 
(n=258) 
0.87 (0.83, 0.84) 
Day 90 Local mRS  
(n=258) 
0.89 (0.87, 0.91) 
Day 30 Adj mRS 
(n=280) 
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0.87 (0.85, 0.89) 
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Day 90 Local mRS 
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0.95 (0.94, 0.96) 
Day 30 Adj mRS 
(n=280) 
0.93 (0.92, 0.94) 
Day 30 Local mRS 
(n=280) 
0.93 (0.92, 0.94) 
Figure 32 - Unadjusted proportional odds logistic regression of 
relationship between Home Time and each method of mRS assessment. 
Day 30 (n=280) and Day 90 (n=258). Odds Ratio (95% CI) 
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When included in the adjusted model with bNIHSS, SBP and Blood Glucose, only home time 
and bNIHSS remained significantly associated with mRS outcome.  There was no change in 
the relationship using either local or adjudicated mRS scores. Day 90 home time: Table 32 
and Figure 33. Results for Day 30 are shown in Appendix C (Table 41 and Figure 51)   
 
Table 32 - Adjusted proportional odds logistic regression of relationship between 
bNIHSS, SBP, blood glucose and home time at 90 days with each method of mRS 
assessment. Day 30 and 90 mRS 
 Odds Ratio (OR) 95% CI for OR p 
Day 30 Local mRS (n=280) 
Baseline NIHSS 1.151 1.085 – 1.222 <0.0001 
Systolic Blood Pressure 1.007 0.999 – 1.015 0.096 
Blood Glucose 1.059 0.959 – 1.169 0.257 
Home Time Day 90 0.945 0.934 – 0.957 <0.0001 
Day 30 Adjudicated mRS (n=280) 
Baseline NIHSS 1.174 1.101 – 1.252 <0.0001 
Systolic Blood Pressure 1.006 0.997 – 1.014 0.207 
Blood Glucose 1.084 0.977 – 1.204 0.130 
Home Time Day 90 0.941 0.928 – 0.954 <0.0001 
Day 90 Local mRS (n=258) 
Baseline NIHSS 1.104 1.040 – 1.172 0.001 
Systolic Blood Pressure 1.008 1.000 – 1.017 0.052 
Blood Glucose 1.094 0.995 – 1.203 0.062 
Home Time Day 90 0.956 0.945 – 0.967 <0.0001 
Day 90 Adjudicated mRS (n=258) 
Baseline NIHSS 1.113 1.042 – 1.190 0.002 
Systolic Blood Pressure 1.007 0.998 – 1.016 0.123 
Blood Glucose 1.044 0.943 – 1.155 0.408 
Home Time Day 90 0.945 0.932 – 0.959 <0.0001 
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Figure 33 -Adjusted proportional odds logistic regression of relationship 
between bNIHSS, SBP, blood glucose and home time at 90 days with each 
method of mRS assessment. Day 30 (n=280) and 90 mRS (n=258) 
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6.4. Conclusions 
We report sufficient agreement between local and adjudicated mRS scores to demonstrate 
validity of an adjudicated mRS outcome, without any significant or systematic bias.  This 
validity has been demonstrated in relation to the local mRS assessment and has been 
demonstrated to correlate well with other independent factors known to affect stroke 
outcome.    
There are limitations to this analysis.  As there is no method of quantifying the “true”  
disability of a participant we are reliant on a scale to document this. Through use of endpoint 
committee review we hope to score the “true” mRS of the study participant. In the absence 
of a gold standard disability assessment we are unable to assess this directly. We are 
encouraged that there was a degree of disagreement between local and adjudicated mRS 
(suggesting that the adjudication process adds something to standard assessment); but this 
variability was not too large (which may suggest that adjudicated mRS is systematically 
different to traditional mRS).   
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Chapter 7  
Factors associated with 
variability in mRS scoring 
7.1. Introduction 
Inter-observer variability in mRS has been apparent and documented since inception of the 
scale. As we have discussed, even with dedicated training and increasing familiarity with the 
scale this variability remains. The reasons for the high variability in clinical mRS scoring are 
likely to be multifactorial. Arguably vague definitions used to define each mRS grade allows 
for a degree of subjectivity in assessment. The inherently unstructured nature of the 
traditional mRS allows the investigator the freedom to explore the functional aspects that 
are relevant to each individual patient, without the need to concentrate on mobility or 
continence where these factors may not be relevant. Despite the perception that the 
application of mRS is more consistent at extremes of disability; because high and low mRS 
grades are better defined or as a reflection that variability can be in one direction only; we 
have found disagreement in assigning mRS grades at all levels of the scale.   
There are potential factors associated with variability a) specific to the interviewer; b) 
specific to the interview subject and c) specific to the interview situation. If these sources of 
variability were better understood, one might be able to predict “problem” mRS cases and 
target interventions to improve reliability. We aimed to identify factors noted in our cohort 
of mRS assessment videos that might be associated with variability in  mRS scores. 
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7.2. Methods 
7.2.1. mRS scores and variability grading 
All mRS videos scored by the endpoint committee in the CARS study were included.  Those 
clips that did not have an adjudicated score were excluded.  Table 19 in Section 4.2.8.1 
describes the reasons for missing adjudicated scores.  The majority were due to duplicate 
clips, incorrect file type, poor audio that precluded scoring or incomplete assessment.  
Each clip was scored by a minimum of six independent assessors (local mRS, four adjudicated 
committee scores and a further independent mRS score from an assessor that did not 
participate in the original trial).  All assessors were trained and certified in mRS.  The final 
adjudicated mRS score was not included in the analysis as it was generated by the four 
committee scores and was therefore not an independent score. 
Variability in mRS scores for each clip was graded by determining the number of mRS scores 
that agreed from the six mRS scores. (Range 2-6) 
7.2.2. Identification of factors predictive of variability 
For each of the mRS interviews studied, we collated descriptive data on the participant and 
the quality and content of the interview. The variables chosen for study were those domains 
thought to be factors potentially associated with mRS variability based upon the results of 
previous qualitative analysis204. Clips were reviewed by two assessors, noting variables felt to 
impact upon scoring; if either rater felt that the variables contributed to difficulty in scoring 
then they were included in analysis. 
Patient specific variables included participant age, pre stroke mRS, baseline stroke severity as 
graded by baseline NIHSS (bNIHSS) and presence of language disorder. Interview specific 
variables included length of interview, poor sound quality, location of the interview, use of a 
proxy or discussion of prior disability. 
Variables included were continuous and categorical. For continuous variables (such as 
interview length or participant age) all clips were included as a potential factor associated 
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with variability. For each categorical variable a standard was identified as the most common 
factor in the cohort of videos.  From this standard, analysis was based upon whether the less 
frequent variable was associated with variability in scoring.  For location of interview, the 
majority of clips were recorded in an outpatient clinic setting; there were a minority of clips 
recorded in either the participant’s home or in an inpatient hospital setting (most commonly 
a rehabilitation facility). The majority of clips did not involve a proxy. In describing the use of 
a proxy a minority of clips used a proxy to provide the entire interview (e.g. a nurse or other 
caregiver) and some included both the participant and a proxy in the interview (e.g. the 
participant together with their relative or caregiver). Most clips did not include discussion of 
prior disability; in those that did this was noted as due to either prior stroke or to other 
comorbidity (e.g. arthritis / lung disease).   
7.2.3. Statistical Analysis 
Each of the variables were input as factors potentially associated with variability in mRS 
scoring using ordinal logistic regression with the proportional odds model (see section 
6.2.2.1). The dependant variable was mRS variability grade.  Odds ratios with corresponding 
95% confidence intervals and p values generated by the Cochrane-Mantel-Haenszel (CMH) 
test are reported.  Day 30 and day 90 scores were analysed independently as they represent 
repeated measures on each subject. 
7.3. Results 
538 video clips were included in the analysis (Day 30: 281 and Day 90: 257).  Variability 
grading for video clips ranged from 2 (2 scores of 6 in agreement) to 6 (all scores in 
agreement).  21% of clips at each study visit noted full agreement in mRS scores (59/281, 
21% at 30 days and 56/257, 21.8% at 90 days).  The distribution of variability grading was 
similar at each visit. Table 33 
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Table 33 - Variability rating for videos at 30 and 90 days 
Variability Rating Day 30 
N=280 (%) 
Day 90 
N=258 
2 3 (1.0%) 6 (2.3%) 
3 68 (24.2%) 45 (17.5%) 
4 80 (28.5%) 76 (29.6%) 
5 71 (25.3%) 74 (28.8%) 
6 59 (21.0%) 56 (21.8%) 
 
Continuous variables included in analysis were similar at both 30 and 90 days. There was 
some variation in the population of participants included at 30 and 90 days due to missed 
visits and missing videos. There were no statistically significant differences between the two 
groups for any variable. Table 34.  Categorical variables were similarly represented in the day 
30 and day 90 groups. In some cases there were very small group numbers for categorical 
variables (e.g. poor sound quality, full proxy interview and discussion of prior disability due to 
stroke). Table 35. 
Table 34 - Continuous variables as predictors of scoring variability in proportional 
odds logistic regression model 
Continuous 
Variables 
Day 30 
N=280 
Day 90 
N=258 
 
Range Median 
(IQR) 
Mean  
(SD) 
Range Median 
(IQR) 
Mean (SD) p 
Age 22-99 69 (59-77) 67.3 (13.2) 22-99 69 (60-76) 67.5 (12.4) 0.691 
Pre-stroke 
mRS 
0-4 0 (0-1) 0.4 (0.8) 0-3 0 (0-0) 0.3 (0.7) 0.128 
Baseline 
NIHSS 
0-23 4 (2-7) 5.6 (4.8) 0-22 4 (2-7) 5.4 (4.4) 0.560 
Interview 
Length 
(min:sec) 
00:52-
23:51 
5:08  
(3:19-7:16) 
5:45  
(3:20) 
1:00–
22:39 
4:30  
(3:18-6:54) 
5:15  
(3:19) 
0.066 
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Table 35 - Categorical variables as predictors of scoring variability in proportional 
odds logistic regression model 
  
Categorical Variables 
Day 30 
N=280 
Day 90 
N=258 
N (%) N (%) 
Location of Interview 
(Standard: Outpatient Clinic) 
Participants home 40 (14.2%) 48 (18.7%) 
Inpatient / Rehab 48 (17.1%) 15 (5.8%) 
Poor Sound Quality 
(Standard: No) 
Yes 11 (3.9%) 9   (3.5%) 
Presence of Language disorder 
(Standard: No) 
Yes 89 (31.7%) 56 (21.8%) 
Use of Proxy 
(Standard: No Proxy) 
Yes – full interview 12 (4.3%) 8   (3.1%) 
Yes – participant & proxy  45 (16.0%) 40 (15.5%) 
Pre-stroke disability 
(Standard: None) 
Yes – previous stroke 8   (2.8%) 6   (2.3%) 
Yes – other co-morbidity 62 (22.1%) 47 (18.3%) 
 
Prior disability was poorly reflected in the pre-stroke mRS score. 22.9% (123/538) videos 
discussed prior disability; only 1.6% (9/538) of videos had a pre-stroke mRS of ≥ 3.  
At both 30 and 90 days only “interview length” was significantly associated with agreement 
in mRS scoring. Tables 36 and 37.  Baseline NIHSS at 30 days was inversely related to 
variability in mRS scoring, however this did not reach statistical significance using the CMH 
significance test. The small numbers in some groups limited analysis in some categorical 
variables and the regression model provided very wide confidence intervals. In plotting the 
data groups with n ≤ 15 have been removed. Figures 34 and 35. 
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Table 36 - Factors associated with variability in mRS scoring at 30 days. Frequency 
of variable and odds ratio (95% CI) from proportional odds logistic regression. P 
value generated from CMH test. 
    
Day 30 (n=280) 
 
N Odds Ratio (95% CI) CMH  
p value 
Categorical Variables    
Prior disability – stroke 8 1.44 (0.41-5.12) 0.448 
Prior disability – other comorbidity 62 1.69 (1.01-2.82) 0.448 
Proxy – full interview 12 0.16 (0.05-0.52) 0.119 
Proxy – participant and proxy 45 2.11 (1.18-3.79) 0.119 
Language Disorder 89 0.62 (0.40-0.98) 0.139 
Poor sound quality 11 1.59 (0.54-4.69) 0.149 
Location – inpatient/rehab 48 0.35 (0.20-0.63) 0.238 
Location – patient’s home 40 1.37 (0.74-2.56) 0.238 
Continuous Variables    
Interview length 281 1.12 (1.05-1.19) 0.023 
Age 281 1.01 (0.99-1.02) 0.913 
Baseline NIHSS 281 0.95 (0.91-0.99) 0.263 
Pre Stroke mRS 281 0.90 (0.68-1.12) 0.380 
 
Table 37 – Factors associated with variability in mRS scoring at 90 days. Frequency 
of variable and odds ratio (95% CI) from proportional odds logistic regression. P 
value generated from CMH test. 
    
Day 90 (n=258) 
 
N Odds Ratio (95% CI) CMH  
p value 
Categorical Variables    
Prior disability – stroke 6 3.30 (0.76-14.47) 0.146 
Prior disability – other comorbidity 47 1.78 (0.99-3.16) 0.146 
Proxy – full interview 8 1.93 (0.50-7.49) 0.072 
Proxy – participant and proxy 40 1.72 (0.93-3.18) 0.072 
Language Disorder 56 0.94 (0.55-1.61) 0.360 
Poor sound quality 9 0.32 (0.09-1.06) 0.002 
Location – inpatient/rehab 15 1.14 (0.44-2.91) 0.876 
Location – patient’s home 48 1.17 (0.66-2.07) 0.876 
Continuous Variables    
Interview length 257 1.13 (1.06-1.21) 0.001 
Age 257 1.01 (0.98-1.02) 0.511 
Baseline NIHSS 257 1.01 (0.96-1.06) 0.683 
Pre Stroke mRS 257 1.15 (0.84-1.56) 0.189 
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Figure 34- Forest Plot: Factors associated with variability in mRS scoring at 30 
days. Odds ratio (95% CI) and CMH p value. 
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Figure 35 - Forest Plot: Factors associated with variability in mRS scoring at 90 
days. Odds Ratio (95% CI) and CMH p value  
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7.4. Conclusions 
As we have previously described, inter-observer variability limits the utility of mRS scoring.  
There are several proposed strategies to minimise this but tools to predict potential 
“problem” mRS cases might allow targeted interventions to minimise misclassification. We 
aimed to assess which factors in the mRS video interview affect variability in scoring to 
identify the features of an optimal adjudication video.   
In this study, the selection of factors potentially associated with variability was arbitrary by 
necessity due to a paucity of published background literature on predictors of mRS 
variability. Our selection of variables was guided by prior qualitative study204. Other factors 
that might have been relevant such as employment status, socio-economic status, marital 
status etc. may be pertinent but the corresponding data were not captured at the time of 
initial interview. 
The majority of factors identified as possible factors associated with variability were not 
demonstrated as such in this study. This is in part attributable to the small numbers in some 
groups. The use of a proxy, presence of language disorder or location of the interview does 
not appear to impact upon scoring variability. There is a perception that at the extremes of 
disability there is less variability in mRS scoring; however measures of initial stroke severity 
were not associated with improved reliability in this study. 
We were only able to identify one factor associated with agreement in mRS scoring. 
Increasing length of interview was associated with less variability. This was unexpected in 
light of the experience of end point committee discussions.  In several instances adjudication 
committee members commented that longer recorded interviews were difficult to follow and 
contained unnecessary information.  However, on the basis of this data we might surmise 
that extra information, which may be interpreted as superfluous, could be useful in forming 
an mRS judgement.   
The clinical implications of these data are uncertain, although duration of mRS interview may 
be associated with variability the effect seems small and by its nature duration of interview 
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cannot be predetermined or assessed until the interview is complete.  Perhaps we should 
conclude that interviewers should not deliberately prolong the interview but should take as 
much time as is needed to cover all the salient points of a complete mRS assessment. 
7.4.1. Scoring controversies in CARS study 
During the course of the CARS study the endpoint committee met to discuss all mRS videos 
that had resulted in disagreement. This permitted focussed discussion to highlight potential 
areas that may contribute to mRs uncertainty. There were common themes discussed during 
these meetings that cause difficulty in mRS grading. In several instances the controversies 
arose simply because of a value judgement and were individual to each interview. Factors 
that frequently generated discussion were with regards to possible non stroke symptoms or 
incomplete information. We did not formally study the details of these conversations in a 
qualitative manner; however, it is worth brief discussion of these controversies as potential 
topics in the content of a clip that might impact upon mRS variability in. Across each mRS 
boundary there were recurring themes. 
Post stroke symptoms (mRS 1 boundary): A wide array of post stroke symptoms and 
syndromes are recognised; those which are easily recognisable such as paralysis or dysphasia 
and others which are less objective such as post stroke pain, fatigue or mood disorder. There 
is a clear distinction between interpretation of physical and psychological symptoms after 
stroke, largely related to the objective / subjective nature of their impact. The interpretation 
of more subjective symptoms (such as fatigue or mood disorder) may vary more among 
individuals and the link between them and functional ability may be less clearly related to the 
initial stroke insult or any response to treatment. 
Should all of these symptoms be regarded as equal in terms of the limitations that they place 
on the stroke survivor?  This is not clear in mRS scoring guidance; an inability to perform 
ADLs due to hemiplegia is noticeably different to an inability to perform ADLs due to fatigue.  
In some societies it must be acknowledged that the extent and impact of symptoms can have 
consequences in terms of physical and financial support or welfare.  These influences are 
difficult to extricate in accurate functional assessment for clinical trial purposes, particularly 
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where a participant knows that a recording of their description of disability is going to be 
stored.  It is important that the nature and effect of all symptoms is fully explored, 
acknowledging the limits and possible motivations in these discussions. 
Return to previous activities (mRS 2 boundary): For the purposes of the mRS scale, a regular 
activity is defined as one which was carried out at least once monthly in the time period 
immediately prior to stroke.  Controversy may arise where a participant may be able to 
perform an activity, but they feel that they perform less well than prior to the stroke.  An 
example might be a participant who had a complex hobby prior to their stroke (playing an 
instrument / painting); if their music or art is perceived to be of poorer quality after stroke 
should this be deemed a loss of activity?  Where an individual is able to perform physical 
tasks to a degree that allows resumption of normal activities, then perhaps caution should be 
exercised before giving a score of mRS 2. 
In some situations participants may not have had the requirement or opportunity to attempt 
such activities. Such a situation arises when participants are scored during inpatient 
rehabilitation. Our prejudice is likely to be that during an inpatient stay, where assistance 
with personal care, meals and domestic tasks is provided; a participant must mandate a score 
of mRS 3.  Length of stay in rehabilitation facilities and the activities that are expected of 
patients during their stay vary widely across geographical areas in relation to healthcare 
systems, facilities and funding.  On this basis it is impossible to offer international guidance 
on how to score this population except to highlight that consideration should given to ensure 
that the assistance received is absolutely required.   
Societal barriers to functional recovery:  The primary issue here arose in discussions 
regarding a participant’s return to driving. Where participants have not returned to an 
activity due to a legal constraint it is unclear if this should be scored as a disability. Similar 
issues arise with return to work, caring roles and other societal roles. As the CARS study was 
performed across sites subject to similar laws and regulations this was fairly easy to deal 
with. Agreement was reached that where a legal constraint regarding driving was the only 
limitation with an otherwise good recovery, this must not be scored as a disability. There was 
an acknowledgement that where a central adjudication model might be adopted on an 
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international basis there are likely to be other “societal barriers” to full, functional recovery 
and these must each be considered on their own merits. 
Definition of Requiring Assistance (mRs 3 Boundary): Activities of daily living (ADL) can be 
grouped into two categories of basic and instrumental ADL’s. Basic ADL’s include self care 
tasks such as personal hygiene, dressing, eating, transfers, elimination and mobility. If help 
with these is required then a score of at least 3 should be assigned. Instrumental ADL’s are 
not necessary for fundamental functioning, but allow an individual live independently in a 
community. These are again of equal importance but given that they are more complex, the 
range of activity is great. Examples of such activities are doing light housework, preparing 
meals, taking medications, shopping for groceries or clothes, using the telephone, managing 
money. If a patient is able to perform each of these activities in a basic form then they would 
not warrant a score of 3.  An example might be a patient who is able to visit the local shop 
daily for a small selection of groceries but couldn’t manage a large supermarket shop.  This 
should not in isolation warrant a score of 3. The ability to complete the task in question at a 
simple level is the crucial point. In this circumstance, if minor modification within their 
physical capabilities could obviate need for such help (e.g. more frequent smaller shopping 
trips) this may not warrant a score of 3. 
What constitutes independent mobility? (mRS 4 boundary): The mRS scoring guidance is 
clear that where a participant can mobilise without the help of another person they are 
considered independent. The use of walking aids is permissible but it must be clear that the 
participant can transfer independently and use the aid without the assistance of another 
person. However, in our cohort we discussed a few examples where this description was not 
clear cut. The use of a wheelchair is a complex issue.  Many would consider this to be an 
exclusion to “mobility”, but where a participant is able to move freely and independently 
using this aid (similar to the use of a cane or walking frame) they might be considered 
mobile. This is a particular issue where a participant used a wheelchair prior to stroke; often 
for reasons not attributable to stroke disease.  
What constitutes “bedbound” or “constant nursing care”? (mRS 5 boundary): The mRS 
scoring guidance for mRS 5 requires a participant to be bedbound, incontinent and requiring 
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constant nursing care.  If any one of these criteria is met it would be reasonable to consider a 
score of mRS 5.  However, we encountered several situations where these descriptions 
became less clear.  If a patient has been hoisted from bed to sit in a chair with support, does 
this remove them from the category of bedbound? If a participant is physically able but has 
cognitive impairment following stroke that requires constant supervision could this scored as 
mRS 4 or 5 despite mobility?   
These factors raise questions about the mRS scoring guidance that require thought and 
discussion amongst the stroke community. Although there are clear uncertainties, these are 
less important where there is consistency in scoring. By describing common themes relating 
to difficulties in grading mRS, other mRS assessors might be able to incorporate this into their 
future assessments. These topics might contribute in future to extended guidance on mRS 
scoring in clinical trials; for example paying particular attention to local regulations 
concerning driving, return to work; or taking account of pre-morbid disability during 
interview.   
In conclusion we have not convincingly demonstrated factors associated withmRS variability.  
Difficulties in mRS grading appear to be specific to the patient, assessor and interview.  
Difficult mRS cases cannot be prospectively identified on the basis of this work indicating that 
strategies to improve reliability should be applied universally.  However, we acknowledge the 
preliminary nature of this exercise and further prospective studies may better inform the 
debate.   
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Chapter 8  
Translation of mRS 
assessments: Validity, 
reliability and feasibility of 
incorporation in the central 
adjudication model. 
8.1. Introduction 
Stroke is a leading cause of death and disability worldwide. For acute stroke trials to be 
generalisable to an international population it is important that participants are enrolled 
from geographically, culturally and genetically diverse backgrounds. Thus, contemporary 
randomised controlled trials in stroke are international, multicultural and multilingual.   
Including patient reported outcomes is a challenge in international trials. Participant 
responses must be documented in a way that is standardised, repeatable and reliable.  
Researchers must consider in their study design how they will address language barriers and 
consider the use of translators and interpreters in the collection of data. 
The use of translated materials in international medical research is accepted and the 
methodological difficulties posed are acknowledged. There is a body of literature to offer 
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guidance on the translation of standardised tools used in research of patient reported 
outcomes. However, this guidance pertains to the use of structured assessment tools with a 
fixed query : response model, such as patient questionnaires or quality of life measures.  
There is little guidance in the use of translation with qualitative or semi-structured tools such 
as patient interviews as an outcome measure. Translation with the aim of achieving direct 
lexical equivalence and that with the aim of achieving cultural and conceptual equivalence 
may be quite different, further complicated by the communication difficulties that are 
common after stroke. 
Social, cultural and linguistic factors may affect perception of disability after stroke which in 
turn may influence mRS scoring.  For central adjudication of mRS outcome assessments to be 
successful in this context it is important to consider the challenges that may be posed in 
achieving culturally sensitive translation; how to address these challenges in the central 
adjudication model described whilst ensuring that validity and reliability are maintained.   
The aims of our translation study were twofold.  Firstly we aimed to determine the validity 
and reliability of translated mRS assessments in collaboration with a team in Beijing, China.  
We then aimed to assess the feasibility of incorporating a translation step into the central 
adjudication model and evaluate the reliability of these translated assessments. 
8.2. Methods 
8.2.1. mRS translation pilot study 
Our pilot study was conducted in collaboration with a team of stroke researchers from the 
Department of Neurology, Peking University First Hospital, Beijing, China. Ten assessors (5 
Glasgow, UK and 5 Beijing, China), trained and certified in the use of mRS, scored digitally 
recorded mRS assessments of consenting patients from each site. UK Ethical approval was 
granted by Scotland A Research Ethics Committee. mRS videos were scored in English and 
Mandarin, with each assessor working in his or her native language and after translation.  
Translations were provided by written transcript which accompanied the mRS video file.  
Both native language and translated versions were scored by the respective teams. 
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A convenience sample of mRS clips in English was selected from the CARS cohort of video 
mRS assessments. A further convenience sample of mRS clips in Mandarin was filmed in 
China specifically for this study. The translation pilot study was undertaken in two parts. In an 
initial sample, to assess the impact of language disorder, two versions of the translated 
transcript were prepared (dual translation); one with the input of an mRS certified clinician 
and one by a linguist with no medical background. The translated mRS interviews were 
scored twice, using each transcript in turn at least 2 months apart. In the second phase a 
larger sample of mandarin clips was translated and subsequently scored to assess inter-
observer variability with a larger sample size. 
8.2.2. CARS translation sub study 
Using a sample of the original CARS mRS video clips we assessed the feasibility and reliability 
of using translated mRS assessments in the central adjudication model. Ethical approval for 
this study extension was granted by Scotland A Research Ethics Committee and Essex 2 
Research Ethics committee. Trained and certified mRS assessors from the original CARS 
investigator team and end point committee were involved in both translation and scoring 
roles. Training in the translation procedures was provided face to face or by telephone 
depending upon the distance involved and was supplemented by written information (see 
appendix B) 
We used study sites in Scotland and in England/Wales to represent distinct geographical 
areas. There was no true language barrier in scoring clips from each area; however they were 
used to signify different countries in the CARS web portal model. All clips were in the English 
language but there were local variations in accent and colloquialisms evident. A sample of 
clips to meet certain criteria was selected from the cohort of CARS videos using R statistical 
software. The criteria used to limit the CARS sample were as follows: 90 day assessments 
only (to ensure no duplication of participant videos), equal number from Scotland : 
England/Wales and equal number of classified : misclassified clips, maximum clip length 10 
minutes.   Using these criteria clips were randomly selected from the CARS video cohort using 
R statistical software. 
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The sample of translation clips was allocated to the trial outcome manager through the web 
portal to appear as a newly uploaded video file. The origin of the file was identified in the 
mRS upload list. The file was checked for quality by the outcomes manager before being 
allocated to an investigator in a “translator” role who was based in the alternative 
geographical area (i.e. Scottish clips were “translated” by English investigators and vice 
versa). The investigator allocated as “translator” was notified by automated email that a clip 
had been allocated for translation; from here they were able to log in to the web portal to 
view the clip. Translations were provided using a digital dictation device (Phillips Digital 
Pocket Memo© and SpeechExec© software) in mp3 format. Translators were advised to 
provide their translations in plain, clear English without the use of colloquialisms where 
possible. They were also requested to provide clear and unambiguous statements of what 
was said in the clip by both the assessor and the participant. The dictated mp3 file was 
uploaded to the web portal by USB connection and on receipt it was automatically merged 
with the original .wmv video file. This provided a new file with the original video but replaced 
audio component (a video dubbed with the translation file). The translated file was again 
checked by the trial outcome manager for quality and verified as ready for committee 
review. In the translation sub study the end point committee was broadened beyond that 
used in the main CARS trial to include several investigators from other sites. Four committee 
members from both Scotland and England/Wales were then selected to review and score the 
translated clip. Each endpoint committee member was notified by automated email that 
there was a translated clip ready for review. Endpoint committee members based at the 
centre from which each clip originated were excluded from final review.   
Translated clips were scored by four endpoint committee members not less than one year 
after first review of the original clip.  The original four endpoint committee scores were then 
compared to the four translated endpoint committee scores to assess validity and reliability.  
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8.2.3. Statistical Analysis 
Validity of translated mRS assessments was assessed by analysis for any systematic 
differences in the distribution of native language and translated mRS scores using the Kruskal 
Wallis test of distributions for non parametric data.  Reliability of translated mRs assessments 
was assessed using kappa (), weighted kappa (w) and ICC statistics.  
All analyses were undertaken using Statsdirect statistical software. 
 
8.3. Results 
8.3.1. mRS translation pilot study 
Sixty nine mRS clips were scored (9 English and 60 mandarin). Twenty mRS clips underwent 
dual translation (9 English and 11 Mandarin). . Median mRS score was 3 (IQR 2-4). There was 
no significant or systematic bias in native or translated mRS scores. The distribution of native 
language and translated scores (mean (95% confidence interval) and median (IQR)) are 
displayed in figures 36 to 41.  There was no significant or systematic difference between all 
clips scored by native language scorers and all translated assessments (p=0.896) or in the 
groups that underwent dual translation (medical translation p=0.999; linguist translation 
p=0.999). 
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Figure 36 - Distribution of mRS scores in native language and all 
translated clips (n=69). Mean ± 95% Confidence Interval. p value 
represents the Kruskal Wallis test of difference between 
distributions. 
Figure 37 - Distribution of mRS scores in native language and all 
translated clips (n=69). Median ± IQR, Range. P value represents 
the Kruskal Wallis test of difference between distributions. 
p = 0.896 
p = 0.896 
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Figure 38 - Distribution of mRS scores in native language and medical 
translated clips (n=20). Mean ± 95% Confidence Interval. P value 
represents the Kruskal Wallis test of difference between distributions. 
Figure 39 - Distribution of mRS scores in native language and 
medical translated clips (n=20). Median ± IQR. P value represents 
the Kruskal Wallis test of difference between distributions. 
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p = 0.999  
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Figure 40 - Distribution of mRS scores in native language and linguist 
translated clips (n=20). Mean ± 95% Confidence Interval. P value 
represents the Kruskal Wallis test of difference between distributions. 
Figure 41 - Distribution of mRS scores in native language and 
linguist translated clips (n=20). Median ± IQR. P value represents 
the Kruskal Wallis test of difference between distributions. 
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Inter-observer reliability for native language assessment was good (n=69),  0.61 (95% CI 
0.59-0.64), w 0.91 (95% CI 0.86-0.96). ICC 0.91.  Translated mRS assessments maintained 
good reliability (n=69),  0.59 (95% CI 0.55-0.62), w 0.89 (95% CI 0.82-0.97), ICC 0.89. Putting 
an mRS trained clinician in the translation role had no demonstrable impact on the reliability 
of translated mRS assessments;  0.67 (95% CI 0.62-0.72), w 0.91 (95% CI 0.81-1.01), ICC 
0.91 with medical input (n=20) and  0.64 (95% CI 0.59-0.69), w 0.91 (95% CI 0.82-1.01), 
ICC0.91 with linguist only transcription (n=20).  Table 38 and Figure 44. 
8.3.2. CARS translation sub study 
Sixty mRS assessments were selected for inclusion in the CARS translation sub study (n=30 
Scotland, n=30 England/Wales).  Six investigators were allocated the role of “translator” (n=3 
Scotland, n=3 England/Wales), each providing a modified audio summary for ten mRS video 
clips.  Fourteen investigators were involved in providing committee scores for the modified 
mRS clips (n=11 Scotland, n=3 England/Wales).  The translated videos were limited to include 
those less than 10 minutes long, range 1min 4 secs to 9mins 30secs (Mean (SD) 4mins 27secs 
(2mins 18secs)) 
All “translation” audio files were uploaded and merged with the video file successfully 
through the CARS translation web portal.  There were no technical failures. 
Median mRS in native language clips was 1.5 (IQR 1 – 2.5). Median mRS in translated mRS 
clips was 2 (IQR 1-3). Using the median mRS there was a trend towards lower mRS scores in 
the native language clips driven by two of four scores (Figure 43) but this did not result in any 
significant or systematic bias in the distributions of mRS scores in either group (p=0.705). 
Figures 42 and 43.   
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Figure 42 - Distribution of mRS scores in CARS translation sub study: Original and Modified Clips 
(n=60). Mean and 95% Confidence Interval. P value represents the Kruskal Wallis test of 
difference between distributions. 
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Original 4 
Original 3 
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min -[ mean ± 95% confidence interval ]- max 
p = 0.705  
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Figure 43 - Distribution of mRS scores in CARS translation sub study: Original and 
Modified Clips (n=60). Median and IQR. P value represents the Kruskal Wallis test 
of difference between distributions. 
Inter observer reliability seen in the modified clips ( 0.58 (95% CI 0.53-0.64), w 0.85 (95% CI 
0.74-0.95). ICC 0.85) was similar to that seen in the original video files ( 0.64 (95% CI 0.58-
0.70), w 0.88 (95% CI 0.78-0.99), ICC 0.88) Table 38 and Figure 45. 
Table 38 - Summary results – Inter-observer reliability of translated mRS (, w 
and ICC) 
 N  (95% CI) w (95% CI) ICC 
Translation Reliability     
All Native 69 0.62 (0.58 – 0.65) 0.91 (0.86 – 0.99) 0.91 
All Translated 69 0.59 (0.55 – 0.62) 0.89 (0.82 – 0.97) 0.89 
Medical Translation 20 0.67  (0.60 – 0.73) 0.91 (0.77 – 1.04) 0.91 
Linguist Translation 20 0.64 (0.58 – 0.71) 0.91 (0.76 – 1.05) 0.91 
Translation Feasibility 
Original  60 0.64 (0.58 – 0.70)  0.88 (0.78 – 0.99) 0.88 
Modified 60 0.58 (0.53 – 0.64) 0.85 (0.74 – 0.95) 0.85 
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p = 0.705 
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Figure 44 - Summary Results - mRs translation pilot study 
 
Inter observer Reliability in Native Language mRS clips (n=69) 
 
Mandarin n=60 
[Scored in Mandarin by Chinese Investigators] 
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[Scored in English by UK investigators] 
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Inter observer Reliability in Translated mRS clips (n=69) 
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[Scored with English Transcript by UK Investigators] 
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[Scored with Mandarin Transcript by Chinese investigators] 
 
 (95% CI) 0.59 (0.55 – 0.62) 
w (95% CI) 0.89 (0.82 – 0.97) 
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Dual translated mRS clips (n=20) 
[Two transcripts prepared for each clip 1] by mRS certified clinician and 2] by linguist with no medical training] 
 
Mandarin n=11 
[Scored with English Transcript by UK Investigators] 
 
English n=9 
[Scored with Mandarin Transcript by Chinese investigators] 
 
 1] mRS certified transcript   2] Linguist transcript 
 (95% CI) 0.67  (0.60 – 0.73)    (95% CI) 0.64 (0.58 – 0.71)  
w (95% CI) 0.91 (0.77 – 1.04)   w (95% CI) 0.91 (0.76 – 1.05) 
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Figure 45 - Summary results - CARS translation sub study 
 
 
8.4. Conclusions 
Regulatory agencies such as the European Medicines Agency EMEA and US Food and Drug 
Administration FDA recommend the use of patient reported outcome measures in clinical 
research of medicinal products205, 206. It is acknowledged that the application of these 
measures in a modified form, such as use in a different population or language, may not have 
equal validity or utility206. Even within the same language, cultural differences may affect the 
acceptability of outcome measures in various populations207; for example Canadian French 
vs. the dialect of French spoken in France. In order to achieve the sample sizes required for 
successful phase III randomised controlled trials it is necessary to pool data from 
multinational sources. Pooling of clinical trial data from culturally and linguistically diverse 
groups may lead to misleading results if these issues are not considered in trial design208    
The use of translated materials in medical research is common. When using a patient 
reported outcome, translation is frequently limited to the modification of a structured tool 
(e.g. scale or patient questionnaire) which is then administered and assessed in the native 
language. When using a tool such as the mRS, which is inherently unstructured and flexible, 
this brings added challenges if multinational, multicultural and multilingual outcomes are to 
be assessed centrally.  
Original 
n=60 
 
 (95% CI) 0.64 (0.58-0.70) 
w (95% CI) 0.88 (0.78-0.99) 
ICC 0.88 
Modified 
n=60 
 
 (95% CI) 0.58 (0.53-0.64) 
w (95% CI) 0.85 (0.74-0.95) 
ICC 0.85 
 161 
8.4.1. Translation in medical research 
Four levels of language competence are described in the translation literature209. 
Grammatical competence – this is the goal of most beginner’s language courses, to 
understand basic vocabulary and grammar, the ability speak and write simple sentences.  
Discourse competence – this demands a more complex understanding of vocabulary and 
grammar, the ability to converse and follow everyday conversations and to understand oral 
and written communication with complex sentence structure. Sociolinguistic competence – 
this demands the ability to express and negotiate the meaning of words and phrases 
according to the culture using the language, to integrate cultural norms into the 
communication process; for example to demonstrate appropriate politeness and respect in 
social situations. Strategic competence – this requires an ability to compensate for any lack 
of knowledge by using alternative vocabulary or non verbal cues appropriate to local culture. 
This level of linguistic competence allows the speaker to manage unexpected scenarios and 
social situations without being highlighted as a non native speaker. For research purposes a 
translator should have a minimum of sociolinguistic competence.  
There are several levels of equivalence that must be obtained for a valid and reliable 
translation210. Conceptual equivalence – refers to constructs that exist, are relevant and 
acceptable in both cultures. Semantic equivalence – ensures that items mean the same thing 
to different groups. Operational equivalence – methods of administration of the assessment 
tool are appropriate for all cultures. Measurement equivalence – ensures that the test 
measures the same metrics in the source and target population. Item equivalence – confirms 
that items are not biased and carry equal weight in each culture. Criterion equivalence – 
ensures that the interpretation of scores is the same across groups. 
In the translation of specific tools (e.g. questionnaires) there is a clear recommended 
multistep process to ensure that translations are valid and acceptable for use in medical 
research across countries. Regulatory agencies suggest that the method of translation is 
clearly and transparently described in publications of trial methods and results206 
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Details of the recommended translation procedures are widely published211-213. There is 
general agreement that the translation process must include: Synthesis of translation by at 
least two translators independently followed by a joint meeting to combine their translations 
where a written report is made to document issues and describe how these were resolved; 
then back translation by a further two independent translators is performed, blinded to the 
original version. There then must be some form of expert central committee review including 
clinicians and all involved translators to discuss any discrepancies. The modified tool must 
then be tested in a sample population with accompanying interviews before the process 
documentation is submitted to regulatory authorities.  
The complexities involved in this process of translation would prohibit the use of this 
approach in translating patient interviews. There are reports of translated patient interviews 
used in qualitative research but the numbers are small. A qualitative study with patient 
translated patient interviews in Cantonese : English reported no significant differences in 
major categories but minor themes had some variation214. An alternative is to consider the 
use of an interpreter during the interview.  This has advantages, any queries can be clarified 
by the researcher in real time; however the validity of this approach has been questioned215.  
An interpreter may summarise responses and without knowledge of the research field this 
may place limitations on data collection and threaten the content of the interview.   
8.4.2. Translation in the Stroke literature  
There have been several reports of translated outcome measures in the field of stroke. 
Translated outcome scales such as NIHSS (Italian150, Portugese66, German216), Barthel Index 
(Portugese66, Persian217, German119), Stroke Impact Scale (German218, 219),  Motor assessment 
scale (German220, Dutch221), European Stroke Scale (German216), Satisfaction with stroke 
questionnaire (German222) and Stroke and aphasia quality of life scale-39 (Spanish223) are 
available. 
There have been two documented studies assessing a translated mRS scale; in German216 
and in Portugese66. These successful translation reports refer to modification of the wording 
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of the mRS scale, with subsequent application and scoring of this modified scale in the native 
language. There are no prior reports of translation of the mRS assessment itself. 
We chose two linguistically and culturally diverse populations to assess the validity and 
reliability of the translated mRS. There has been one prior report of translation of a scale 
used in a Chinese population224, but this has not been published in full.    
8.4.3. mRS translation project 
The challenges posed in the central adjudication of multilingual mRS assessments are clear.  
The number of interviews involved and the heterogeneity of content within precludes the 
use of recommended standardised translation techniques. The added complexity, time and 
expense involved in the multistep process may not enhance the reliability of results more 
than a single critical review by an independent bilingual observer209. A more pragmatic 
approach to translation is required and this is what we sought to investigate in the mRS 
translation project.   
There are several factors for consideration in the application of translated, centrally 
adjudicated mRS assessments in clinical trials. We have demonstrated that translated mRS 
assessments appear to have equivalent reliability to native language mRS assessment and 
that incorporation of a translation step using digital dictation is feasible. However, there are 
limitations to the findings in this study and further research is required before we can 
confidently state that a translated mRS assessment is useful, valid and reliable. 
The mRS pilot study included a small sample with only one language comparison. We 
deliberately chose two culturally and linguistically diverse populations and the focus of 
determining disability was noticeably different in the content of mRS interviews in each 
group. It is clear that the concepts relevant to health or illness are not equivalent in culturally 
diverse populations. In the Mandarin clips there was a strong focus on discussion regarding 
issues such as domestic tasks and caring for relatives where the UK clips were less likely to 
focus on these issues as a priority.  The descriptors of independence in Chinese mRS clips 
included activities such as the ability to ride a pedal bicycle. This was not evident in the UK 
clips which were more likely to focus on driving a car or using public transport. With this in 
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mind it is important to highlight that the native language of the clips was not equally 
distributed, (English n=9 and Mandarin n=60). Each clip was scored in the native language 
and after translation, but the bias of Chinese clips does place limitations on the 
generalisability of the results. Many of the assessors in the Chinese group were bilingual. 
Although they performed the interviews in their native language; it is difficult to quantify any 
subtle changes that may have been made to the interview questions or technique as they 
had an English speaking audience in mind. 
In the mRS pilot study each group of clips was translated by the same translator (medical or 
linguist), in the CARS sub study there were multiple translators. We have demonstrated that 
there is no significant difference in this sample using either a medically trained and mRS 
certified clinician or a linguist in the role of translator. This flexibility is important in the 
application of the model in a real clinical trial; the option of choosing a single or multiple 
translators with no necessity for experience in the relevant research area is a logistical 
advantage. Again, it must be emphasised that our sample of dual translated clips was small 
(n=20) and further study is indicated to ensure that these pilot study results are reproducible. 
8.4.4. Summary 
Including patient reported outcome measures is a challenge in multicultural and multilingual 
trials. There is no guidance for using translated patient interviews as an outcome measure 
but we have demonstrated in a small pilot study that the reliability of the mRS as an outcome 
measure is maintained when scoring translated assessments from two culturally diverse 
populations. The incorporation of a translation step into the central adjudication process 
seems technically feasible. Further work with multiple languages and a larger sample size is 
desirable to ensure generalisability of our results. 
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Chapter 9  
Ranking within Rankin: can 
disability be graded within 
mRS grades? 
9.1. Introduction 
The mRS is an ordinal, hierarchical scale with broad descriptions between ranks. As we have 
discussed, the mRS descriptions are arguably vague and there is inherent variability in the 
scores allocated by independent observers.  This limits the utility of the mRS as a clinical trial 
outcome measure. 
In considering the mRS, or any other scale which contains grades, it is most useful 
conceptually to think of each grade as being distinct and discrete, with clear boundaries 
between ranks.  However, in practice, the underlying distribution of subjects is likely to be 
more uniform, blurring the boundaries between grades.  Figure 46. 
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Figure 46 - Diagrammatic representation of the underlying distribution of 
disability within the mRS scale. 
 
Between mRS grades, the underlying spectrum of disability within the scale is subtle, with 
some participants likely to sit clearly within an mRS grade where others might sit close to the 
line between grades. It is these participants, close to the boundaries, who are likely to 
contribute to inter-observer variability and misclassification.  
Our aim is to accurately describe disability as an outcome measure in stroke trials.  A method 
of detecting a difference both between and within ranks in the mRS might help us better 
understand the underlying “true” disability of stroke survivors and identify those who are 
closer to the boundary or more controversial in assigning mRS grade. Detection of discernible 
differences between participants within mRS grades may enrich the quality of data that are 
collected using the mRS as an outcome measure. We sought to assess the ability of stroke 
researchers to measure a more subtle effect on outcome through grading of outcomes 
within mRS categories. A method of identifying where in the spectrum of disability a 
participant lies has not previously been investigated. We used the CARS study video resource 
to determine the ability of stroke researchers to detect a difference in participants scored at 
each grade on the mRS scale.    
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9.2. Methods 
The CARS videos represent a large sample of mRS assessments with multiple mRS scores.  
Each clip was scored remotely by four experienced mRS assessors and has an adjudicated 
consensus score.  The local mRS score was not included in this analysis as it was based upon 
direct patient contact and therefore was not generated using identical source data. 
These video assessments can be divided into two distinct groups. 1) Classified (Agreement): 
The original four adjudication committee assessments agreed and the video was 
automatically allocated the agreed mRS score. 2) Misclassified (Disagreement): There was 
disagreement in one or more of the adjudication committee assessments and a consensus 
score was allocated following group review and discussion. The degree and direction 
(towards greater or less disability) of disagreement can be identified by the spread of 
available mRS scores for each individual clip. The classified (agreement) clips can be 
considered “gold standard” examples of disability pertaining to that rank of the mRS, unlikely 
to represent a contentious mRS assessment.  The misclassified (disagreement) clips exhibit a 
degree of controversy and can be considered to represent one of the mRS assessments that 
is likely to sit closer to the boundary between mRS grades. 
In order to determine if mRS assessors were able to correctly identify the presence and 
direction of disagreement, pairs of “matched” mRS clips were compared.  Ten trained and 
certified mRS assessors were asked to view each pair of mRS assessments for a subjective 
opinion regarding which participants’ function was better or worse than their counterpart in 
the pair.  We used only day 90 mRs assessments from the CARS video cohort in order to 
ensure that no duplicate clips containing the same participant were selected. We included 
two distinct samples in the comparison. 
1. We selected a sample of classified (agreement) clips where there was no controversy 
within the original reviewing committee over mRS grade.  
2. We selected a sample of misclassified (disagreement) clips, where there was more 
than one possible score on the mRS prior to consensus opinion. The spread of original mRS 
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scores in the misclassified clip was used to identify the direction of disagreement (i.e. to 
more or less disabled). 
Each clip from the samples above was considered the “active” clip and was paired with a 
“control” clip.  The “control” videos were all classified (agreement) clips selected from the 
day 90 CARS video cohort.  Each pair had matched adjudicated mRs scores, generated 
automatically by agreed initial committee scores (in the “active” classified (agreement) and 
“control” groups) or by consensus following endpoint committee discussion (in the “active” 
misclassified (disagreement) group). See figure 47 for a summary of the study design. 
 
Figure 47 - "Classified" and "Misclassified" Pairs. [mRS 2 is used as an illustration, 
this process was repeated across the spectrum of mRS within the random 
sample.] 
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Each pair of video clips (active : control) was randomly allocated to four mRS assessors. The 
order in which the clips were viewed by the assessors (labelled simply as A and B) was also 
randomly allocated.  Raters were given instruction to watch each pair of clips, in the order 
provided and blinded to each other’s responses.  After viewing each pair of mRS clips the 
rater was asked to note which of the participants (A or B) was “less disabled”.  They were not 
asked to provide a score on the mRS scale. We anticipated that there would be a proportion 
of clips (matched active classified (agreement) : control clips) where it may be very difficult to 
distinguish varying degrees of disability, due to the matched mRS scores involved. Despite 
this, raters were not permitted to provide a neutral response.  This was to ensure that 
judgement was made in all clips and to simplify analysis.   
Random sampling and allocation of clips, reviewer and order of viewing was done using R 
statistical software. A summary of the sampling process is shown in figure 48. Video clips 
were provided to each assessor on an individual CD with clips identified as A or B in the 
allocated viewing order.  An electronic scoring sheet was provided to be completed during 
viewing and sent back to the study outcomes manager.  The identity of the clips (control and 
active) was not unblinded until all assessors scores had been collated.   
9.2.1. Statistical Analysis   
Raters were asked to provide a judgement regarding which mRS assessment clip in each pair 
represented less disability. Half of the sample comprised matched pairs of classified 
(agreement) clips in which we anticipated this judgement would be difficult and might 
generate an arbitrary response or “guess”.  We sought to identify if the judgements were 
more predictable in the misclassified (disagreement) pairs and if this could be quantified.  
The ability of assessors to identify the direction of disagreement was quantified by 
comparing the clip identified as representing “less disability” to the clip with the lower mean 
mRS in adjudication scores. Our hypothesis was that raters would be able to identify those 
clips that had generated disagreement during original committee scoring by agreeing 
consistently that those clips with a lower mean committee mRS were “less disabled”.  The 
proportion of assessments where this was identified correctly and the rater agreed with the 
original mRS assessors was calculated.  Equality of two proportions was tested using a test of 
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two proportions with a null hypothesis that there is no difference between the two 
proportions.  
In order to determine if the agreement among assessors for the classified (agreement) clips 
and misclassified (disagreement) clips is more than that which would be expected by chance 
alone the agreement between raters was compared using kappa statistics (). Weighted 
kappa statistics (w Fleiss-Cohen Weights [1-[(i-j)/(1-)]
2) and intraclass correlation coefficient 
(ICC) were not relevant in this analysis due to the categorical nature of the data. 
Statistical analysis was performed using StatsDirect statistical software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 90 mRS video clips for random sampling 
(n=258) 
Classified Pairs 
(n=20) 
 
[Two classified mRS clips with 
equal adjudicated mRS] 
Misclassified Pairs 
(n=20) 
 
[Two misclassified mRS clips 
with equal adjudicated mRS] 
Random sample of pairs from n=258 day 90 
mRS clips  
(generated using R statistical software) 
Clip 
A 
Clip 
B 
Random allocation of pairs and order of viewing 
(generated using R statistical software) 
Each pair reviewed 
by n = 4 assessors 
Figure 48 - Sampling of "Classified" and "Misclassified” pairs 
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9.3. Results 
We randomly selected n=40 pairs of clips for review; n=40 active clips in each group (n=20 
classified (agreement) and n=20 misclassified (disagreement) and n=40 control clips (Total 
clips reviewed n=80). 
Ten mRS raters each reviewed sixteen pairs of clips. Each pair was reviewed by 4 
independent assessors. In total we received data for 160 paired assessments (n=80 for 
classified (agreement) video pairs and n=80 for misclassified (disagreement) video pairs. 
There was no difference between the proportion of raters who agreed which participant was 
“less disabled” in the classified (agreement pairs) group [54 / 80 (67.5%)] or the misclassified 
(disagreement pairs) group [55 / 80 (68.75%)]. There was no difference between proportions 
(p=>0.999) Table 39. 
 
Table 39 - 2x2 Table displaying proportions of raters in agreement for each group. 
Misclassified (disagreement) pairs: agreement represents correct identification of 
“less disabled” clip. Classified (agreement) pairs: agreement represents chance 
agreement between raters. 
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The mean mRS was equal in the classified (agreement) group of paired clips due to the initial 
agreed mRS at adjudication review. In the misclassified (disagreement) group the difference 
in mean mRS between active and control clips ranged from -0.4 (suggesting less disability) to 
0.8 (suggesting more disability).  There was no pattern to suggest that greater disagreement 
(as demonstrated by difference in mean mRS) was likely to result in correct identification of 
the direction of disagreement at initial mRS review. Table 40. 
Table 40 – Number of assessors who correctly identified the direction of 
disagreement in Misclassified (disagreement).  Mean difference in mRS represents 
the magnitude of disagreement.  
 Difference 
(mean mRS) 
1 correct 2 correct 3 correct 4 correct Total  
Less Disability 
 
 
 
 
 
More Disability 
-0.4 1  1 1 3 
-0.2 1  2 2 5 
0  1   1 
0.2  1 2  3 
0.4 1 2 1 1 5 
0.6    2 2 
0.8  1   1 
 Total correct 3 5 6 6 20 
 
There was no pattern to suggest greater ability to correctly identify the “less disabled” mRS 
clip at any level on the mRS scale.  This was also seen in the control group, with no pattern in 
agreement among raters at any level on the mRS scale. Figure 49. 
There was poor agreement between raters for all paired assessments,  (95% confidence 
interval) 0.075 (-0.033 – 0.183).  Agreement between assessors for the clips that were 
classified (agreement pairs) and misclassified (disagreement pairs) was equivalent. ( (95% 
confidence interval); Classified pairs 0.077 (-0.065 – 0.218) and Misclassified pairs 0.078 (-
0.084 – 0.241).  
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Figure 49 – Frequency of agreement between raters for Misclassified 
(disagreement) paired clips [indicating correct identification of “less disabled” 
mRS clip] and Classified (agreement) paired clips [indicating chance agreement] 
for each rank on mRS scale.  
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9.4. Discussion 
The spectrum of disability seen in stroke survivors ranges widely. Converting this complexity 
into ranks on an ordinal scale is challenging.  There is a degree of error in all measurements, 
but that error can be significant where it results in grouping error; i.e. a participant is placed 
in the incorrect outcome grade or is “misclassified”.   
There have been studies in the neurotrauma literature highlighting the difficulties in 
misclassification of outcomes.  The result is reduced power and treatment effect size144, 145.  
Outcome assessment following head injury presents similar challenges to that following 
stroke – heterogeneous insults resulting in a wide variety of possible functional deficits. 
The optimal number of outcome grades on a scale is debated.  It is acknowledged that 
compressing a scale to a small number of grades (dichotomy, trichotomy etc.) wastes 
valuable information and may limit the detection of a genuine treatment effect154.  However, 
there is also evidence to suggest that an increased number of ranks on an outcome scale 
results in greater inter-observer variability and misclassification.  The Glasgow Outcome Scale 
(GOS) used following head injury is a disability outcome scale very similar to the mRS.  In its 
original format there are 5 grades, an extended Glasgow Outcome Scale (GOSE) with 8 
grades is also in widespread use. Versions of the scale with more ranks have been found to 
result in greater variability, threatening the utility of the extended scale225, 226.   
The mRS in its traditional form has 7 ranks.  Ordinal analysis of the mRS provides more 
information than a binary outcome104; but even this is much less sensitive to change than a 
continuous outcome measure. The ability of an ordinal scale to accurately quantify outcome 
is determined by the width interval of each rank. Broad ranks result in the disposal of 
potentially useful information whilst finer distinctions between ranks may make it more 
difficult to distinguish between function in each group.  In an interval scale, the size of the 
difference between each outcome group is equal or quantifiable, however using an ordinal 
scale there are likely to be non-uniform steps between grades.   
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Using a procedure developed by the WHO Global Burden of Disease Project (WHO-GBDP) the 
interval distances between mRS grades have been reported using disability weights111. Figure 
50.  This clearly depicts the continuous nature of the disability spectrum within the mRS.  It 
also helps to define the difference between a change from mRS 3 to mRS 4 (broad interval) 
and between mRS 5 to mRS 6 (fine interval).   
 
 
Figure 50 - Disability Weight (and 95% CI) for each grade of mRS. Disability 
weights generated using WHO Global Burden of Disease111.  
 
We aimed to explore the potential for experienced mRS raters to be able to identify these 
finer distinctions within groups. If it is possible to rank disability within mRS grades this could 
be used to display outcome data in a more continuous form, allowing for alternative 
statistical strategies.   
We have found that our team of mRS raters could not reliably identify those clips that 
represent “less disabled” mRS participants.  Our hypothesis was that the clips in the “active” 
group; i.e. those that contained a clip that resulted in disagreement paired with a gold 
standard agreed mRS clip; would be identifiable to the raters as ones which clearly depicted a 
participant at the “good” or “bad” end of an mRS grade in comparison to one in the middle 
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of an mRS grade.  The results suggest that comparison of the “active” and “control” pairs 
were similar enough to prevent identification of the “active” pairs.  There was no pattern to 
suggest that raters were more likely to identify pairs with a greater change in mean mRS 
score and no pattern to suggest that identification of the “active” pairs was more likely at any 
level on the mRS scale. From the disability weights data we could postulate that it should be 
easier to define the difference between mRS participants in the middle grades of the scale 
than at the more extreme end of the disability spectrum but we cannot support this 
hypothesis using our data. 
The grading of the mRS with “good” or “bad” forms of each grade is not reliable on the basis 
of this exploratory study.  There are limitations to this study due to the small number of clips 
and assessors involved, however the results are equivocal in every sense.  Significance testing 
and kappa statistics indicate that there is no agreement between assessors beyond that 
which we could expect by chance alone. Perhaps alternative methods of converting the 
ordinal ranks of the mRS scale into a more continuous distribution should be investigated; 
such as the use of a mean mRS score following multiple mRS ratings. 
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Chapter 10    
Discussion and Conclusions 
The outcome measures available for use in stroke trials are large in number and diverse in 
content.  The choice available is testament to the fact that there has been a lack of 
uniformity in the outcome measures used and that no one tool is infallible. The aim is to 
identify a tool that is universally accepted and can be used in a standard form in most stroke 
trials, aiding interpretation of the relative risks and benefits among treatment strategies. 
The mRS has become the preferred primary outcome measure in most stroke trials and has 
gained favour for many reasons29, 227. Experience and familiarity with the mRS is widespread; 
there are accepted procedures to complete training and gain certification in its use.  A 90 day 
mRS outcome is available for the majority of stroke trials conducted over the last decade, 
although not consistently as a primary outcome measure.  The availability of this data is 
useful in comparing and pooling the results of clinical trials, for example using the Virtual 
International Stroke Archive (VISTA)228. The mRS is also a useful measure in terms of quality 
of life110, 111 and economic measures94; metrics which are crucial in the application of novel 
treatment strategies. 
This thesis has examined the potential benefit of improving reliability of the traditional mRS 
in stroke research and has detailed a novel assessment technique utilising a central 
adjudication model. 
 
 178 
Statistical modelling techniques using real stroke trial data distributions have demonstrated 
that there are meaningful gains in sample size to be realised if we can reduce variability in 
mRS scoring and improve the reliability in stroke trials.  The reliability of the standard mRS is 
likely to be poor based on available estimates. We have reported a possible reduction in 
sample size of 20% to 25% with improvement of mRS reliability from baseline  0.25 to  0.5 
or  0.7.   
This may translate to important financial and ethical benefits for trialists.  The ethical 
benefits in reducing the number of participants in clinical trials are clear; we must strive to 
randomise as few participants as possible in order to gain the required evidence to guide 
optimal treatment.  The financial gain in including fewer participants is less clear and less 
immediately justifiable.  The cost analysis of every clinical trial is individual to that trials aims, 
however, a reduction in participants by 25% would translate to significant saving in terms of 
cost and time to completion of recruitment. 
We do not propose that mRS reliability can be included in sample size calculations, the 
complexities involved clinically and statistically are too great.  However, we have illustrated 
that there is an inherent degree of inter-observer variability in mRS assessment that impacts 
upon trial power and strategies to reduce variability would be of benefit in general terms.   
We have found that the use of remotely assigned mRS scores may be feasible in a 
multicentre acute stroke trial.  Our web based outcomes portal was successful with very few 
technical failures.  Of course in a clinical trail the loss of any data through technical failure is 
unacceptable, scientifically and ethically.  However, it is important to note that with the CARS 
trial design there would always have been a locally assigned mRS score to be used in the 
event that a centrally assigned score was unavailable. The video equipment that we used has 
long since been superseded by smaller, cheaper versions that are easily connected to the 
internet through wireless technology.  This can only offer advantage to our model in the 
future. 
The central adjudication model was an entirely new concept to investigators and 
participants. We found no reluctance from investigators to be involved in the video process.  
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Some sites were more active in recruiting than others, largely reflected by the research staff 
available. Some investigators required a little more guidance than others in negotiating the 
technological aspects of the trial but we found a clear learning effect as the trial progressed.   
Participant withdrawal was substantial and 17% of study visits were missed. Although the 
majority of withdrawals took place before any study procedures we cannot conclude that the 
video process did not have an effect on this withdrawal rate. We must be cautious in drawing 
the conclusion that this model is feasible and acceptable, in a real RCT missing outcome data 
on this scale would have a substantial effect on analysis and the interpretation of results.  
Our data suggest that central adjudication may be acceptable and accessible to investigators 
and participants but further study is necessary in the context of a true RCT.  Investigation of 
the model with larger scale application must be undertaken; our findings may not be 
applicable in other countries or cultures where infrastructure and health care facilities differ.   
The real challenge in documenting mRS outcomes is that we are trying to use an ordinal scale 
to accurately document function on a continuous spectrum of disability. From our data we 
cannot conclude that a remotely allocated score more or less accurately reflects the “true” 
disability.  There are no means by which we can assign a numerical score with the sensitivity 
and precision required to score “true” disability.  This unknowable and unquantifiable 
concept is an unrealistic target for comparison.  The best alternative is to compare 
assignment of outcome to current gold standard practice; which is local mRS assessment by a 
trained and certified investigator. We have found that remotely assigned mRS scores are 
valid, in comparison to current best practice and factors known to be related to outcome 
after stroke. In the future validity could be further tested in comparison to a standard mRS 
assessment in the detection of a treatment effect that we have previously recognised (such 
as rtPA) or may find to exist in ongoing or future clinical trials. 
We have demonstrated reliability in the CARS study that is favourable in comparison to 
current estimates of mRS reliability. Reliability among the adjudication panel was  0.59.  In 
light of the published estimate of mRS reliability in a multi-centre trial100 and the result of our 
simulations, this may indeed translate to a reduction in sample size of between 20% and 
25%.  Our translation pilot and sub-study have provided encouraging data to support the use 
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of central adjudication in an international, multicultural and multilingual trial. Further study 
with several languages is warranted.   
We have investigated methods of identifying the “difficult” mRS assessments likely to 
contribute to inter-observer variability.  Our data do not suggest that there are any 
consistent predictors of variability in mRS scoring and that the difficulties in scoring individual 
clips arise through factors that are individual to that participant, that investigator and that 
interview.  Analysis of paired mRS clips to assess raters ability to identify “good” or “bad” 
examples of each mRS grade was also unsuccessful.  
Where the hypothesis had been that we might be able to pre-determine those assessments 
likely to need assistance in mRS grading, our data suggest that any strategy to improve 
reliability in mRS grading must be applied to all outcome assessments. Our central 
adjudication model was to provide multiple scores for each assessment, allowing estimation 
of the reliability among observers. This has been feasible but labour intensive for the 
adjudicators involved. In practice there might be alternative and more pragmatic approaches 
to providing central adjudication and quality control without full committee review of all 
clips.  A single independent adjudicator might review each clip and only proceed to full 
committee review where there is disagreement. These strategies have not been formally 
tested and require further validation.   
The major opponent to the use of centrally adjudicated mRS outcomes are the numerous 
structured forms of mRS assessment. Several structured mRS assessment tools have been 
proposed to limit variability in mRS outcomes.  A simplified modified Rankin questionnaire 
has found very good reliability with a very fast administration time (average 1.67 minutes) in 
a sample of 50 paired mRS assessments132. A simple nine question interview only allowing 
binary “yes/no” responses demonstrates excellent reliability131.  A more comprehensive 
structured mRS interview was originally developed by Wilson et al105 and has been adapted 
to the Rankin Focussed Assessment (RFA) by Saver et al133.  This structured four page form is 
designed to be completed in conjunction with interview of the participant, relative or 
caregiver and review of participant medical records.  The RFA reports excellent inter observer 
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reliability (w 0.99) in a sample of 50 paired mRS assessments and has been prospectively 
validated as part of the ongoing FAST-MAG trial.   
There is currently much uncertainty regarding the relative benefits of a traditional mRS 
approach and that of the many structured mRS interviews available, such as the Rankin 
Focussed Assessment (RFA).  Despite the improved reliability quoted for the structured mRS 
tools there are some advantages to the traditional mRS model.  There are formal training 
tools with rigorous assessment and a freedom within the assessment tool to explore the 
complexities of symptoms and limitations specific to each participant. This may in part be 
why previous study has not convincingly shown benefit of structured interviews99. Initial 
positive results of structured mRS tools have not been replicated in independent cohorts and 
further independent validation is required before any of the tools become the method of 
choice for documenting outcome in acute stroke trials. In a randomised evaluation of 
traditional mRS vs. Wilson’s structured mRS tool the promised benefits in reliability were not 
replicated199. The global and unstructured nature of the traditional mRs is a great advantage; 
without relying on individual activities of daily living there are no floor or ceiling effects in its 
application which are common to structured instruments. Any potential benefit of the 
structured interview is at the cost of increased interview time and complexity. However, the 
same is likely to be true of novel interventions currently being piloted, such as video based 
mRS or off-line group assessment. In a large-scale clinical trial that may recruit hundreds of 
patients, the cumulative effect of even minor increases in interview complexity could have 
major effects on overall costing and time to completion. Further study of each approach to 
mRS assessment is required in large multicentre trials. The benefit of a structured 
assessment such as the RFA and central adjudication together may hold potential.  An 
advantage of the central adjudication model is that it can be used regardless of the method 
of mRS adopted – traditional, structured or questionnaire based. It could readily be used 
alongside a shortened Rankin assessment to ensure consistency and quality.  
Beyond reliability, the benefits seen with central adjudication are numerous. Any central 
adjudication panel allows a degree of “expert” review and we have demonstrated that no 
important data are lost in the process of video recording and remote assessment.  Blinding is 
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crucial to the integrity of trial outcomes and a remote group adjudication approach may be 
of use in these circumstances where this is difficult e.g. neurosurgical interventions or 
complex rehabilitation trials.  Central adjudication provides a method of ensuring quality 
control; repeat assessment or further information can be gathered if an assessment is 
inadequate or below standard.  In these circumstances a group review approach may prevent 
a potentially erroneous outcome score being recorded.  The video approach also allows 
storage of a “hard copy” of the outcome assessment allowing trialists to re-examine 
functional outcome data where there are data queries.  Finally, it offers remote source data 
verification of the patient’s existence and consent in a way that no document can offer. 
A criticism of the video mRS interview would be that not all information gathered by an 
investigator in their contact locally with a participant can be captured on film and transferred 
to the adjudication centre.  Intuitively it seems likely that some information is lost where the 
mRS score is based only on the video clip. There may be clues to function and disability in 
each encounter that are not captured on the clip. i.e. How did the participant travel to the 
hospital, did they struggle to walk to the consultation room etc.  Pilot work comparing face to 
face interview and video interview did not suggest this was a limitation of video mRS. It is 
important to acknowledge that in its definition, the mRS score is based upon a patient 
interview. A properly conducted interview should contain all the detail required. It is 
recognised that for scales clinicians may not perform a comprehensive assessment but will 
estimate the results based upon initial meeting, watching the participant in a consultation 
and clinical intuition229.  This is not accurate for mRS199. Any assumption based on visual clues 
should be clarified and explored by a diligent reviewer on questioning. Where there were 
non-verbal cues we encouraged interviewers to highlight these in their interview where they 
felt these might be relevant. No guidance was given to investigators regarding the length of 
the video clip, where there were more complex issues we encouraged full discussion of these 
to aid in scoring.  One piece of information that is concealed in the video clip is treatment 
assignment: subtle prejudice that could cause bias in scoring for an open label or PROBE trial 
can be prospectively excluded. 
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For many reasons the mRS is sub-optimal; however the traditional mRS is likely to remain the 
outcome measure of choice for trialists and regulators. An imperfect tool applied consistently 
is preferable to multiple versions of that tool with individual modifications. There is a 
temptation to modify or alter an existing scale to improve its efficiency or reliability; for 
example to add, omit or re-write certain items.  This adds complexity and may reduce the 
utility of single outcome measure applied constantly in clinical research.  To pool data, such 
as the pooled analysis of the landmark thrombolysis trials44, it is necessary to have a shared, 
consistent and identical primary outcome measure. For this reason we should accept the 
mRS in the format that it is commonly applied and work to improve its use in trial design. 
We have demonstrated that mRS assessment can be performed remotely via a method that 
is feasible, acceptable to participants and investigators and is valid and reliable in comparison 
to current known metrics of disability assessment.   
There is now a need to apply our approach to real world intervention trials. Based on our 
encouraging initial experiences, central adjudication using our infrastructure is already being 
used in the following trials: CLEAR-3 Clot Lysis Evaluating Accelerated Resolution trial of 
intraventricular thrombolysis in the treatment of intraventricular haemorrhage 
(NCT00784134, NIH funded), EuroHyp-1 trial of therapeutic cooling after ischaemic stroke 
(EU FP7 grant), MISTIE-III Minimally Invasive Surgery plus rtPA for ICH Evacuation Phase III 
(NCT01827046, NIH funded) and the SITS-OPEN trial investigating the safety and efficacy of 
thrombectomy after initiation with intravenous rtPA in ischaemic stroke (charitable and 
industry funded).  
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2. Introduction 
 
Acute stroke require a robust measure of functional outcome. At present, the modified Rankin Scale (mRs) is 
the most popular outcome measure (table 1) and is an ordinal scale with 6 categories ranging from zero (no 
symptoms) to five (complete physical dependence). A sixth category can be added to signify death. Despite 
being the most commonly used assessment, there are some concerns. Considerable inter-observer variability is 
recognised meaning that observers often disagree even when assessing the same patient. 
 
Table 1 – The Modified Rankin Scale 
Description Score 
No symptoms at all 0 
No significant disability despite symptoms; able to carry out all usual duties and activities 1 
Slight disability; unable to carry out all previous activities, but able to look after own affairs 
without assistance 
2 
Moderate disability; requiring some help, but able to walk without assistance 3 
Moderately severe disability; unable to walk without assistance and unable to attend to 
own bodily needs without assistance 
4 
Severe disability; bedridden, incontinent and requiring constant nursing care and attention 5 
Dead 6 
 
We have already established that agreement between observers can be worryingly low when they assign scores 
to the same patients.  This raises the possibility, should disagreement be across an endpoint cut-off point in a 
clinical trial, that patients could be placed in the wrong outcome group. This reduces statistical power and could 
compromise a clinical trial. 
 
Digital video recording of mRs assessments in a large clinical trial could address this concern. It will limit the 
effect of inter-observer variability by allowing central “off-line” scoring by a small number of expert 
investigators. It will also permit validation and re-scoring of initially misclassified patients, or in situations where 
disagreements occur (there will always be some disagreement but a consistent approach to these subjects is 
crucial). It will also help ensure quality of data (via source data verification and by ensuring adherence to 
interview procedures) and improve blinding of endpoint assessment in studies where this is difficult (such as 
neurosurgical studies). It may also afford examination of more subtle gradations of disability.  
 
3. The Aim of The CARS Study 
 
The aim is to evaluate use of digitally recorded and centrally adjudicated mRs assessments in a multi-centre 
acute stroke trial. Before digital recording of outcomes and central adjudication could be widely adopted, it 
must be rigorously assessed. Even though this study is based upon an adaptation of an already commonly used 
method there are several areas we must note. First, the mRs by nature is subjective and whether extra 
information (such as how the patient travelled to hospital or other background details) contributes and by how 
much is unclear. Further, this approach will add to complexity of trial design and although we feel this 
additional complexity is marginal, the technique must yield benefit before it could be deemed worthwhile 
 
4. Observer Training 
 
All investigators must be trained in mRs and NIHSS assessment using a validated web-based training 
programme.  A link to the training web-sites can be found in the training section of the web portal.  You require 
to register your own account on each site. For mRS training, the link is http://trials-rankin.trainingcampus.net . 
For NIHSS training, the link is 
http://learn.heart.org/ihtml/application/student/interface.heart2/index2.html?searchstring=583 .  
 You will be unable to upload any assessments if training has not been completed. 
 
All will also be shown how to operate the video camera and given a practical demonstration on video upload 
procedures and use of the Rankin Outcome Adjudication web portal. 
 189 
 
The reference booklet can of course be referred to and the co-ordinating centre contacted at any point. 
 
5. Getting Started 
 
Before starting the study there are some simple tasks we ask you to follow (as well as completing training). 
These are to make sure you are comfortable using the equipment, that you have performed a test upload and 
that you have completed all relevant training. 
 
We also require that you install AVS Video Converter version 6 software on your computer (we will provide 
discs and activation codes).  You may need to liase with your local IT department for this to be performed. You 
should also make a folder on your computer hard drive called “CARS Assessments.” This can be located 
anywhere as long as you know how to find it. 
 
6. The Study Population 
 
The aim is to recruit a minimum of 300 patients from between 5 and 10 centres. The inclusion and exclusion 
criteria are detailed below.  We hope each centre will recruit at least 15 patients. 
 
Main Inclusion Criteria 
Diagnosis of acute stroke (ischaemic or haemorrhagic) 
Onset within 48 hours of ictus 
Demonstrable deficit on the National Institutes of Health Stroke Scale (NIHSS)  
 
Main Exclusion Criteria 
Pre-morbid modified Rankin score of ≥3 
 
7. Identification of Participants and Consent 
 
Potential participants should be identified by a member of the treating clinical team as soon as possible after 
admission to the Stroke Unit.  Suitable patients and/or their nearest relative should be approached by the study 
clinician or nurse and will have the project explained briefly to them.  Those who are willing to consider it 
further can then be approached by a member of the research team (who may also be part of the treating 
clinical team) to have the study explained in more detail and consent will be sought for participation. 
 
Since no study specific procedures that differ from usual care are required in the first days of participation, the 
patient and relatives will be allowed at least 48 hours to decide.  However, consent can be obtained earlier, 
including less than 24 hours, if participants are willing to proceed on that basis.  The first video interview does 
not take place until one month later and of course participants can decline involvement at that stage.   
 
Participants should be asked to sign the consent form. Two copies will be signed (one each for the participant 
and the site file). The consent form should be copied with the copy placed in the case notes. Consent can be 
taken by one of the investigators or by a study research nurse (in which case it will be countersigned by an 
investigator). 
 
Participants who are unable to consent for themselves can be included; assent from a relative / welfare 
guardian will be sought. In Scotland this is done under the Adults with Incapacity (Scotland) Act and similar 
provisions are in place in England and Wales under the Mental Capacity Act.  In practice, the early procedures 
are indistinguishable from normal care and it is only the later video interviews that are "intrusive".  Those who 
are able to consent at this stage will be asked to do so at this stage. For those who remain unable to consent at 
this stage due to severe disability, continued assent / agreement from the relevant relative or welfare guardian 
will be accepted. 
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No participant will be included in England and Wales or Scotland against the wishes of a relative / next of kin. 
Importantly, in the case of severely affected participants it is more likely to be a member of staff or a 
relative/carer who will be interviewed, though the patient may be seen in the video recording. 
 
8. Trial Design and Conduct (figure 1) 
 
 
Baseline Assessment 
At recruitment, baseline demographic details including a measure of stroke severity (NIHSS) should be 
gathered. No intervention or change to normal routine care will occur during this study. These data should be 
entered into the paper case report form (CRF) and the electronic (e) CRF at the time of the visit. 
 
Day 30 
A digitally recorded mRs assessment should be performed. An assessment for any serious adverse event should 
also be made. This visit should last under 15 minutes. Data from this assessment should also be entered into the 
paper case report form (CRF) and the electronic (e) CRF at the time of the visit. An mRs score must be assigned 
by the local observer at this point and any comments regarding dysphasia or other problems noted in the CRF. 
 
Day 90 
A digitally recorded mRs assessment should be performed, as should a recorded NIHSS assessment.  An 
assessment for any serious adverse event should also be made. This visit should last under 30 minutes. Data 
from this assessment should also be entered into the paper case report form (CRF) and the electronic (e) CRF at 
the time of the visit. An mRs score must be assigned by the local observer at this point. 
 
9. Guide to Performing The mRs Assessment 
 
These will be performed on survivors in standard fashion according to each centre’s normal practice, although 
guidance is available here. The assessment should ideally be performed in a quiet and private clinic room, or if 
needed by a patient’s bedside with the curtains drawn or at home if they are unable to attend the hospital. 
Before an assessment is performed outwith a hospital site, it should be ensured that a local Lone Worker Policy 
is in place and that this is followed. 
 
Whenever possible, the assessor should remain constant across the follow-up period for a given patient. We 
recognise these restrictions may sometimes be impractical.  
 
The main mRs assessment must be recorded using a digital video camera, unless the participant clearly has a 
mRs score of 5 where a proxy should be interviewed on video in their stead. A suitable proxy is a relative, 
member of nursing staff or other carer.  
 
Note that only symptoms arising since the stroke should be considered.  Walking aids or other necessary 
mechanical devices are disregarded provided that the patient can use these without external assistance. 
 
The score of 0 is awarded to patients who have no residual symptoms after their stroke, not even minor 
symptoms. 
 
If patients have any symptoms resulting from the stroke, whether physical or mental, then they should be 
scored at least 1 on the Rankin scale.  For example, if they have any new difficulty in speech, reading or writing, 
Recruitment 
Demographic Data 
Day 30 
Clinical Review 
mRs Assessment 
Day 90 
Clinical Review 
mRs Assessment 
NIHSS Assessment 
Figure 1 – Participant Flow Chart 
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in physical movement, sensation, vision or swallowing, or any change in their mood that does not limit their 
activities, they still should score 1.  Patients in this category can continue to take part in all of their previous 
work, social and leisure activities.  For this purpose, “usual” is regarded as any activity that they used to 
undertake for a monthly basis or more frequently. 
 
If there is any activity that they used to undertake that they can no longer do since the stroke, whether because 
of a physical limitation or because they have chosen to give up the activity as a result of the stroke, then they 
should be scored 2 on the Rankin.  In this category the patient has slight disability and is unable to carry out all 
his previous activities, but he is still able to look after all of his own affairs without any external assistance.  For 
example, a patient would be scored in this category if he used to drive a car and is no longer able to do so, or if 
he used to have a job whereas he now no longer works.  The patient should still be able to look after himself 
without any daily help.  In other words he will be able to dress, move around, eat, go to the toilet, prepare 
simple meals, undertake shopping and make short journeys by himself.  He will not require any supervision 
from other people and could safely be left at home for periods of a week or more without any concern. 
 
Rankin category 3 is for patients who have moderate disability.  These patients require some external help for 
daily activities but are able to walk without assistance.  They may use a stick or a frame for walking but the 
assistance of another person is not required for this.  They will be able to manage daily activities such as 
dressing, toileting, feeding etc, but will need help for more complex tasks such as shopping, cooking or cleaning 
or will need to be visited more often than weekly for some other purpose.  The external help may simply be 
advisory, for example supervision for their financial affairs. 
 
Patients with moderately severe disability who are unable to walk without assistance and unable to attend to 
their own bodily needs by themselves are given a score of 4.  These patients are not independently mobile and 
will need help with daily tasks such as dressing, toileting or eating.  They will need to be visited at least daily or 
will need to live in close proximity to a carer.  To discriminate patients in category 4 from those in the most 
severe category, consider whether the patient can regularly be left alone for moderate periods of a few hours 
during the day. 
 
Patients who cannot be left alone even for a few hours should be given the score of 5.  Patients in category 5 
have severe disability and are usually bedridden, incontinent and require constant nursing care and attention.  
Someone else will always need to be available during the day and at time during the night, although this will not 
necessarily be a trained nurse. 
 
Thus, in summary, to distinguish between patients in category 0 or 1 consider whether the patient has any 
remaining symptoms.  To distinguish between categories 1 and 2 consider whether the patient can undertake 
all of his previous activities.  If the patient is independent of others in activities of daily living, then he should be 
scored 2 rather than 3.  To distinguish between category 3 and category 4 the crucial question is whether the 
patient can walk without the assistance of other people.  Finally, a patient who can be left by himself for a few 
hours during the day would be given a score of 4 rather than 5. 
 
It is important to note that patients do not always fall neatly into one category and some judgement is usually 
required when scoring them.  When in doubt between 2 categories, always stick to the key discriminators of the 
scale.  Thus if the patient has remaining symptoms he scores at least 1.  If the patient is unable to undertake 
previous activities he scores at least 2.  If he is dependent upon others in activities of daily living he must score 
at least 3.   If the patient is unable to walk without assistance he must score at least 4 and if the patient is 
bedridden and requires constant nursing care he will score 5.  Finally, if there is still some doubt between two 
alternatives on the scale, and both options appear equally valid, then the worse option should be chosen. 
 
There are some key discriminating questions that should be considered when using the modified Rankin scale.  
These are shown in more detail below (the official definitions of each category are shown below in bold and the 
italicized text provides guidance that may reduce interobserver variability, without requiring a structured 
interview). 
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0. No symptoms at all 
 
The patient should be unaware of any new limitation of symptom caused by the stroke, however minor. 
 
1. No significant disability despite symptoms; able to carry out all usual duties and activities 
 
The patient has some symptoms as a result of the stroke, whether physical or cognitive – for example affecting 
speech, reading or writing; or physical movement; or sensation; or vision; or swallowing; or mood – but can 
continue to take part in all previous work, social and leisure activities.  The crucial question to distinguish grade 
1 from grade 2 (below) may be, ‘is there anything that you can no longer do that you used to do until you had 
the stroke?’  As a guide, an activity that was undertaken more frequently than monthly could be regarded as a 
‘usual activity’. 
 
2. Slight disability; unable to carry out all previous activities but able to look after own affairs without 
assistance 
 
The patient will be unable to undertake some activity that was possible before the stroke (e.g. driving a car, 
dancing, reading or working) but is still able to look after him/herself without help from others on a day to day 
basis.  Thus, the patient can manage dressing, moving around, feeding, toileting, preparing simple meals, 
shopping, and travelling locally without needing assistance from anyone else.  Supervision is not necessary.  This 
grade assumes that the patient could be left alone at home for periods of a week or more without concern. 
 
 
3. Moderate disability; requiring some help, but able to walk without assistance 
 
At this grade the patient is independently mobile (using a walking aid of frame if necessary) and can manage 
dressing, toileting, feeding, etc but needs help from someone else for more complex tasks.  For example, 
someone else may need to undertake shopping, cooking or cleaning and will need to visit the patient more often 
that weekly to ensure that these activities are completed.  The assistance can be advisory rather than physical: 
for example, a patient who needs supervision or encouragement to cope with financial affairs would be in this 
grade. 
 
 
4.  Moderately severe disability; unable to walk without assistance and unable to attend to own bodily 
needs without assistance 
 
The patient requires someone else to help with some daily tasks, whether walking, dressing, toileting or eating.  
This patient will be visited at least once and usually twice or more times daily, or must live in proximity to a 
carer.  To distinguish grade 4 from grade 5 (below), consider whether the patient can regularly be left alone for 
moderate periods during the day. 
 
5. Severe disability: bedridden, incontinent, and requiring constant nursing care and attention 
 
Someone else will always need to be available during the day and at times during the night, though not 
necessarily a trained nurse. 
 
10.  Recording the mRs Assessment 
 
A Canon HF100 video camera will be used. The camera records direct to an internal memory card. In 
conjunction, a desktop omni-directional condenser boundary microphone will be used (ATR97, Audio-technica, 
Ohio USA; Specifications: Frequency response: 50-1500Hz). An easily portable desktop tripod will be used to 
mount the video camera (Hama Minipod). 
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It is crucial to ensure that the microphone is correctly connected and switched on before commencing the 
recording. Also ensure there is enough battery power in the camera or that it is plugged into the power supply. 
It is also recommended that, prior to any recording, that a do not disturb sign is placed on the outside of the 
door and that ward or clinic staff are informed recording is taking place to minimise external noise. 
 
Please do not alter the settings on the camera as these have been adapted for the purposes of this study.  For 
your information, these settings will be shown in the on-line appendix. 
 
 
It is recommended that the assessment is performed with the assessor, participant and equipment positioned 
as shown below (figure 3).  
 
 
 
 
The camera should be mounted on the desktop tripod. 
 
 
 
 
 
 
 
Once the camera is mounted, it should be turned on and it is also recommended that the power supply to the 
camera be connected to maintain full charge. 
 
 
TABLE 
Camera / 
Tripod     
Observer 
P
atie
n
t 
Microphone 
Figure 3. Camera placement 
The desktop tripod has extendable legs (1) 
which may not be required, although can be 
used to optimise the height of camera and 
views of patients obtained. It also has an 
adjustable lever to change angulation of the 
camera (2). 
 
The camera is attached by aligning the in 
built screw on the tripod (3) with the 
corresponding area on the lower surface of 
the camera and then turning the circular disc 
located just below the camera mount on the 
tripod (4). 
 
To give maximum stability, it is 
recommended that the camera lies directly 
above and not between one of the tripod 
legs. 
1 
2 
3 
4 
Figure 4. The Hama Mini-pod 
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The boundary microphone should be connected to the “microphone in” socket on the camcorder (shaded red. 
The headphone socket which is not to be used for the microphone is green).  The boundary microphone must 
be switched on. The switch is located on the bottom of the microphone.  This should then be placed on the 
table between the patient and the assessor as shown above. 
 
Once the equipment is set up, the LCD screen should be opened and the position of the camera adjusted so that 
the patient’s face and trunk are seen.  Once this has been done, the recording can begin. Either the remote 
control or the record button (shown above) on the camera can be used.  Always ensure the red light on the 
LCD screen is present (which means the camera is recording) before starting your assessment. 
Figure 6. The ATR 97 Omnidirectional Microphone 
The on-off switch is located on the lower 
surface of the microphone. It must always 
be confirmed this is switched on before 
recording commences. This should also be 
switched off at the end of recording to 
preserve battery life. 
This is the side view of the Canon 
HF 100 camcorder. The LCD screen 
can be gently opened the camera at 
the finger groove (1). 
 
The on-off switch is located on the 
superior aspect of the camera (2) 
1 
2 
Figure 5A. The Canon HF 100 camcorder. 
This is the rear view of the Canon HF 
100 camcorder. The record switch can 
be seen (1). The microphone and 
power sockets are located behind a 
protective cover (2 and 3) which can 
be gently opened. 
 
The menu on the LCD screen is 
navigated by using the small knob at 
its side (4). 
1 
3 2 4 
Figure 5B. The Canon HF 100 camcorder. 
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After the assessment is complete, remember to stop recording and we recommend that you switch off the 
microphone. 
 
11. Saving the Assessment and Converting the File 
 
First, the camera needs to be connected to a USB port on your computer. The computer should automatically 
recognise the camera. Sometimes a window of files located on the camera will automatically open. This should 
be closed.  The recorded clips are very large (at least 200 to 400 megabytes) and require to be converted to a 
smaller size prior to upload to the study web portal. However, a copy of the full size clip should be recorded to 
compact disc and archived locally along with other source data.  This can be done as normal and details of how 
to locate the file and how to name it are given later. 
 
A step by step illustrated guide of how to do convert the file is shown below. The converted files should range 
between 10 and 30 megabyte in size. 
 
 
 
 
 
 
  
 
 
 
 
The file format needs to be 
converted to reduce file size.  
 
We will use AVS video 
converter version 6 software 
to do this.  
 
Double click on this icon to 
open the software. 
When the software is 
opened, this window will 
appear and it is important to 
ensure that the WMV icon is 
highlighted. 
 
The first step is to locate the 
file that you wish to convert 
(the mRs assessment you 
have just recorded). Do this 
by clicking “browse” next to 
the input file name bar. 
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The camera will be 
identified as a removable 
disc (usually by the letter 
“E” or “F”) and the files are 
located in the “STREAM” 
folder.  
 
To open this first click on  
the removable disc that 
represents the camera 
then “PRIVATE” then 
“AVCHD” then “BDMV” 
then “STREAM”. 
The camera automatically 
saves and labels files as a 
number. The last video 
recorded has the highest 
number so should 
therefore be the last mRs 
assessment performed. 
 
Once you have highlighted 
the files you wish to 
convert, click open.  
You then need to identify the 
folder you wish to save the 
assessment to. We recommend 
you use the CARS assessments 
folder that you have created.  
 
To locate this, click on browse 
and this screen will appear. 
Then type in the file name 
which should start with the 
participant number then the 
type of assessment (for 
example “003 mRs Day 30”). 
This name should also be used 
for the copy you save to 
compact disc. 
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11. The Rankin Outcome Adjudication Web Portal and File Upload 
 
The web portal provides tools for investigators to enter their subjects’ modified Rankin Scale assessments and 
upload accompanying videos. Demographic and other outcome data should also be entered via the web portal. 
The portal is administered by the Robertson Centre for Biostatistics in Glasgow. 
 
The web portal is secure and end-users access the system by entering a username and password. On first use, 
users will be asked to change their password. Smart passwords will be required and users will be prompted to 
change these routinely.  Access to the portal is restricted to named co-investigators. 
 
The web portal also includes a system that will make videos available to the co-ordinating centre for quality 
checks and pre-review editing and transcription. In addition, it will allocate clips to investigators for review and 
mRs scoring. For confidentiality reasons, such access will be restricted to those at the outcome coordinating 
centre at the Western Infirmary Acute Stroke Unit, Glasgow, UK. 
 
A step by step guide of how to use the portal is shown below. 
 
The web portal can be located at the web address www.glasgowctu.org/cars 
 
 
The profile refers to the 
conversion parameters and 
this will be automatically 
determined during the site 
initiation visit. The profile will 
be named (CARS study).  
 
You must ensure this has 
been selected before 
beginning the conversion. 
 
This can be selected from the 
drop down menu. 
Once all these steps have 
been followed, you are ready 
to perform the conversion 
which takes about 10 
minutes.  To start this, click 
on “convert now” and this 
screen will appear. 
 
The bar at the bottom will 
tell you the progress of the 
conversion. When conversion 
is finished you will be asked if 
you want to “open the 
folder” in which the new 
assessment is located. This 
window can be closed. 
 198 
 
 
 
 
 
 
 
 
 
 
 
 
To enter the portal you are 
required to enter your 
personal user name and 
password 
 
Once you are inside the 
portal, you will see the menu 
bar at the top right of the 
screen. This will contain links 
to study resources, CRFs and 
the clip upload section. 
 
 
To upload a clip, clip on the 
“uploads” link. 
 
To upload a clip, clip on 
“upload video”. 
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12. Video NIHSS Assessments 
 
A day 90 video NIHSS assessment will also be performed and uploaded to the web portal in the same fashion as 
the mRS assessment. To capture the full NIHSS assessment, it may be helpful to place the camera approximately 
10 feet from the patient, near the foot of the bed and on the opposite side of the bed from the examiner. 
 
13. Recording of Participant Events 
 
Although this is not an interventional clinical trial, we hope to capture serious adverse events. This will allow us 
to better identify individuals where the video technique is unsuitable or problematic should that scenario arise. 
Events do not require to be reported to the sponsor but should be recorded in the paper and eCRF. 
 
A serious adverse event (SAE) is defined as any event that;  
 a. results in death  
 b. is life threatening  
 c. requires hospitalisation or prolongation of existing hospitalisation  
 d. results in persistent or significant disability or incapacity  
 e. consists of a congenital anomaly or birth defect.  
  
You will then be required to 
enter the participant number 
and the assessment day (day 
30 or 90). 
 
Then you will need to locate 
the file for upload by clicking 
browse. 
The file should be located in 
the CARS assessment folder 
you created. 
 
Once the clip has been 
identified, click on open and 
then upload. The duration of 
the upload will depend upon 
the size of the file and the 
network speed but should be 
under 5 minutes. The portal 
will tell you if the file has been 
successfully incorporated into 
the database. 
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Appendix B   
Written information given to 
translators and assessors in 
the CARS translation 
substudy. 
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CARS TRANSLATION SUBSTUDY 
 
BOOKLET OF INFORMATION AND INSTRUCTIONS 
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Contents of the Translation Guide 
 
 
Summary……………………………………………………………………………  3 
 
 
Philips Digital Pocket Memo Dictaphone…………………………………………....  6 
 
 
Phillips Speech Exec Software………………………………………………….. 13 
 
 
Using the CARS portal in the “Translator” role………………………………… 26 
 
 
Using the CARS portal in the “Committee Assessor” role……………………  33  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contacts: 
 
For new login details for the CARS portal please contact the CARS helpdesk at CARS@glasgowctu.org 
or Kate McArthur at kate.mcarthur@glasgow.ac.uk 
 
For any other queries contact Kate McArthur at kate.mcarthur@glasgow.ac.uk  
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Summary 
 
The translation substudy is designed to test the feasibility and validity of introducing a translation 
step into the central adjudication model.  Most large stroke trials are international and multilingual.  
A method for dealing with this is necessary if central adjudication is to be feasible in a typical RCT. 
 
The CARS study has been performed exclusively in English, with various different local accents and 
colloquialisms.  Despite the common language used, we do have an arbitrary “border” between 
Scotland and England/Wales which we can use for these purposes as a language boundary. 
 
A selection of clips (n=60) has been randomly sampled from the pool of adjudicated 90 day CARS 
videos.  There are 30 clips from either side of the “border” and these will be translated by 
investigators from the other side of the UK.  I.e. Scottish clips will be “translated” by investigators in 
England/Wales and vice versa.  
 
The translation will be done with a digital dictaphone and the file uploaded to the CARS web portal.  
This will be merged with the original video file to create a dubbed clip which can then be re-scored on 
the mRS. 
 
The scores generated from the translated clips will be compared to the original “native language” 
scores to see if there are any significant differences. 
 
 
The “translated” video file: 
 
The allocated translator of each clip will watch the video and dictate a “dubbed” version of the sound 
on the clip.  The translator will find that they need to start and stop the video and may rewind and 
overwrite bits of their dictation – this is expected and a less smooth version of the sound file (in 
comparison to the original) is inevitable.  We do not wish translators to spend a large amount of time 
getting the translation word perfect - simply a close copy of the conversation between the assessor 
and the patient (and / or proxy).   
 
If there are more than two people in the clip they can identified by voice on the dictated file before 
each person speaks.  i.e. “patient says……….”, “assessor says……….”, “relative says………..” throughout.  
Don’t worry it if sounds a bit more disjointed, we expect this and are testing to see if these 
“translated” clips are still valid despite the added sound file.   
 
The dictated file may end up longer or shorter than the original clip, don’t worry about this, the 
automated file merging system will still dub them together successfully.  The scorer may find that the 
sound continues to play after the video stops or vice versa – this is expected.  The sound file will not 
dub perfectly with each word / sentence.  We anticipate that the merged videos will appear 
disjointed, however visualising the patient / proxy and listening to the content of the interview should 
allow a score to be allocated. 
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CARS online portal 
 
The translation portal has been built into the CARS portal which you will have used for the main 
study.  
 
 
A new tab has been added in the top right of the screen to direct you to your translation worklist, you 
will not need to use any other part of the portal for this substudy. 
 
 
 
 
 
 
For new login details for the CARS portal please contact the CARS helpdesk at CARS@glasgowctu.org 
or Kate McArthur at kate.mcarthur@glasgow.ac.uk 
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There are two roles in the substudy: 
 
 
 
Translator:   
 
In this role you will be assigned clips for translation and clips for scoring.  You will be asked to enter 
an mRS score for every clip you view, either as translator or as a committee assessor.  You will not be 
allocated your own translated clips for review. 
 
What you will need: 
 
 Computer with internet access, a USB socket and speakers / headphones 
 
 Login details for the CARS online portal 
 
 Phillips Digital Pocket Memo Dictaphone (LFH9370/5) 
 
 Phillips Speech Exec Dictation Software 
 
Before starting the translation work it is a good idea to have a few practices with the dictaphone and 
get used to using the controls. 
 
 
 
 
Committee Assessor:  
 
In this role you will be assigned clips for review and scoring only – these will previously have been 
translated.  
 
What you will need: 
 
 Computer with internet access and speakers / headphones 
 
 Login details for the CARS online portal 
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Philips Digital Pocket Memo Dictaphone 
 
 
 
 
 
Contents of the box: 
 
 Dictaphone 
 Leather case 
 Digital Memory Card                                                         
 Batteries 
 USB cable 
 Speech Exec software CD 
 Instruction Manuals 
 
 
The digital Dictaphone is easy to use.   
 
The pictures below highlight the relevant functions and buttons. 
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Getting Started: 
 
Insert the memory card and batteries as shown below. 
 
 
 
 
 
 
 
 
 
 
On / Off switch 
Record Button 
Press once to start 
and once to stop 
recording 
Forward/Rewind 
This can be used to rewind 
and over-write any errors 
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Recording: 
 
 
 
 
 
 
 
 
 
 
 
 
 
When you switch the dicatphone 
on, ready to start recording, the 
screen will look like this. 
 
 Length of recording 
 
 Arrow to denote 
progress 
 
 File number on the 
memory card 
 
 File name on memory 
card 
When you press the red record 
button on the right hand side the 
recording will begin.  The length 
of your recording will be seen on 
the clock. 
 
You will know that it is recording 
due to several indicators. 
 
 Red light on top right 
corner 
 
 Clockwise spinning 
wheel 
 
 Solid recording spot 
 
 Play and Stop buttons 
appear 
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To rewind and listen or overwrite: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You can pause recording by 
pressing the red record button 
again. 
 
If you do this the spinning wheel 
will stop moving and the 
recording spot will flash to 
indicate that you have paused. 
 
The timer will pause until you 
resume recording by again 
pressing the red record button. 
Flash when 
paused 
This arrow shows where you are in the recording (1) 
 
In the above pictures you see that it can be moved back if you want to rewind and listen to your 
dictation or record over an error. 
 
To do this press the upper part of the forward/rewind button on the side panel and watch the 
arrow move backwards.  The timer will move backwards to demonstrate how far you have gone. 
(2) 
 
To listen to your dictation press the play button in the bottom left of the screen (3) 
To overwrite an error simply press the red record button again and re-recored over it (4) 
1
. 
2
. 
3
. 
4
. 
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To finish a recording: 
 
 
 
 
 
 
To listen to a finished recording: 
 
 
 
 
 
To start a new recording file: 
 
We recommend that you only dictate one file at a time to avoid confusion.  As you cannot rename the 
files while they are on the Dictaphone there is a risk that the wrong audio file may be merged with 
the incorrect clip.  We would suggest dictating one at a time, uploading it (which will automatically 
wipe it from the Dictaphone) and then starting a new file for the new clip.  
 
If you have to start a second file for dictation this done as follows: 
To finish a completed recording 
press the stop button at the 
bottom right of the screen. 
Press the Begin button at 
the bottom left hand 
corner of the screen 
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Connecting the Dictaphone to the computer: 
 
 
 
 
This USB cable is contained within the Phillips 
box 
 
There is a small connector for the Dictaphone 
and a regular USB connector for the computer 
Press the New button at 
the bottom right hand 
corner of the screen 
The screen will refresh 
with a new timer and #2 
displayed on the screen 
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The two ends of the USB 
cable connect to the 
devices as shown 
When the cable has been inserted 
correctly the screen on the Dictaphone 
will demonstrate a successful 
connection 
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Phillips Speech Exec Software 
 
 
 
 
 
The SpeechExec software provided with the dictaphone will be either version 5 or version 7.  Both 
work in exactly the same way.  Before use the software will need to be installed on your PC.  This is 
straightforward to complete with the following instructions but may need to be sanctioned by the 
local NHS IT dept. 
 
Enter the SpeechExec disc into the CD drive of your PC.  Open “My Computer” to locate the disc on 
the screen.  Click on the Dictate (D:) icon to open software. 
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Once the software has opened, click on option 1 – Install to start up the installation wizard. 
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A box will appear requesting that you pick a setup language from the drop down list.  Select English 
(United States).   
 
Unfortunately it doesn’t offer a UK English option. 
 
 
Next click Install at the bottom of the open box to begin the process.   
 
A green progress bar will move along the bottom of the box to indicate that the software is being 
accessed. 
 
 
 
The SpeechExec Dictate – InstalShield Wizard will open once the green progress bar has finished 
moving.   
 
Close all other open applications (e.g. email inbox / word files) before progressing 
 
Click next to begin installation. 
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Click to accept the terms of the license agreement and again proceed by clicking Next. 
 
 
 
You will now be asked to enter the license key code that is printed on the back of the CD sleeve.  In 
this example the Licence Key is PSP DS05 2042.   
 
SpeechExec Version 7 sleeves will have a longer licence key in a similar format. 
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Enter the Licence Key as shown and click Next.  These are not case sensitive. 
 
 
 
In Version 7 you will be prompted to enter your details.  Enter your name but in the institution please 
enter University of Glasgow as this is where the licence was purchaced.  Do not enter an email 
address, this is unnecessary and will avoid junk email.  NB This step is not necessary in Version 5. 
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The software will offer you an option to customise your user profile.  This is not necessary.  Click 
“Typical” and Next to progress through installation. 
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You are now ready to install SpeechExec. 
 
 
 
Click Install to begin and again several green progress bars will appear in the installation box to 
indicate that the software is being installed successfully. 
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Once complete the following screen will appear to indicate that the process is complete.  Click Finish. 
 
 
 
The SpeechExec Software may now open automatically.  If not, open the software by clicking on the 
new icon on your desktop.   
 
You will be prompted to set up your user profile before you begin to use the software.  A New User 
Wizard will open automatically, click Next. 
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First it will automatically enter your PC username as the SpeechExec user name.  This is designed for 
professional dictation purposes so that typing pools are able to identify where a piece of work has 
come from.  This is less important for our purposes.  Accept the automatic username offered and 
proceed using the next button. 
 
You are then requested to confirm where the completed dictation will be saved in your files.  Click on 
the Modify button.  
 
  
 
This will open a further box with two fields.   
 
Name: Finished Dications 
Path: This will display the location where your completed dictation will be saved when you connect 
the dictaphone to the PC.  Click on the small folder icon as shown below to see where the files are 
sent.   
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The package will automatically set up a folder in My Documents.  We recommend that you accept this 
folder (unless there is a local IT reason that it is best saved elsewhere) and click OK   
 
 
 
This will bring you back to the previous box, click OK to proceed. 
 
 
 
Finally you will be returned to the Folder Settings wizard box, click Next to continue. 
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The wizard will then offer the option of setting up the device, this is not necessary so simply click 
“next” to move on. 
 
 
 
Do not check the box in the Additional Information section. 
 
Next click Finish to complete the process.   
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There is one change necessary to the settings of the SpeechExec software for use in the CARS 
translation portal. 
 
For the portal to accept the files the audio format requires to be changed, this can be configured 
through the settings menu at this stage so that each time you upload an audio file there is a one click 
conversion process. 
 
Open the SpeechExec software via the start menu or the desktop icon. 
 
 
 
Open the “Settings” Menu and click on “General Settings” 
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This will open a “General Settings” box which displays the audio format of the uploaded dictations. 
 
The format should read: 
 
WAV 
Philips CELP 
CELP Mono, 16kHz 
 
 
 
 
To change this click on “Configure”.  A new box will appear as shown. 
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Click on the “format” dropdown menu and select PCM.   
 
 
 
Then click OK 
 
 
 
This will change the description of the Audio Format to read: 
 
WAV 
PCM 
8.000kHz, 16 bit, Mono 
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Ensure that the “Convert automatically when opening a dictation” is checked.  
Click OK to complete the change in settings. 
Using the CARS portal in the “Translator” role 
 
When you are allocated a clip for translation you will receive an automated email to prompt you to 
enter the portal. 
 
Login using your username and password to enter the portal 
 
 
 
Access the translation section of the portal using the tab at the top right of the screen 
 
 
 
You will see a list of clips that are ready for translation.  Each has a number to identify it (Assess ID) at 
the left of the list.  Click on “select” to start with each clip.   
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The selected clip will turn yellow in the list.  Under the heading “review” you can download the video 
to watch it.  Click “open” to open the video file in windows movie maker.  Do not “save” the file to 
your computer due to data protection rules.   While watching remember that you will need to enter a 
mRS score for the clip.  While watching the clip use the dictaphone to provide a dictated translation 
file (see page 4).  For details in the use of the Philips PocketMemo see page 6.    
 
 
 
 
Once you have completed the dictation, connect the dictaphone to the PC using the USB cable as 
shown on page 11.  Depending upon the set up of your PC this may or may not automatically be 
recognised by your PC as a removable disc (similar to a memory stick) and the folder may appear on 
the screen.  It may not appear – this is not a problem as you will access it through SpeechExec 
instead. 
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Use the “start” menu to open the SpeechExec software.  If it doesn’t appear in the initial list you will 
be able to locate it via the “All Programs” list. 
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The new dictation file will automatically be downloaded into SpeechExec and will be seen on the list 
as a .dds file. This is seen below, highlighted in blue.  Download to the computer will delete the file 
from the dictaphone so that there is no confusion when you start to dictate the next file. 
 
 
 
 
 
 
 
This .dds file needs to be converted to a .wav file before it can be uploaded to the portal.  If you have 
set up the configuration of the software as shown on pages 23-25 then this will happen automatically 
when you double click on the highlighted dictation file to open it (the conversion will change the file 
ending from .dds to .wav and it changes colour. 
 
If you haven’t configured the software you can easily convert the file manually as follows.  Open the 
File menu and select “convert” as shown below. 
 
 
 
 
The options for audio format will be displayed, one change is required.  The dropdown menu which 
displays “Philips CELP” should be changed to “PCM”, then click “OK”. 
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The conversion will change the file to .wav, ready for upload to the portal. 
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Next return to the CARS portal, where the clip you have dictated a translation for should remain 
highlighted.  If the connection to the portal has timed out (this happens after 30 minutes of inactivity) 
– log back in and be sure to highlight the same Assess ID to ensure the correct translation goes with 
the correct clip, you may wish to watch a little bit of the clip again to ensure it is the right one. 
 
 
Once you have the clip highlighted, clip on the “Browse” button to locate the dictated file.  This is 
exactly the same as locating an attachment for an email from your computer files.  
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Locate the file in “My Documents” >>  “speechexec” >> “a_finish” where your dictation file will be 
saved.  There will be two versions of your file (ignore the Welcome to SpeechExec files).  One version 
is the sound file .wav (identified by the musical note) and one is not for use .wav.xml (ignore this file).  
Highlight the file with the musical note and click “Open” 
 
 
 
This will enter the file in the upload box, click “Upload” in the portal webpage and the file will be 
uploaded and automatically merged with the original video clip.   
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A green progress bar will demonstrate the upload / file merge progress.  Do not click anything further 
until the mRS score sheet appears on the screen – this may take a few minutes.  Enter an mRS score 
and any comments you might have.  Click “Submit” to save your score. 
 
 
 
 
 
The clip will then be sent back to the co-ordinating centre for distribution amongst the other 
reviewers. 
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Using the CARS portal in the “Committee Assessor” role 
 
When you are allocated a clip for review you will receive an automated email to prompt you to enter 
the portal. 
 
Login using your username and password to enter the portal 
 
 
 
Access the translation section of the portal using the tab at the top right of the screen 
 
 
 
You will see a list of clips that are ready for review.  Each has a number to identify it (Assess ID) at the 
left of the list.  Click on “select” to start with each clip.   
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The selected clip will be highlighted in yellow.  Click as indicated to download and view the translated 
video file.  Click “open” to open the file in windows movie maker.  Do not “save” the file to your 
computer due to data protection rules.  
 
Enter your mRS score and any comments you might have in the scoring sheet below.  Click “Submit” 
to save your score. 
 
 
 
To review the next clip click “select” to highlight another clip and repeat the process. 
 
 
 
 
 
 
Contacts: 
 
Study co-ordinator   kate.mcarthur@glasgow.ac.uk 
 
CARS helpdesk CARS@glasgowctu.org  
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Appendix C  
Supplementary results of 
Validity Analyses 
 
Table 41 -  Adjusted proportional odds logistic regression of relationship between 
bNIHSS, SBP, blood glucose and home time at 30 days with each method of mRS 
assessment. Day 30 and 90 mRS 
 Odds Ratio (OR) 95% CI for OR p 
Day 30 Local mRS 
Baseline NIHSS 1.191 1.124 – 1.263 <0.0001 
Systolic Blood Pressure 1.008 1.000 – 1.016 0.046 
Blood Glucose 1.053 0.955 – 1.161 0.030 
Home Time Day 30 0.902 0.878 – 0.927 <0.0001 
Day 30 Adjudicated mRS 
Baseline NIHSS 1.198 1.125 – 1.276 <0.0001 
Systolic Blood Pressure 1.008 0.999 – 1.016 0.083 
Blood Glucose 1.073 0.969 – 1.189 0.177 
Home Time Day 30 0.894 0.868 – 0.920 <0.0001 
Day 90 Local mRS 
Baseline NIHSS 1.151 1.058 – 1.220 <0.0001 
Systolic Blood Pressure 1.011 1.002 – 1.019 0.013 
Blood Glucose 1.082 0.979 – 1.196 0.123 
Home Time Day 30 0.913 0.888 – 0.938 <0.0001 
Day 90 Adjudicated mRS 
Baseline NIHSS 1.148 1.075 – 1.226 <0.0001 
Systolic Blood Pressure 1.010 1.001 – 1.019 0.037 
Blood Glucose 1.008 0.904 – 1.124 0.890 
Home Time Day 30 0.890 0.862 – 0.918 <0.0001 
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Day 30 mRS 
0.5 1 2 
0.89 (0.87, 0.92) 
0.90 (0.88, 0.93) 
1.07 (0.97, 1.19) 
1.05 (0.96, 1.16) 
1.01 (1.00, 1.02) 
1.01 (1.00, 1.02) 
1.20 (1.13, 1.28) 
1.19 (1.12, 1.26) 
Home Time Day 30  
Blood Glucose  
Systolic Blood Pressure  
Baseline NIHSS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Day 90 mRS 
0.5 1 2 
0.89 (0.86, 0.92) 
0.91 (0.89, 0.94) 
1.01 (0.90, 1.12) 
1.08 (0.98, 1.20) 
1.01 (1.00, 1.02) 
1.01 (1.00, 1.02) 
1.15 (1.08, 1.23) 
1.15 (1.06, 1.22) 
Home Time Day 30  
Blood Glucose  
Systolic Blood Pressure  
Baseline NIHSS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Adj mRS 
Local mRS 
Figure 51 - Adjusted proportional odds logistic regression of relationship between 
bNIHSS, SBP, blood glucose and home time at 30 days with each method of mRS 
assessment. Day 30 and 90 mRS. Odds Ratio (95% CI) 
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Professor Keith 
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